Administration of kynurenine depleting enzymes for tumor therapy by George M. Georgiou et al.
COMUNE CELAL ONLINE FITUTION TO 
US009975959B2 
( 12 ) United States Patent 
Georgiou et al . 
( 10 ) Patent No . : US 9 , 975 , 959 B2 
( 45 ) Date of Patent : May 22 , 2018 
FOREIGN PATENT DOCUMENTS ( 54 ) ADMINISTRATION OF KYNURENINE 
DEPLETING ENZYMES FOR TUMOR 
THERAPY 
( 71 ) Applicant : BOARD OF REGENTS , THE 
UNIVERSITY OF TEXAS SYSTEM , 






WO 2012 / 031744 
WO 2012 / 079000 
WO 2012 / 099441 
WO 2013 / 059593 
WO 2015 / 031771 
3 / 2012 
6 / 2012 
7 / 2012 
4 / 2013 
3 / 2015 
OTHER PUBLICATIONS ( 72 ) Inventors : George Georgiou , Austin , TX ( US ) ; 
Everett Stone , Austin , TX ( US ) ; 
Nicholas Marshall , Austin , TX ( US ) ; 
John Blazeck , Austin , TX ( US ) ; 
Wei - Cheng Lu , Austin , TX ( US ) 
( 73 ) Assignee : BOARD OF REGENTS , THE 
UNIVERSITY OF TEXAS SYSTEM , 
Austin , TX ( US ) 
( * ) Notice : Subject to any disclaimer , the term of this 
patent is extended or adjusted under 35 
U . S . C . 154 ( b ) by 33 days . 
( 21 ) Appl . No . : 14 / 839 , 293 
( 22 ) Filed : Aug . 28 , 2015 
( 65 ) Prior Publication Data 
US 2016 / 0058845 A1 Mar . 3 , 2016 
Related U . S . Application Data 
Provisional application No . 62 / 120 , 418 , filed on Feb . 
25 , 2015 , provisional application No . 62 / 043 , 663 , 
filed on Aug . 29 , 2014 . 
( 60 ) 
Phillips , R . S . Structure and mechanism of kynureninase , Archives 
of Biochemistry and Biophysics 544 ( 2014 ) 69 - 74 . * 
“ SIDS2vsH1 YAV1 , " UniProt 201609 , dated Mar . 21 , 2012 . 
Alberati - Giani et al . , “ Isolation and expression of a cDNA clone 
encoding human kynureninase , ” Eur J Biochem . , 239 : 460 - 468 , 
1996 . 
Gailani et al . , “ Studies on tryptophan metabolism in patients with 
bladder cancer , ” Cancer Research . , 33 : 1071 - 1077 , 1973 . 
Hoyos et al . , “ Genetic modification of human T lymphocytes for the 
treatment of hematologic malignancies , ” Haematologica . , 97 ( 11 ) : 
1622 - 31 , 2012 . 
Schottler et al . , “ Protein engineering of the restriction endonuclease 
EcoRV - structure - guided design of enzyme variants that recognize 
the base pairs flanking the recognition site , ” Eur . J . Biochem . , 
258 ( 1 ) : 184 - 91 , 1998 . 
Veronese et al . , " Peptide and protein PEGylation : a review of 
problems and solutions , ” Biomaterials , 22 ( 5 ) : 405 - 417 , 2001 . 
“ KYNU _ Human , ” UniProt Submission Q16719 , dated Jul . 24 , 
2013 . 
“ Kynureninase ( EC 3 . 7 . 1 . 3 ) human ” , GenBank accession No . 
G02652 , 1999 . 
Chen and Guillemin , “ Kynurenine pathway metabolites in humans : 
disease and healthy states , ” Int . J . Tryptophan Res . , 2 : 1 - 19 , 2009 . 
Curran et al . , “ PD - 1 and CTLA - 4 combination blockade expands 
infiltrating T cells and reduces regulatory T and myeloid cells within 
B16 melanoma tumors , ” Proc . Natl . Acad . Sci . US A , 107 : 4275 
4280 , 2010 . 
de Jong et al . , " Serum tryptophan and kynurenine concentrations as 
parameters for indoleamine 2 , 3 - dioxygenase activity in patients 
with endomenial , ovarian , and vulva cancer , ” Int . J . Gynecol . 
Cancer , 21 ( 7 ) : 1320 - 1327 , 2011 . 
Della Chiesa et al . , “ The tryptophan catabolite L - kynurenine inhib 
its the surface expression of NKP46 - and NKG2D - activating recep 
tors and regulates NK - cell function , ” Blood , 108 ( 13 ) : 4118 - 4125 , 
2006 . 
Godin - Ethier et al . , “ Indoleamine 2 , 3 - Dioxgenase Expression in 
Human Cancers : Clinical and Immunologic Perspectives , ” Clinical 
Cancer Research , 7 ( 22 ) : 6985 - 6991 , 2011 . 
Holmgaard et al . , “ Indoleamine 2 , 3 - dioxygenase is a critical 
resistance mechanism in antitumor T cell immunotherapy targeting 
CTLA - 4 , ” The Journal of Experimental Medicine , 210 : 1389 - 1402 , 
2013 . 
Kaper et al . , “ Nanosensor detection of an immunoregulatory tryp 
tophan influx / kynurenine efflux cycle , ” PLOS Biology , 5 ( 10 ) : e257 , 
2007 . 
( Continued ) 
( 51 ) 
( 52 ) 
Int . CI .
A61K 38 / 46 ( 2006 . 01 ) 
C12N 9 / 14 ( 2006 . 01 ) 
CO7K 19 / 00 ( 2006 . 01 ) 
CO7K 16 / 28 ( 2006 . 01 ) 
C12N 9 / 96 ( 2006 . 01 ) 
A61K 47 / 48 ( 2006 . 01 ) 
A61K 39 / 395 ( 2006 . 01 ) 
A61K 35 / 17 ( 2015 . 01 ) 
A61K 38 / 00 ( 2006 . 01 ) 
U . S . CI . 
CPC . . . . . . CO7K 16 / 2887 ( 2013 . 01 ) ; A61K 39 / 3955 
( 2013 . 01 ) ; A61K 47 / 48215 ( 2013 . 01 ) ; CO7K 
16 / 2818 ( 2013 . 01 ) ; COZK 16 / 2827 ( 2013 . 01 ) ; 
CO7K 16 / 2896 ( 2013 . 01 ) ; C12N 9 / 14 
( 2013 . 01 ) ; C12N 9 / 96 ( 2013 . 01 ) ; C12Y 
307 / 01003 ( 2013 . 01 ) ; A61K 35 / 17 ( 2013 . 01 ) ; 
A61K 38 / 00 ( 2013 . 01 ) ; C07K 2317 / 622 
( 2013 . 01 ) ; CO7K 2319 / 01 ( 2013 . 01 ) 
Field of Classification Search 
None 
See application file for complete search history . 
Primary Examiner — Maria Marvich 
( 74 ) Attorney , Agent , or Firm — Parker Highlander PLLC ( 58 ) 
( 56 ) References Cited 
U . S . PATENT DOCUMENTS 
( 57 ) ABSTRACT 
Methods and compositions related to the use of a protein 
with kynureninase activity are described . For example , in 
certain aspects there may be disclosed a modified kynureni 
nase capable of degrading kynurenine . Furthermore , certain 
aspects of the invention provide compositions and methods 
for the treatment of cancer with kynurenine depletion using 
the disclosed proteins or nucleic acids . 
7 , 109 , 304 B2 
8 , 465 , 743 B2 
2009 / 0304666 Al 
2015 / 0064154 Al * 
9 / 2006 Hansen et al . 
6 / 2013 Rosenberg 
12 / 2009 Harrison 
3 / 2015 Georgiou . . . . . C12N 9 / 14 
424 / 93 . 71 16 Claims , 10 Drawing Sheets 
US 9 , 975 , 959 B2 
Page 2 
( 56 ) References Cited 
OTHER PUBLICATIONS 
Lima et al . , “ Crystal structure of the Homo sapiens kynureninase 
3 - hydroxylrippuric acid inhibitor complex : insights into the 
molecular basis of kynureninase substrate specificity , ” J . Med . 
Chem . , 52 ( 2 ) : 389 - 396 , 2009 . 
Lipowska - Bhalla et al . , “ Targeted immunotherapy of cancer with 
CAR T cells : achievements and challenges , ” Cancer Immunology 
Immunotherapy , 61 ( 7 ) : 953 - 962 , 2012 . 
Lob et al . , “ Inhibitors of indoleamine - 2 , 3 - dioxygenase for cancer 
therapy : can we see the wood for the trees ? ” Nat . Rev . Cancer , 
9 ( 6 ) : 445 - 452 , 2009 . 
Mandi and Vecsei , “ The kynurenine system and immunoregula 
tion , ” J . Neural Transm . , 119 ( 2 ) : 197 - 209 , 2012 . 
Mezrich et al . , “ An interaction between kynurenine and the aryl 
hydrocarbon receptor can generate regulatory T cells , ” The Journal 
of Immunology , 185 ( 6 ) : 3190 - 3198 , 2010 . 
Opitz et al . , “ An endogenous tumour - promoting ligand of the 
human aryl hydrocarbon receptor , " Nature , 478 ( 7368 ) : 197 - 203 , 
2011 . 
Opitz et al . , “ The Indoleamine - 2 , 3 - Dioxygenase ( IDO ) Inhibitor 
1 - Methyl - D - tryptophan Upregulates IDO1 in Human Cancer 
Cells , ” PLoS One , 6 ( 5 ) : e19823 , 2011 . 
Phillips , “ Structure , mechanism , and substrate specificity of 
kynureninase ” , Biochimica et Biophysica Acta , 1814 : 1481 - 1488 , 
2011 . 
Pilotte et al . , “ Reversal of tumoral immune resistance by inhibition 
of tryptophan 2 , 3 - diogenase , " Proc . Natl . Acad . Sci . USA , 
109 ( 7 ) : 2497 - 2502 , 2012 . 
Prendergast , " Cancer : Why tumours eat tryptophan , ” Nature , 
478 ( 7368 ) : 192 - 194 , 2011 . 
Rutella et al . , “ Targeting indoleamine 2 , 3 - dioxygenase ( IDO ) to 
counteract tumour - induced immune dysfunction : from biochemistry 
to clinical development , ” Endocr . Metab . Immune Disord . Drug 
Targets , 9 ( 2 ) : 151 - 177 , 2009 . 
Shin et al . , “ Modulation of natural killer cell antitumor activity by 
the aryl hydrocarbon receptor , " Proc . Natl . Acad . Sci . USA , 
110 ( 30 ) : 12391 - 12396 , 2013 . 
Simpson et al . , “ Fe - dependent depletion of tumor - infiltrating regu 
latory T cells co - defines the efficacy of anti - CTLA - 4 therapy against 
melanoma , ” J . Exp . Med . , 210 ( 9 ) : 1695 - 1710 , 2013 . 
Song et al . , “ L - Kynurenine - induced apoptosis in human NK cells is 
mediated by reactive oxygen species , " International 
Immunopharmacology , 11 ( 8 ) : 932 - 938 , 2011 . 
Yao et al . , " Serum metabolic profiling and features of papillary 
thyroid carcinoma and nodular goiter , ” Mol . Biosyst . , 7 ( 9 ) : 2608 
2614 , 2011 . 
Yoshikawa et al . , " Serum concentration of L - kynurenine predicts 
the clinical outcome of patients with diffuse large B - cell lymphoma 
treated with R - CHOP , " Eur . J . Haematol . , 84 ( 4 ) : 304 - 309 , 2010 . 
Toma et al . , “ Cloning and recombinant expression of rat and human 
kynureninase , ” FEBS Letters . , 408 ( 1 ) : 5 - 10 , 1997 . 
* cited by examiner 
U . S . Patent May 22 , 2018 Sheet 1 of 10 US 9 , 975 , 959 B2 
2 3 4 5 
. '
50 kDam 
. . . . . . . 
FIG . 1 
U . S . Patent May 22 , 2018 Sheet 2 of 10 US 9 , 975 , 959 B2 
muuttaminen 
. 
% Activity menentanimation senyalitzades unmomentet ministratoren * 
20 40 60 80 100 
Time ( hours ) 
FIG . 2 
U . S . Patent May 22 , 2018 Sheet 3 of 10 US 9 , 975 , 959 B2 
Combined tumor growth data 
VODOUDOUDOUDOU w ninase or deactivated 
enzyme injected on 
days 10 , 13 , 16 
19 , 22 25 VUVUVUVUVUVUVU Tumor size(m 2) * * * * * * * * ov . > * * 
* 
* 
••••••••• * * * * * * * * 
www 
* * * * 
10 12 14 16 18 20 22 24 26 28 30 
Day 
FIG . 3 
U . S . Patent May 22 , 2018 Sheet 4 of 10 US 9 , 975 , 959 B2 
house 
* * * * 1 . 4 . 4 . 4 . 4 . 4 . . 4 . 4 . 4 . . 4 . 4 . 4 . 4 . 4 . 4 . 4 . 4 . . 4 . 4 . 4 . 4 . 4 . 4 . 4 . 4 . 4 . 4 . 4 . 4 . 4 . 4 . 4 . 4 . : 
Fraction survivinge bene ÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖÖG wwws . . . . . . . . . 0 5 10 15 20 21 22 23 24 25 26 27 28 29 Kea 
FIG . 4 
U . S . Patent May 22 , 2018 Sheet 5 of 10 US 9 , 975 , 959 B2 
Enzyme treated
Tumor -infiltratingCD8+cells W WWWWWWWWWWWWWW 44444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444 . 333333 Control p =0.3
A 
6 446
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * WH 
5B 
FIG $.5A-B
1 :# Enzyme treated
p =0.001
Circulating D4+ce lsth tareTregs mu - AX41474444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444.
# Control 
5A of CD4 + cells 
U . S . Patent May 22 , 2018 Sheet 6 of 10 US 9 , 975 , 959 B2 
Lawn No growth 
No grow Lawn 
FIG . 6 
FIG . 7 
Time ( hrs ) 
80 70 60 50 40 30 20 10 0 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * o 
8 wiiiiiiiiiiiwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww % Activity 8 
8 
US 9 , 975 , 959 B2 Sheet 7 of 10 May 22 , 2018 U . S . Patent 
U . S . Patent May 22 , 2018 Sheet 8 of 10 US 9 , 975 , 959 B2 
4 A 
seu rendesenteren * til man
* 
> *
* * * deactive PEG - PEKYNU 
wmr active PEGAR KYNO 
* * * anti - p . 1 










Time ( days ) 
FIG . 8 
U . S . Patent May 22 , 2018 Sheet 9 of 10 US 9 , 975 , 959 B2 
cu 




* * PDL . 1 / PEG MU - XYNU ttttttttttthu 
B 
- ??? ?????????????? ?????????????? ?????????????????????????? ???????? ?????? *
8 
7 
motion PD - 1 / PEG - PEKYNU 
8 
2009 8 nuimtinianus 
" Warnishe
8 J 
. 11 .3003145 ** 





EUR PD - 1 
moyen PD - 1 / PEG - MI - KYNU 
other PD - 1 / PEG - PEKYNU 
www mini 
Day 
FIG $ . 9A - C 













May 22 , 2018 
is altisss 
WW szis own 

















US 9 , 975 , 959 B2 
US 9 , 975 , 959 B2 
will 
ADMINISTRATION OF KYNURENINE inhibited by 1 - DL - methyltryptophan ( Pilotte et al . , 2012 ) . 
DEPLETING ENZYMES FOR TUMOR There are also additional concerns with the D - isomer of 
THERAPY 1 - DL - methyltryptophan ( 1 - D - MT ) currently in phase 1 and 
2 clinical trials . Paradoxically , 1 - D - MT can upregulate 
The present application claims the priority benefit of U . S . 5 IDO1 expression , actually increasing KYN levels and induc 
provisional application No . 62 / 120 , 418 , filed Feb . 25 , 2015 ing immunosuppression in certain cancers ( Opitz et al . , 
and U . S . provisional application No . 62 / 043 , 663 , filed Aug . 2011 ) . 
29 , 2014 , the entire contents of each of which is incorporated Controlling tumor production of KYN is the focus of 
herein by reference . much research and has the potential to treat , among others , 
The invention was made with government support under 10 cancers such as breast cancer , ovarian , glioblastoma , and 
Grant No . R01 CA154754 awarded by the National Insti pancreatic carcinoma . KYN is known to suppresses prolif 
tutes of Health . The government has certain rights in the eration as well as induce apoptosis in T cells and NK cells 
invention . ( Opitz et al . , 2011 ; Mandi and Vacsei , 2012 ) enabling tumors 
to evade detection and destruction by a patient ' s immune 
INCORPORATION OF SEQUENCE LISTING 15 system . KYN is a potent ligand of the aryl hydrocarbon 
receptor ( AHR ) whose activation in T cells induces differ 
The sequence listing that is contained in the file named entiation into CD25 + FoxP3 + T regulatory cells ( Tregs ) 
" UTSBP1035US _ ST25 . txt " , which is 341 KB ( as measured ( Mezrich et al . , 2010 ) . KYN has also been shown to prevent 
in Microsoft Windows® ) and was created on Aug . 28 , 2015 , cytokine mediated up - regulation of specific receptors 
is filed herewith by electronic submission and is incorpo - 20 ( NKp46 and NKG2D ) required for NK mediated cell killing 
rated by reference herein . tumor cell lines ( Della Chiesa et al . , 2006 ) , an action that is 
also likely mediated by its agonistic effect on AHR ( Shin et 
BACKGROUND OF THE INVENTION al . , 2013 ) . There is also clinical evidence linking elevated 
serum KYN levels and decreased survival in multiple types 
1 . Field of the Invention 25 of cancer . In healthy patients , KYN levels in serum are in the 
The invention generally relates to compositions and meth - range of 0 . 5 to 1 uM . In patients with cancer types that 
ods for the treatment of cancer with enzymes that deplete produce KYN , such as diffuse large B - cell lymphoma , 
L - kynurenine or L - 3 - hydroxykynurenine . More particularly , serum KYN levels were measured to be as much as 10 times 
it concerns the engineering , pharmacological optimization higher ( Yoshikawa et al . , 2010 ; de Jong et al . , 2011 ; Yao et 
and use of bacterial and mammalian enzymes with 30 al . , 2011 ) and were prognostic for survival among lym 
L - kynurenine degrading activity suitable for human therapy . phoma patients receiving the same treatment regimen ; those 
2 . Description of Related Art th serum levels below 1 . 5 uM exhibited a 3 year survival 
Overexpression of indolamine - 2 , 3 - dioxygenase isoforms rate of 89 % , compared to only 58 % survival for those with 
( IDO1 or IDO2 ) by cancer cells or reprogramming of cancer KYN levels above 1 . 5 uM . This difference in survival was 
infiltrating leukocytes to express either of these enzymes has 35 attributed to the immune suppressing effects of KYN ( Yo 
been shown to have a profound effect on attenuating adap shikawa et al . , 2010 ) . The use of small molecule IDO 
tive immune responses to cancer . IDO1 and IDO2 as well as inhibitors , such as 1 - D - MT , has demonstrated the utility of 
the enzyme tryptophan 2 , 3 - dioxygenase ( TDO ) , whose controlling KYN levels in restoring immune function , but 
expression by stromal cells may be induced by some tumors , the off target effects of IDO1 up - regulation by 1 - D - MT and 
catalyze the rate limiting step in tryptophan ( Trp ) catabolism 40 lack of inhibition for TDO and the IDO1 isoform are of 
to L - kynurenine ( KYN ) ( Godin - Ethier et al . , 2011 ) . Tumors concern . 
exchange a cytosolic KYN molecule for an extracellular Trp The present invention discloses the use enzymes for the 
molecule using a LAT1 - like amino acid exchanger ( Kaper et specific depletion of KYN and its metabolites in tumors 
al . , 2007 ) , which has the dual effect on immune cells of and / or in the blood . KYN depleting enzymes are used to 
locally elevating levels of KYN while locally depleting Trp 45 lower KYN concentrations for the treatment of tumors 
levels . Neighboring immune cells internalize KYN , where it expressing IDO1 , IDO2 , or TDO thus preventing tumor 
is an activating ligand for the aryl hydrocarbon receptor mediated tolerogenic effects and instead mediating tumor 
( AHR ) resulting in the expression of numerous cytokines ablating pro - inflammatory responses . Notably , the use of 
and chemokines that lead to tumor tolerance through enzymes for the depletion of KYN and KYN metabolic 
immune cell differentiation and / or induction of apoptosis 50 byproducts circumvents the problems associated with small 
( Della Chiesa et al . , 2006 ; Opitz et al . , 2011 ; Song et al . , molecule inhibitors of IDO isoforms and TDO discussed 
2011 ) . Additionally , other KYN - related compounds formed above and further completely circumvents off target effects 
from kynurenine , most notably kynurenic acid also exert an that are very commonly accompany small molecule drugs 
immunosuppressive effect by serving as agonists of the and lead to unpredicted toxicities and side effects . 
orphan GPCR GPCR35 . Inhibition of KYN formation ( and 55 
thus inhibition of the formation of KYN metabolism byprod SUMMARY OF THE INVENTION 
ucts , including kynurenic acid , 3 - hydroxyl kynurenine and 
quinolinic acid , via the inhibition of IDO1 or TDO has Aspects of the present invention overcome a major defi 
received a significant amount of attention as a cancer target ciency in the art by providing enzymes that comprise 
( Chen and Guillemin , 2009 ; Rutella et al . , 2009 ; Prender - 60 bacterial and mammalian polypeptide sequences capable of 
gast , 2011 ) . Substrate analog inhibitors , such as 1 - DL - degrading L - kynurenine and 3 - hydroxy - L - kynurenine and 
methyltryptophan , for IDO1 have been developed and have displaying favorable pharmacokinetics in serum as desired 
shown initial promise in overcoming cancer induced tumor for cancer therapy . In some aspects , the kynureninase 
tolerance thus restoring the ability of the native immune enzyme has greater catalytic activity towards kynurenine 
system to fight tumors ( Lob et al . , 2009 ) . However , KYN is 65 than 3 ' OH - kynurenine . A kynureninase from a bacterial 
also produced by tryptophan 2 , 3 - dioxygenase ( TDO ) , which species may be used . Such an enzyme may have an amino 
is also frequently expressed in tumors and this enzyme is not acid sequence selected from the group consisting of SEQ ID 
US 9 , 975 , 959 B2 
NOs : 7 and 13 - 52 or a modified version thereof . In particu - polypeptide may comprise at least or up to about 10 , 20 , 30 , 
lar , the therapeutic may be derived from the Pseudomonas 40 , 50 , 60 , 70 , 80 , 90 , 100 , 150 , 200 , 250 , 300 , 350 , 400 , 415 
fluorescens enzyme , kynureninase ( Pf - KYNU ) . Alterna residues ( or any range derivable therein ) of the sequence of 
tively , a kynureninase from Saccharomyces cerevisiae or SEQ ID NO : 8 or 10 - 12 . 
Neurospora crassa may be used . The therapeutic may be 5 In some embodiments , the native kynureninase is modi 
derived from the Mucilaginibacter paludis kynureninase fied by one or more other modifications , such as chemical 
enzyme . Further , to prevent adverse effects due to the modifications , substitutions , insertions , deletions , and / or 
immunogenicity of heterologous kynureninases , the Homo truncations . For example , the modifications are at a substrate 
sapiens enzyme or other primate kynureninases display recognitions site of the native enzyme . In a particular 
ing > 95 % sequence identity to the human enzyme may be 10 embodiment , the native kynureninase is modified by sub 
used . For example , a novel enzyme may have an amino acid stitutions . For example , the number of substitutions may be 
sequence selected from the group consisting of SEQ ID one , two , three , four or more . In further embodiments , the 
NOs : 7 - 9 . native kynureninase is modified in the substrate recognition 
In other aspects , there are provided polypeptides com site or any location that may affect substrate specificity . 
prising either a native or modified human or primate 15 In one embodiment , an isolated , modified human 
kynureninase capable of degrading KYN and having activity k ynureninase enzyme is provided , wherein the modified 
towards the degradation of 3 - hydroxykynurenine or enzyme has at least one substitution relative to native human 
kynurenic acid . In some embodiments , the polypeptides are kynureninase ( see SEQ ID NO : 8 ) , and wherein the at least 
capable of degrading KYN under physiological conditions . one substitution includes a Met or Leu substitution for a Phe 
For example , the polypeptides have a catalytic efficiency for 20 normally found at position 306 of native human kynureni 
KYN ( k / Kw ) of at least or about 0 . 01 , 0 . 05 , 0 . 1 , 0 . 2 , 0 . 3 , nase . Thus , in one aspect , an isolated , modified human 
0 . 4 , 0 . 5 , 0 . 6 , 0 . 7 , 0 . 8 , 0 . 9 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 20 , 30 , kynureninase enzyme is provided that comprises a 
40 , 50 , 60 , 70 , 80 , 90 , 100 , 200 , 300 , 400 , 500 , 600 , 700 , Phe306Met substitution . In another aspect , an isolated , 
800 , 900 , 1000 , 2000 , 3000 , 4000 , 5000 , 6000 , 7000 , 8000 , modified human kynureninase enzyme is provided that 
9000 , 104 , 10° , 100 M - s - 1 or any range derivable therein . 25 comprises a Phe306Leu substitution . 
A modified polypeptide as discussed above may be char - In one embodiment , an isolated , modified human 
acterized as having a certain percentage of identity as kynureninase enzyme is provided , wherein the modified 
compared to an unmodified polypeptide ( e . g . , a native enzyme has at least one substitution relative to native human 
polypeptide ) or to any polypeptide sequence disclosed kynureninase ( see SEQ ID NO : 8 ) , and wherein the at least 
herein . For example , the unmodified polypeptide may com - 30 one substitution includes a substitution at least at amino acid 
prise at least , or up to , about 150 , 200 , 250 , 300 , 350 , 400 position H41 , L59 , F71 , A98 , A99 , G101 , H102 , 1110 , G112 , 
residues ( or any range derivable therein ) of a native M120 , K121 , D122 , 1131 , N135 , A136 , T138 , H142 , F148 , 
kynureninase . The percentage identity may be about , at most F149 , K157 , S167 , A171 , 0175 , Q229 , N232 , G248 , F249 , 
or at least 40 % , 50 % , 55 % , 60 % , 65 % , 70 % , 75 % , 80 % , E259 , W272 , S274 , A282 , 1285 , G287 , A288 , P300 , V303 , 
85 % , 90 % , 95 % , 96 % , 97 % , 98 % , 99 % or 100 % ( or any 35 F306 , L320 , L322 , S332 , N333 , P334 , L337 , V339 , 1404 , 
range derivable therein ) between the modified and unmodi 1405 , S408 , or A436 relative to SEQ ID NO : 8 . In further 
fied polypeptides , or between any two sequences in com - aspects , the at least one substitution is at a position ( s ) 
parison . It is also contemplated that percentage of identity selected from the group consisting of : ( a ) A99 , F306 , and 
discussed above may relate to a particular modified region of A436 ; ( b ) A99 , G112 , F306 , L337 , 1405 , S408 ; ( c ) G112 , 
a polypeptide as compared to an unmodified region of a 40 F306 , L337 , and 1405 ; ( d ) A99 , T138 , F306 , and A436 ; ( e ) 
polypeptide . For instance , a polypeptide may contain a A99 , G112 , F306 , V339 , 1405 , and S408 ; ( f ) A99 and F306 ; 
modified or mutant substrate recognition site of a kynureni - ( g ) F306 , L337 , V339 , 1405 , and S408 ; ( h ) G112 , F306 , 
nase that can be characterized based on the identity of the V339 , and 1405 ; ( i ) G112 , F306 , V339 , S408 ; ( k ) F71 , A99 , 
amino acid sequence of the modified or mutant substrate G112 , T138 , F306 , L337 , V339 , 1405 , S408 , and A436 ; ( 1 ) 
recognition site of the kynureninase to that of an unmodified 45 A99 , G112 , F306 , L337 , V339 , 1405 , and S408 ; ( m ) A436 ; 
or mutant kynureninase from the same species or across the ( n ) A99 , G112 , T138 , V339 , and 1405 ; ( p ) A99 , G112 , F306 , 
species . A modified or mutant human polypeptide charac - 1405 , S408 , and A436 ; ( q ) F71 , A99 , 1131 , F249 , and L322 ; 
terized , for example , as having at least 90 % identity to an ( r ) A99 , 1131 , F249 , E259 , and F306 ; ( s ) F71 , A99 , and 
unmodified kynureninase means that at least 90 % of the E259 ; ( t ) F71 , A99 , S167 , and E259 ; ( u ) 1131 , F249 , and 
amino acids in that modified or mutant human polypeptide 50 S274 ; ( v ) L59 , G112 , F306 , V339 , 1405 , and S408 ; ( w ) 1110 
are identical to the amino acids in the unmodified polypep - and F306 ; ( x ) A99 , 1131 , F249 , and E259 ; ( y ) F71 , E259 , 
tide . and L322 ; ( z ) H41 , 0175 , and A436 ; ( a ' ) A99 , 1131 , and 
Such an unmodified polypeptide may be a native F249 ; ( b ' ) 1131 and F249 ; ( c ' ) T138 and A436 ; ( d ' ) T138 ; ( e ' ) 
kynureninase , particularly a human isoform or other primate F71 , A99 , 1131 , E259 , and V303 ; ( f ) A99 , G112 , F306 , 
isoforms . For example , the native human kynureninase may 55 V339 , 1405 , and S408 ; ( g ' ) F71 , A99 , 1131 , E259 , and A282 ; 
have the sequence of SEQ ID NO : 8 . Non - limiting examples ( h ' ) F71 , F249 , E259 , and V303 ; ( i ' ) 1110 ; and ( j ' ) F306 . In 
of other native primate kynureninase include Pongo abelii various aspects , the at least one substitution is selected from 
kynureninase ( Genbank ID : XP _ 009235962 . 1 , GI : the group consisting of : ( a ) A99S , F306L , and A436T ; ( b ) 
686708656 ; SEQ ID NO : 10 ) , Macaca fascicularis A99V , G112A , F306Y , L337V , 1405L , S408N ; ( c ) G112A , 
kynureninase ( Genbank ID : EHH54849 . 1 , GI : 355750522 ; 60 F306Y , L337V , and 1405L ; ( d ) AI9S , T138S , F306L , and 
SEQ ID NO : 11 ) , and Pan troglodytes kynureninase ( Gen A436T ; ( e ) A99V , G112A , F306Y , V339A , 1405L , and 
bank ID : XP _ 003309314 . 1 , GI : 332814521 ; SEQ ID NO : S408N ; ( f ) AI9S and F306L ; ( g ) F3061 , L337V , V3391 , 
12 ) . Exemplary native polypeptides include a sequence 1405F , and S408T ; ( h ) G112A , F306Y , V339M , and 1405L ; 
having about , at most or at least 50 % , 55 % , 60 % , 65 % , 70 % , ( i ) G112S , F306L , V339T , S408T ; ( j ) G112A , F306Y , 
75 % , 80 % , 85 % , 90 % , 95 % , 96 % , 97 % , 98 % , 99 % or 100 % 65 V339S , 1405L ; ( k ) F710 , A991 , G112A , T138S , F306Y , 
identity ( or any range derivable therein ) of SEQ ID NO : 8 L337V , V3391 , 1405L , S408N , and A436T ; ( 1 ) A99V , 
or 10 - 12 or a fragment thereof . For example , the native G112A , F306Y , L337V , V3391 , 1405F , and S408N ; ( m ) 
re 
0 
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A436T ; ( n ) A99V , G112A , T138S , V339A , and 1405F ; ( 0 ) In some embodiments , the vectors are introduced into 
G112S , F306Y , V339T , and 1405L ; ( p ) A991 , G112A , host cells for expressing the kynureninase . The proteins may 
F306Y , 1405L , S408N , and A436T ; ( q ) F71L , A991 , 1131V , be expressed in any suitable manner . In one embodiment , the 
F249W , and L322P ; ( r ) A991 , 1131V , F249W , E259P , and proteins are expressed in a host cell such that the protein is 
F306L ; ( s ) F71L , A991 , and E259P ; ( t ) F71L , A991 , S167T , 5 glycosylated . In another embodiment , the proteins are 
and E259P ; ( u ) 1131M , F249W , and S274G ; ( v ) L59M , expressed in a host cell such that the protein is aglycosy 
G112S , F306Y , V339A , 1405L , and S408N ; ( w ) I110L and lated . 
F306L ; ( x ) A991 , 1131V , F249W , and E259P ; ( y ) F71L , Certain aspects of the present invention also contemplate 
E259P , and L322P ; ( 2 ) H41R , Q175L , and A436T ; ( a ' ) A991 , methods of treatment by the administration of the kynureni 1131V , and F249W ; ( b ' ) 1131V and F249W ; ( c ' ) T138S and 10 nase peptide , the nucleic acid encoding the kynureninase in A436T ; ( d ) T138S ; ( e ' ) F71L , A991 , 1131V , E259P , and 
V303S ; ( f ) A99F , G112A , F306Y , V339A , 1405L , and a gene therapy vector , or the formulation of the present 
S408N ; ( g ' ) F71L , A991 , 1131V , E259P , and A282P ; ( h ' ) invention , and in particular methods of treating tumor cells 
F71L , F249W , E259P , and V303S ; ( i ' ) 1110L ; and ( j ' ) F306Y . or subjects with cancer . The subject may be any animal , such ors 
In some aspects , a kynureninase enzyme comprises one of 15 as a mouse . For example , the subject may be a mamma prises one of 15 as a mouse . For example , the subject may be a mammal , 
the foregoing amino acid substitutions or combination of particularly a primate , and more particularly a human 
substitutions and further comprises no more than 1 . 2 . 3 . 4 . patient . In some embodiments , the method may comprise 
5 , 6 , 7 , 8 , 9 or 10 additional amino acid substitutions . In selecting a patient with cancer . 
various aspects , the isolated , modified human kynureninase In some embodiments , the cancer is any cancer that is 
enzyme has a sequence according to any one of SEQ ID 20 sensitive to kynurenine depletion . In one embodiment , the 
NOs : 55 , 56 , and 58 - 93 . present invention contemplates a method of treating a tumor 
In some aspects , the present invention also contemplates cell or a cancer patient comprising administering a formu 
polypeptides comprising a kynureninase linked to a heter - lation comprising such a polypeptide . In some embodi 
ologous amino acid sequence . For example , the kynureni ments , the administration occurs under conditions such that 
nase may be linked to the heterologous amino acid sequence 25 at least a portion of the cells of the cancer are killed . In 
as a fusion protein . In a particular embodiment , the another embodiment , the formulation comprises such a 
kynureninase is linked to amino acid sequences , such as an kynureninase with kynurenine - degrading activity at physi 
IgG Fc , albumin , an albumin binding protein , or an XTEN ological conditions and further comprising an attached poly 
polypeptide for increasing the in vivo half - life . ethylene glycol chain . In some embodiment , the formulation 
To increase serum stability , the kynureninase may be 30 is a pharmaceutical formulation comprising any of the above 
linked to one or more polyether molecules . In a particular discussed kynureninases and pharmaceutically acceptable 
embodiment , the polyether is polyethylene glycol ( PEG ) . excipients . Such pharmaceutically acceptable excipients are 
The polypeptide may be linked ( e . g . , Covalently ) to PEG via well known to those of skill in the art . All of the above 
specific amino acid residues , such as lysine or cysteine . For kynureninases may be contemplated as useful for human 
therapeutic administration , such a polypeptide comprising 35 therapy . 
the kynureninase may be dispersed in a pharmaceutically In a further embodiment , there may also be provided a 
acceptable carrier . method of treating a tumor cell comprising administering a 
In some aspects , a nucleic acid encoding such a kynureni - formulation comprising a non - bacterial ( mammalian , e . g . , 
nase is contemplated . In some embodiments , the nucleic primate or mouse ) kynureninase that has kynurenine - de 
acid has been codon optimized for expression in bacteria . In 40 grading activity or a nucleic acid encoding thereof . 
particular embodiments , the bacteria are E . coli . In other The administration or treatment may be directed to the 
aspects , the nucleic acid has been codon optimized for nutrient source for the cells , and not necessarily the cells 
expression in fungus ( e . g . , yeast ) , insects , or mammals . The themselves . Therefore , in an in vivo application , treating a 
present invention further contemplates vectors , such as tumor cell includes contacting the nutrient medium for a 
expression vectors , containing such nucleic acids . In par - 45 population of tumor cells with the kynureninase . In this 
ticular embodiments , the nucleic acid encoding the embodiment , the medium can be blood , lymphatic fluid , 
kynureninase is operably linked to a promoter , including but spinal fluid and the like bodily fluid where kynurenine 
not limited to heterologous promoters . In one embodiment , depletion is desired . 
a kynureninase is delivered to a target cell by a vector ( e . g . . In accordance with certain aspects of the present inven 
a gene therapy vector ) . Such viruses may have been modi - 50 tion , such a formulation containing the kynureninase can be 
fied by recombinant DNA technology to enable the expres - administered intravenously , intradermally , intraarterially , 
sion of the kynureninase - encoding nucleic acid in the target intraperitoneally , intralesionally , intracranially , intraarticu 
cell . These vectors may be derived from vectors of non - viral l arly , intraprostaticaly , intrapleurally , intrasynovially , intra 
( e . g . , plasmids ) or viral ( e . g . , adenovirus , adeno - associated tracheally , intranasally , intravitreally , intravaginally , 
virus , retrovirus , lentivirus , herpes virus , or vaccinia virus ) 55 intrarectally , intratumorally , intramuscularly , subcutane 
origin . Non - viral vectors are preferably complexed with ously , subconjunctival , intravesicularlly , mucosally , intrap 
agents to facilitate the entry of the DNA across the cellular ericardially , intraumbilically , intraocularly , orally , topically , 
membrane . Examples of such non - viral vector complexes by inhalation , infusion , continuous infusion , localized per 
include the formulation with polycationic agents which fusion , via a catheter , via a lavage , in lipid compositions 
facilitate the condensation of the DNA and lipid - based 60 ( e . g . , liposomes ) , or by other method or any combination of 
delivery systems . An example of a lipid - based delivery the forgoing as would be known to one of ordinary skill in 
system would include liposome based delivery of nucleic the art . 
acids . In a further embodiment , the method also comprises 
In still further aspects , the present invention further con - administering at least a second anticancer therapy to the 
templates host cells comprising such vectors . The host cells 65 subject . The second anticancer therapy may be a surgical 
may be bacteria ( e . g . , E . coli ) , fungal cells ( e . g . , yeast ) , therapy , chemotherapy , radiation therapy , cryotherapy , hor 
insect cells , or mammalian cells . mone therapy , immunotherapy or cytokine therapy . In cer 
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tain aspects , the second anticancer therapy may be an an embodiment pertaining to one method or composition 
anti - PD - 1 , anti - CTLA - 4 , or anti - PD - L1 antibody . may be applied to other methods and compositions of the 
In some embodiment , a cell comprising a chimeric anti invention as well . 
gen receptor ( CAR ) and a kynureninase enzyme are con As used herein the terms " encode ” or “ encoding , " with 
templated for use in treating a subject with cancer . In some 5 reference to a nucleic acid , are used to make the invention 
aspects , the cell may be transfected with a DNA encoding readily understandable by the skilled artisan ; however , these 
the CAR and the kynureninase and , in some cases , a terms may be used interchangeably with “ comprise ” or 
transposase . " comprising , " respectively . 
The CAR may target any cancer - cell antigen of interest , As used herein the specification , “ a ” or “ an ” may mean 
including , for example , HER2 , CD19 , CD20 , and GD2 . The 10 one or more . As used herein in the claim ( s ) , when used in 
antigen binding regions or domain can comprise a fragment conjunction with the word “ comprising , ” the words “ a ” or 
of the Vy and V , chains of a single - chain variable fragment " an " may mean one or more than one . 
( scFv ) derived from a particular human monoclonal anti - The use of the term “ or ” in the claims is used to mean 
body , such as those described in U . S . Pat . No . 7 , 109 , 304 , " and / or ” unless explicitly indicated to refer to alternatives 
which is incorporated herein by reference in its entirety . The 15 only or the alternatives are mutually exclusive , although the 
fragment can also be any number of different antigen bind - disclosure supports a definition that refers to only alterna 
ing domains of a human antigen - specific antibody . In a more tives and " and / or . ” As used herein “ another ” may mean at 
specific embodiment , the fragment is an antigen - specific least a second or more . 
scFv encoded by a sequence that is optimized for human Throughout this application , the term “ about ” is used to 
codon usage for expression in human cells . For additional 20 indicate that a value includes the inherent variation of error 
examples of CARs , see , for example , WO 2012 / 031744 , for the device , the method being employed to determine the 
WO 2012 / 079000 , WO 2013 / 059593 , and U . S . Pat . No . value , or the variation that exists among the study subjects . 
8 , 465 , 743 , all of which are incorporated herein by reference Other objects , features and advantages of the present 
in their entireties . invention will become apparent from the following detailed 
The kynureninase may be any kynureninase disclosed 25 description . It should be understood , however , that the 
herein . Methods of transfecting of cells are well known in detailed description and the specific examples , while indi 
the art , but in certain aspects , highly efficient transfections cating preferred embodiments of the invention , are given by 
methods such as electroporation are employed . For example , way of illustration only , since various changes and modifi 
nucleic acids may be introduced into cells using a nucleo - cations within the spirit and scope of the invention will 
fection apparatus . Preferably , the transfection step does not 30 become apparent to those skilled in the art from this detailed 
involve infecting or transducing the cells with virus , which description . 
can cause genotoxicity and / or lead to an immune response to 
cells containing viral sequences in a treated subject . BRIEF DESCRIPTION OF THE DRAWINGS 
A wide range of CAR constructs and expression vectors 
for the same are known in the art and are further detailed 35 The following drawings form part of the present specifi 
herein . For example , in some aspects , the CAR expression cation and are included to further demonstrate certain 
vector is a DNA expression vector such as a plasmid , linear aspects of the present invention . The invention may be better 
expression vector or an episome . In some aspects , the vector understood by reference to one or more of these drawings in 
comprises additional sequences , such as sequence that facili - combination with the detailed description of specific 
tates expression of the CAR , such a promoter , enhancer , 40 embodiments presented herein . 
poly - A signal , and / or one or more introns . In preferred FIG . 1 — SDS - PAGE of ( lane 1 ) PRECISION PLUS PRO 
aspects , the CAR coding sequence is flanked by transposon TEINTM MW standard ( BioRad ) ( lanes 2 - 4 ) increasing con 
sequences , such that the presence of a transposase allows the centrations of Pf - KYNU and ( lane 5 ) PEG 5 , 000 MW 
coding sequence to integrate into the genome of the trans - modified Pf - KYNU . 
fected cell . 45 FIG . 2 - Stability of Pf - KYNU in PBS ( open square ) and 
In certain aspects , cells are further transfected with a pooled human serum ( open circle ) . 
transposase that facilitates integration of a CAR coding FIG . 3 — Efficacy of PEG - Pf - KYNU in an autologous B16 
sequence into the genome of the transfected cells . In some mouse melanoma model as measured by tumor growth rates . 
aspects , the transposase is provided as DNA expression ( Solid square ) Heat inactivated PEG - Pf - KYNU . ( Solid 
vector . However , in preferred aspects , the transposase is 50 circle ) Active PEG - Pf - KYNU . 
provided as an expressible RNA or a protein such that FIG . 4 - Efficacy of PEG - Pf - KYNU in an autologous B16 
long - term expression of the transposase does not occur in mouse melanoma model as measured by survival . ( Solid 
the transgenic cells . Any transposase system may be used in square ) Heat inactivated PEG - Pf - KYNU . ( Solid circle ) 
accordance with the embodiments . In other aspects , cells Active PEG - Pf - KYNU . 
may be infected with a lentivirus to facilitate integration of 55 FIGS . 5A - B - Mice treated with heat - inactivated PEG 
the CAR coding sequence and the kynureninase coding Pf - KYNU . O Mice treated with active PEG - Pf - KYNU . 
sequence into the genome of the cell . FIG . 5A — The population of circulating CD4 + regulatory 
In one embodiment , a composition comprising a T - cell is significantly smaller in the group treated with active 
kynureninase or a nucleic acid encoding a kynureninase is PEG - Pf -KYNU . FIG . 5B — The population of tumor infil 
provided for use in the treatment of a tumor in a subject . In 60 trating CD8 + T - cells shows significantly higher expression 
another embodiment , the use of a kynureninase or a nucleic of granzyme B and interferon y . 
acid encoding a kynureninase in the manufacture of a FIG . 6 — Genetic selection for kynureninase activity in E . 
medicament for the treatment of a tumor is provided . Said coli . E . coli - AtrpE cells plated on M9 minimal media plates 
kynureninase may be any kynureninase of the embodiments . with filter paper disks soaked in L - Trp ( Trp ) , buffer ( - ) , 
Embodiments discussed in the context of methods and / or 65 anthranilic acid ( AA ) , or L - Kyn ( Kyn ) . 
compositions of the invention may be employed with respect FIG . 7 – In vitro stability of Mucilaginibacter paludis 
to any other method or composition described herein . Thus , kynureninase ( Mu - KYNU ) . Activity as a function of time of 
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Mu - KYNU ( open square ) in PBS at 37° C . with a T12 = 6 polypeptide thereof to fall by half in vitro or in vivo , for 
h with an amplitude of 74 % remaining activity and a example , after injection in a mammal . 
subsequent 2T1 / 2 = 150 h , and ( solid circle ) in pooled human The terms “ in operable combination , ” “ in operable order , " 
serum at 37° C . with a T12 = 5 h with an amplitude of 30 % and “ operably linked ” refer to a linkage wherein the com 
remaining activity and a subsequent ? T = 73 h . 5 ponents so described are in a relationship permitting them to 
FIG . 8 — Kaplan - Meier plot of B16 allografts in C57BL / function in their intended manner , for example , a linkage of 
6J treated with either PEG - Pf - KYNU ( - ) , deactivated nucleic acid sequences in such a manner that a nucleic acid 
PEG - Pf - KYNU ( - 60 ) , anti - PD1 ( . . . ) , or anti - CTLA - 4 molecule capable of directing the transcription of a given 
G ) . Arrows indicate treatment days , ( A ) indicates treatment gene and / or the synthesis of desired protein molecule , or a 
with antibody , ( E ) indicates treatment with enzyme . 10 linkage of amino acid sequences in such a manner so that a fusion protein is produced . FIGS . 9A - C - FIG . 9A - C57BL / 6J bearing B16 tumor The term “ linker " is meant to refer to a compound or allografts treated with PBS ( circle ) ( control ) , anti - PD1 alone moiety that acts as a molecular bridge to operably link two ( square ) , anti - PD1 / PEG - Mu - KYNU ( upside - down triangle ) , different molecules , wherein one portion of the linker is or anti - PD1 / PEG - Pf - KYNU ( right - side up triangle ) . FIG . 15 operably linked to a first molecule , and wherein another 9B — Additive effects were observed with anti - PD1 / PEG - Pf portion of the linker is operably linked to a second molecule . 
KYNU combination treatment eliminating 60 % of tumors The term “ PEGylated ” refers to conjugation with poly 
and anti - PD1 / PEG - Mu - KYNU combination eliminating ethylene glycol ( PEG ) , which has been widely used as a 
20 % of tumors compared to 0 % tumor elimination with drug carrier , given its high degree of biocompatibility and 
anti - PD1 alone . FIG . 9C — Corresponding Kaplan - Meier 20 ease of modification . PEG can be coupled ( e . g . , covalently 
plot . linked ) to active agents through the hydroxy groups at the 
FIGS . 10A - B - FIG . 10A - C57BL / 6J bearing B16 tumor end of the PEG chain via chemical methods ; however , PEG 
allografts treated with heat - inactivated PEG - Mu - KYNU ( D ) itself is limited to at most two active agents per molecule . In 
or active PEG - Mu - KYNU ( A ) . FIG . 10B - Corresponding a different approach , copolymers of PEG and amino acids 
Kaplan - Meier plot depicting a median survival time of 25 25 have been explored as novel biomaterial that would retain 
days for PEG - Mu - KYNU ( - - - ) , and median survival time of the biocompatibility of PEG , but that would have the added 
22 days for heat - inactivated PEG - Mu - KYNU G ) . Arrows advantage of numerous attachment points per molecule ( thus 
indicate treatment days . providing greater drug loading ) , and that can be syntheti cally designed to suit a variety of applications . 
DESCRIPTION OF ILLUSTRATIVE 30 The term “ gene ” refers to a DNA sequence that comprises 
EMBODIMENTS control and coding sequences necessary for the production 
of a polypeptide or precursor thereof . The polypeptide can 
Kynurenine is a metabolite of the amino acid tryptophan be encoded by a full - length coding sequence or by any 
generated via the action of either indolamine - 2 , 3 - dioxy portion of the coding sequence so as the desired enzymatic 
genase ( IDO ) or tryptophan - 2 , 3 - dioxygenase ( TDO ) . 35 activity is retained . 
Kynurenine exerts multiple effects on cell physiology , one of The term " native ” refers to the typical form of a gene , a 
the most important of which is modulation of T cell gene product , or a characteristic of that gene or gene product 
responses . Many tumor cells regulate the synthesis of IDO when isolated from a naturally occurring source . A native 
and / or TDO to elevate the local concentration of kynurenine , form is that which is most frequently observed in a natural 
which is accompanied with depletion of tryptophan . High 40 population and is thus arbitrarily designated the normal or 
levels of kynurenine serve as a powerful way to inhibit the wild - type form . In contrast , the term “ modified , " " variant , " 
function of tumor infiltrating T cells that would otherwise or “ mutant ” refers to a gene or gene product that displays 
attack the tumor . modification in sequence and functional properties ( i . e . , 
The present invention provides methods for the use of altered characteristics ) when compared to the native gene or 
kynurenine degrading enzymes as a means for depleting 45 gene product . 
local kynurenine levels in the tumor microenvironment as The term “ vector ” is used to refer to a carrier nucleic acid 
well as in the serum and thus prevent tumor - mediated molecule into which a nucleic acid sequence can be inserted 
suppression of T - cell action . Kynurenine hydrolyzing for introduction into a cell where it can be replicated . A 
enzymes ( kynureninases ) convert kynurenine to alanine and nucleic acid sequence can be " exogenous , " which means 
anthranilic acid , the latter of which is not known to affect 50 that it is foreign to the cell into which the vector is being 
T - cell function . The inventors generated a pharmaceutical introduced or that the sequence is homologous to a sequence 
preparation of kynureninase enzyme to enable the enzyme to in the cell but in a position within the host cell nucleic acid 
persist for prolonged times under physiological conditions . in which the sequence is ordinarily not found . Vectors 
The inventors then showed that intratumoral administration include plasmids , cosmids , viruses ( bacteriophage , animal 
of the enzyme results in dramatic retardation of growth of an 55 viruses , and plant viruses ) , and artificial chromosomes ( e . g . , 
aggressive tumor in mice . YACs ) . One of skill in the art would be well equipped to 
construct a vector through standard recombinant techniques 
I . DEFINITIONS ( see , for example , Maniatis et al . , 1988 and Ausubel et al . , 
1994 , both incorporated herein by reference ) . 
As used herein the terms " protein ” and “ polypeptide ” 60 The term " expression vector ” refers to any type of genetic 
refer to compounds comprising amino acids joined via construct comprising a nucleic acid coding for an RNA 
peptide bonds and are used interchangeably . capable of being transcribed . In some cases , RNA molecules 
As used herein , the term “ fusion protein ” refers to a are then translated into a protein , polypeptide , or peptide . In 
chimeric protein containing proteins or protein fragments other cases , these sequences are not translated , for example , 
operably linked in a non - native way . 65 in the production of antisense molecules or ribozymes . 
As used herein , the term “ half - life ” ( 1 / 2 - life ) refers to the Expression vectors can contain a variety of “ control 
time that would be required for the concentration of a sequences , ” which refer to nucleic acid sequences necessary 
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for the transcription and possibly translation of an operably “ Treatment ” and “ treating ” refer to administration or 
linked coding sequence in a particular host cell . In addition application of a therapeutic agent to a subject or perfor 
to control sequences that govern transcription and transla - mance of a procedure or modality on a subject for the 
tion , vectors and expression vectors may contain nucleic purpose of obtaining a therapeutic benefit of a disease or 
acid sequences that serve other functions as well and are 5 health - related condition . For example , a treatment may 
described infra . include administration of a pharmaceutically effective 
The term “ therapeutically effective amount ” as used amount of a kynureninase . 
herein refers to an amount of cells and / or therapeutic com “ Subject " and " patient ” refer to either a human or non 
position ( such as a therapeutic polynucleotide and / or thera - human , such as primates , mammals , and vertebrates . In 
peutic polypeptide ) that is employed in methods to achieve particular embodiments , the subject is a human . 
a therapeutic effect . The term “ therapeutic benefit ” or “ thera 
peutically effective ” as used throughout this application II . KYNURENINASE POLYPEPTIDES 
refers to anything that promotes or enhances the well - being 
of the subject with respect to the medical treatment of this . Some embodiments concern modified proteins and poly 
condition . This includes , but is not limited to , a reduction in peptides . Particular embodiments concern a modified pro 
the frequency or severity of the signs or symptoms of a tein or polypeptide that exhibits at least one functional 
disease . For example , treatment of cancer may involve , for activity that is comparable to the unmodified version , pref 
example , a reduction in the size of a tumor , a reduction in the erably , the kynurenine degrading activity or the 3 ' - hydroxy 
invasiveness of a tumor , reduction in the growth rate of the 20 kynurenine degrading activity . In further aspects , the protein 
cancer , or prevention of metastasis . Treatment of cancer may or polypeptide may be further modified to increase serum 
also refer to prolonging survival of a subject with cancer . stability . Thus , when the present application refers to the 
The term “ Ku ” as used herein refers to the Michaelis - function or activity of “ modified protein ” or a “ modified 
Menten constant for an enzyme and is defined as the polypeptide , ” one of ordinary skill in the art would under 
concentration of the specific substrate at which a given 25 stand that this includes , for example , a protein or polypep 
enzyme yields one - half its maximum velocity in an enzyme tide that possesses an additional advantage over the unmodi 
catalyzed reaction . The term “ k . cat " as used herein refers to fied protein or polypeptide , such as kynurenine degrading 
the turnover number or the number of substrate molecules activity or 3 ' - hydroxy - kynurenine degrading activity . In 
each enzyme site converts to product per unit time , and in certain embodiments , the unmodified protein or polypeptide 
which the enzyme is working at maximum efficiency . The 30 is a native kynureninase , preferably a human kynureninase 
term “ kcal / Ky ” as used herein is the specificity constant , or the Pseudomonas fluorescens kynureninase . It is specifi 
which is a measure of how efficiently an enzyme converts a cally contemplated that embodiments concerning a “ modi 
substrate into product . fied protein ” may be implemented with respect to a “ modi 
The term “ chimeric antigen receptors ( CARs ) , ” as used fied polypeptide , ” and vice versa . 
herein , may refer to artificial T - cell receptors , chimeric 35 Determination of activity may be achieved using assays 
T - cell receptors , or chimeric immunoreceptors , for example , familiar to those of skill in the art , particularly with respect 
and encompass engineered receptors that graft an artificial to the protein ' s activity , and may include for comparison 
specificity onto a particular immune effector cell . CARs may purposes , the use of native and / or recombinant versions of 
be employed to impart the specificity of a monoclonal either the modified or unmodified protein or polypeptide . 
antibody onto a T cell , thereby allowing a large number of 40 In certain embodiments , a modified polypeptide , such as 
specific T cells to be generated , for example , for use in a modified kynureninase , may be identified based on its 
adoptive cell therapy . In specific embodiments , CARs direct increase in kynurenine and / or 3 ' - hydroxy - kynurenine 
specificity of the cell to a tumor associated antigen , for degrading activity . For example , substrate recognition sites 
example . In some embodiments , CARs comprise an intra of the unmodified polypeptide may be identified . This iden 
cellular activation domain , a transmembrane domain , and an 45 tification may be based on structural analysis or homology 
extracellular domain comprising a tumor associated antigen analysis . A population of mutants involving modifications of 
binding region . In particular aspects , CARs comprise such substrate recognition sites may be generated . In a 
fusions of single - chain variable fragments ( scFv ) derived further embodiment , mutants with increased kynurenine 
from monoclonal antibodies ( such as those described in U . S . degrading activity may be selected from the mutant popu 
Pat . No . 7 , 109 , 304 , which is incorporated herein by refer - 50 lation . Selection of desired mutants may include methods , 
ence in its entirety ) , fused to CD3 - zeta transmembrane and such as detection of byproducts or products from kynurenine 
endodomains . The specificity of other CAR designs may be degradation . 
derived from ligands of receptors ( e . g . , peptides ) or from Modified proteins may possess deletions and / or substitu 
pattern - recognition receptors , such as Dectins . In particular tions of amino acids ; thus , a protein with a deletion , a protein 
embodiments , one can target malignant B cells by redirect - 55 with a substitution , and a protein with a deletion and a 
ing the specificity of T cells by using a CAR specific for the substitution are modified proteins . In some embodiments , 
B - lineage molecule , CD19 . In certain cases , the spacing of these modified proteins may further include insertions or 
the antigen - recognition domain can be modified to reduce added amino acids , such as with fusion proteins or proteins 
activation - induced cell death . In certain cases , CARs com - with linkers , for example . A “ modified deleted protein ” lacks 
prise domains for additional co - stimulatory signaling , such 60 one or more residues of the native protein , but may possess 
as CD3 - zeta , FcR , CD27 , CD28 , CD137 , DAP10 , and / or the specificity and / or activity of the native protein . A “ modi 
OX40 . In some cases , molecules can be co - expressed with fied deleted protein ” may also have reduced immunogenicity 
the CAR , including co - stimulatory molecules , reporter or antigenicity . An example of a modified deleted protein is 
genes for imaging ( e . g . , for positron emission tomography ) , one that has an amino acid residue deleted from at least one 
gene products that conditionally ablate the T cells upon 65 antigenic region that is , a region of the protein determined 
addition of a pro - drug , homing receptors , chemokines , to be antigenic in a particular organism , such as the type of 
chemokine receptors , cytokines , and cytokine receptors . organism that may be administered the modified protein . 
13 
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Substitution or replacement variants typically contain the tumors can include , but are not limited to , a tumor of an 
exchange of one amino acid for another at one or more sites organ selected from the group consisting of pancreas , colon , 
within the protein and may be designed to modulate one or cecum , stomach , brain , head , neck , ovary , kidney , larynx , 
more properties of the polypeptide , particularly its effector sarcoma , lung , bladder , melanoma , prostate , and breast . 
functions and / or bioavailability . Substitutions may or may 5 Exemplary hematological tumors include tumors of the bone 
not be conservative , that is , one amino acid is replaced with marrow , T or B cell malignancies , leukemias , lymphomas , 
one of similar shape and charge . Conservative substitutions blastomas , myelomas , and the like . Further examples of 
are well known in the art and include , for example , the cancers that may be treated using the methods provided 
changes of : alanine to serine ; arginine to lysine ; asparagine herein include , but are not limited to , carcinoma , lymphoma , 
to glutamine or histidine ; aspartate to glutamate ; cysteine to 10 blastoma , sarcoma , leukemia , squamous cell cancer , lung 
serine ; glutamine to asparagine ; glutamate to aspartate ; cancer ( including small - cell lung cancer , non - small cell lung 
glycine to proline ; histidine to asparagine or glutamine ; cancer , adenocarcinoma of the lung , and squamous carci 
isoleucine to leucine or valine ; leucine to valine or isoleu - noma of the lung ) , cancer of the peritoneum , hepatocellular 
cine ; lysine to arginine ; methionine to leucine or isoleucine ; cancer , gastric or stomach cancer ( including gastrointestinal 
phenylalanine to tyrosine , leucine , or methionine ; serine to 15 cancer and gastrointestinal stromal cancer ) , pancreatic can 
threonine ; threonine to serine ; tryptophan to tyrosine ; tyro cer , glioblastoma , cervical cancer , ovarian cancer , liver 
sine to tryptophan or phenylalanine ; and valine to isoleucine cancer , bladder cancer , breast cancer , colon cancer , colorec 
or leucine . tal cancer , endometrial or uterine carcinoma , salivary gland 
In addition to a deletion or substitution , a modified protein carcinoma , kidney or renal cancer , prostate cancer , vulval 
may possess an insertion of residues , which typically 20 cancer , thyroid cancer , various types of head and neck 
involves the addition of at least one residue in the polypep cancer , melanoma , superficial spreading melanoma , lentigo 
tide . This may include the insertion of a targeting peptide or malignant melanoma , acral lentiginous melanomas , nodular 
polypeptide or simply a single residue . Terminal additions , melanomas , as well as B - cell lymphoma ( including low 
called fusion proteins , are discussed below . grade / follicular non - Hodgkin ' s lymphoma ( NHL ) ; small 
The term “ biologically functional equivalent ” is well 25 lymphocytic ( SL ) NHL ; intermediate grade / follicular NHL ; 
understood in the art and is further defined in detail herein . intermediate grade diffuse NHL , high grade immunoblastic 
Accordingly , sequences that have between about 70 % and NHL ; high grade lymphoblastic NHL ; high grade small 
about 80 % , or between about 81 % and about 90 % , or even non - cleaved cell NHL ; bulky disease NHL ; mantle cell 
between about 91 % and about 99 % of amino acids that are lymphoma ; AIDS - related lymphoma ; and Waldenstrom ' s 
identical or functionally equivalent to the amino acids of a 30 macroglobulinemia ) , chronic lymphocytic leukemia ( CLL ) , 
control polypeptide are included , provided the biological acute lymphoblastic leukemia ( ALL ) , Hairy cell leukemia , 
activity of the protein is maintained . A modified protein may multiple myeloma , acute myeloid leukemia ( AML ) and 
be biologically functionally equivalent to its native coun - chronic myeloblastic leukemia . 
terpart in certain aspects . The cancer may specifically be of the following histo 
It also will be understood that amino acid and nucleic acid 35 logical type , though it is not limited to these : neoplasm , 
sequences may include additional residues , such as addi - malignant ; carcinoma ; carcinoma , undifferentiated ; giant 
tional N - or C - terminal amino acids or 5 ' or 3 ' sequences , and spindle cell carcinoma ; small cell carcinoma ; papillary 
and yet still be essentially as set forth in one of the sequences carcinoma ; squamous cell carcinoma ; lymphoepithelial car 
disclosed herein , so long as the sequence meets the criteria cinoma ; basal cell carcinoma ; pilomatrix carcinoma ; transi 
set forth above , including the maintenance of biological 40 tional cell carcinoma ; papillary transitional cell carcinoma ; 
protein activity where protein expression is concerned . The adenocarcinoma ; gastrinoma , malignant ; cholangiocarci 
addition of terminal sequences particularly applies to nucleic noma ; hepatocellular carcinoma ; combined hepatocellular 
acid sequences that may , for example , include various carcinoma and cholangiocarcinoma ; trabecular adenocarci 
non - coding sequences flanking either of the 5 ' or 3 ' portions noma ; adenoid cystic carcinoma ; adenocarcinoma in 
of the coding region or may include various internal 45 adenomatous polyp ; adenocarcinoma , familial polyposis 
sequences , i . e . , introns , which are known to occur within coli ; solid carcinoma ; carcinoid tumor , malignant ; bran 
genes . chiolo - alveolar adenocarcinoma ; papillary adenocarcinoma ; 
chromophobe carcinoma ; acidophil carcinoma ; oxyphilic 
III . ENZYMATIC KYNURENINE adenocarcinoma ; basophil carcinoma ; clear cell adenocar 
DEGRADATION FOR THERAPY 50 cinoma ; granular cell carcinoma ; follicular adenocarcinoma ; 
papillary and follicular adenocarcinoma ; nonencapsulating 
In certain aspects , the polypeptides may be used for the sclerosing carcinoma ; adrenal cortical carcinoma ; endo 
treatment of diseases , including cancers that are sensitive to metroid carcinoma ; skin appendage carcinoma ; apocrine 
kynurenine depletion , with enzymes that deplete kynure adenocarcinoma ; sebaceous adenocarcinoma ; ceruminous 
nine , to prevent tumor - mediated tolerogenic effects and 55 adenocarcinoma ; mucoepidermoid carcinoma ; cystadeno 
instead mediate tumor - ablating pro - inflammatory responses . carcinoma ; papillary cystadenocarcinoma ; papillary serous 
In certain aspects , kynureninases are contemplated for use in cystadenocarcinoma ; mucinous cystadenocarcinoma ; muci 
treating tumors expressing IDO1 , IDO2 , and / or TDO . nous adenocarcinoma ; signet ring cell carcinoma ; infiltrat 
Certain aspects of the present invention provide a modi - ing duct carcinoma ; medullary carcinoma ; lobular carci 
fied kynureninase for treating diseases , such as tumors . 60 noma ; inflammatory carcinoma ; paget ' s disease , mammary ; 
Particularly , the modified polypeptide may have human acinar cell carcinoma ; adenosquamous carcinoma ; adeno 
polypeptide sequences and thus may prevent allergic reac - carcinoma w / squamous metaplasia ; thymoma , malignant ; 
tions in human patients , allow repeated dosing , and increase ovarian stromal tumor , malignant ; thecoma , malignant ; 
the therapeutic efficacy . granulosa cell tumor , malignant ; androblastoma , malignant ; 
Tumors for which the present treatment methods are 65 sertoli cell carcinoma ; leydig cell tumor , malignant ; lipid 
useful include any malignant cell type , such as those found cell tumor , malignant ; paraganglioma , malignant ; extra 
in a solid tumor or a hematological tumor . Exemplary solid mammary paraganglioma , malignant ; pheochromocytoma ; 
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glomangiosarcoma ; malignant melanoma ; amelanotic mela typically depends upon the amount of kynurenine present in 
noma ; superficial spreading melanoma ; malignant mela the material , the desired rate of depletion , and the tolerance 
noma in giant pigmented nevus ; epithelioid cell melanoma ; of the material for exposure to kynureninase . Kynurenine 
blue nevus , malignant ; sarcoma ; fibrosarcoma ; fibrous his and kynurenine metabolite levels in a material , and therefore 
tiocytoma , malignant ; myxosarcoma ; liposarcoma ; leiomyo - 5 rates of kynurenine and kynurenine metabolite depletion 
sarcoma ; rhabdomyosarcoma ; embryonal rhabdomyosar from the material , can readily be monitored by a variety of 
coma ; alveolar rhabdomyosarcoma ; stromal sarcoma ; mixed chemical and biochemical methods well known in the art . tumor , malignant ; mullerian mixed tumor ; nephroblastoma ; Exemplary kynurenine - depleting amounts are described fur hepatoblastoma ; carcinosarcoma ; mesenchymoma , malig ther herein , and can range from 0 . 001 to 100 units ( U ) of nant ; brenner tumor , malignant ; phyllodes tumor , malignant ; 10 kynureninase , preferably about 0 . 01 to 10 U , and more synovial sarcoma ; mesothelioma , malignant ; dysgermi preferably about 0 . 1 to 5 U kyureninase per milliliter ( mL ) noma ; embryonal carcinoma ; teratoma , malignant ; struma of material to be treated . Typical dosages can be adminis ovarii , malignant ; choriocarcinoma ; mesonephroma , malig 
nant ; hemangiosarcoma ; hemangioendothelioma , malig tered based on body weight , and are in the range of about 
nant ; kaposi ' s sarcoma ; hemangiopericytoma , malignant ; 15 15 5 - 1000 U / kilogram ( kg ) / day , preferably about 5 - 100 U / kg 
lymphangiosarcoma ; osteosarcoma ; juxtacortical osteosar day , more preferably about 10 - 50 U / kg / day , and more pref 
coma ; chondrosarcoma ; chondroblastoma , malignant ; mes - erably about 20 - 40 U / kg / day . 
enchymal chondrosarcoma ; giant cell tumor of bone ; Kynurenine - depleting conditions are buffer and tempera 
ewing ' s sarcoma ; odontogenic tumor , malignant ; ameloblas - ture conditions compatible with the biological activity of a 
tic odontosarcoma ; ameloblastoma , malignant ; ameloblastic 20 kynureninase , and include moderate temperature , salt , and 
fibrosarcoma ; pinealoma , malignant ; chordoma ; glioma , pH conditions compatible with the enzyme , for example , 
malignant ; ependymoma ; astrocytoma ; protoplasmic astro - physiological conditions . Exemplary conditions include 
cytoma ; fibrillary astrocytoma ; astroblastoma ; glioblastoma ; about 4 - 40° C . , ionic strength equivalent to about 0 . 05 to 0 . 2 
oligodendroglioma ; oligodendroblastoma ; primitive neu M NaCl , and a pH of about 5 to 9 , while physiological 
roectodermal ; cerebellar sarcoma ; ganglioneuroblastoma ; 25 conditions are included . 
neuroblastoma ; retinoblastoma ; olfactory neurogenic tumor ; In a particular embodiment , the invention contemplates 
meningioma , malignant ; neurofibrosarcoma ; neurilem - methods of using a kynureninase as an antitumor agent , and 
moma , malignant ; granular cell tumor , malignant ; malignant therefore comprises contacting a population of tumor cells 
lymphoma ; hodgkin ' s disease ; hodgkin ' s ; paragranuloma ; with a therapeutically effective amount of kynureninase for 
malignant lymphoma , small lymphocytic ; malignant lym - 30 a time period sufficient to inhibit tumor cell growth . 
phoma , large cell , diffuse ; malignant lymphoma , follicular ; In one embodiment , the contacting in vivo is accom 
mycosis fungoides ; other specified non - hodgkin ' s lympho plished by administering , by intravenous intraperitoneal , or 
mas ; malignant histiocytosis ; multiple myeloma ; mast cell intratumoral injection , a therapeutically effective amount of 
sarcoma ; immunoproliferative small intestinal disease ; leu a physiologically tolerable composition comprising an 
kemia ; lymphoid leukemia ; plasma cell leukemia ; erythro - 35 kynureninase of this invention to a patient , thereby depleting 
leukemia ; lymphosarcoma cell leukemia ; myeloid leukemia ; the kynurenine source of the tumor cells present in the 
basophilic leukemia ; eosinophilic leukemia ; monocytic leu - patient . 
kemia ; mast cell leukemia ; megakaryoblastic leukemia ; A therapeutically effective amount of a kynureninase is a 
myeloid sarcoma ; and hairy cell leukemia . predetermined amount calculated to achieve the desired 
The kynureninase may be used herein as an antitumor 40 effect , i . e . , to deplete kynurenine in the tumor tissue or in a 
agent in a variety of modalities for depleting kynurenine patient ' s circulation , and thereby mediate a tumor - ablating 
and / or 3 ' - hydroxy - kynurenine from tumor tissue , or the pro - inflammatory response . Thus , the dosage ranges for the 
circulation of a mammal with cancer , or for depletion of administration of kynureninase of the invention are those 
kynurenine where its depletion is considered desirable . large enough to produce the desired effect in which the 
Depletion can be conducted in vivo in the circulation of 45 symptoms of tumor cell division and cell cycling are 
a mammal , in vitro in cases where kynurenine and 3 ' - hy - reduced . The dosage should not be so large as to cause 
droxy - kynurenine depletion in tissue culture or other bio - adverse side effects , such as hyperviscosity syndromes , 
logical mediums is desired , and in ex vivo procedures where pulmonary edema , congestive heart failure , neurological 
biological fluids , cells , or tissues are manipulated outside the effects , and the like . Generally , the dosage will vary with age 
body and subsequently returned to the body of the patient 50 of , condition of , sex of , and extent of the disease in the 
mammal . Depletion of kynurenine from circulation , culture patient and can be determined by one of skill in the art . The 
media , biological fluids , or cells is conducted to reduce the dosage can be adjusted by the individual physician in the 
amount of kynurenine accessible to the material being event of any complication . 
treated , and therefore comprises contacting the material to The kynureninase can be administered parenterally by 
be depleted with a kynurenine - depleting amount of the 55 injection or by gradual infusion over time . The kynureninase 
kynureninase under kynurenine - depleting conditions as to can be administered intravenously , intraperitoneally , orally , 
degrade the ambient kynurenine in the material being con - intramuscularly , subcutaneously , intracavity , transdermally , 
tacted dermally , can be delivered by peristaltic means , can be 
The depletion may be directed to the nutrient source for injected directly into the tissue containing the tumor cells , or 
the cells , and not necessarily the cells themselves . Therefore , 60 can be administered by a pump connected to a catheter that 
in an in vivo application , treating a tumor cell includes may contain a potential biosensor for kynurenine . 
contacting the nutrient medium for a population of tumor The therapeutic compositions containing kynureninase 
cells with the kynureninase . In this embodiment , the are conventionally administered intravenously , as by injec 
medium may be blood , lymphatic fluid , spinal fluid and the tion of a unit dose , for example . The term “ unit dose ” when 
like bodily fluid where kynurenine depletion is desired . 65 used in reference to a therapeutic composition refers to 
Kynurenine - and 3 ' - hydroxy - kynurenine - depleting effi - physically discrete units suitable as unitary dosage for the 
ciency can vary widely depending upon the application , and subject , each unit containing a predetermined quantity of 
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active material calculated to produce the desired therapeutic connected in tandem . The linker would be of sufficient 
effect in association with the required diluent , i . e . , carrier , or length to allow proper folding of the resulting fusion protein . 
vehicle . B . Linkers 
The compositions are administered in a manner compat - In certain embodiments , the kynureninase may be chemi 
ible with the dosage formulation , and in a therapeutically 5 cally conjugated using bifunctional cross - linking reagents or 
effective amount . The quantity to be administered depends fused at the protein level with peptide linkers . 
on the subject to be treated , capacity of the subject ' s system Bifunctional cross - linking reagents have been extensively 
to utilize the active ingredient , and degree of therapeutic used for a variety of purposes , including preparation of 
effect desired . Precise amounts of active ingredient required affinity matrices , modification and stabilization of diverse 
to be administered depend on the judgment of the practitio - 10 structures , identification of ligand and receptor binding sites , 
ner and are peculiar to each individual . However , suitable and structural studies . Suitable peptide linkers may also be 
dosage ranges for systemic application are disclosed herein used to link the kynureninase , such as Gly - Ser linkers . 
and depend on the route of administration . Suitable regimes Homobifunctional reagents that carry two identical func 
for initial administration and booster shots are also contem - tional groups proved to be highly efficient in inducing 
plated and are typified by an initial administration followed 15 cross - linking between identical and different macromol 
by repeated doses at one or more hour intervals by a ecules or subunits of a macromolecule , and linking of 
subsequent injection or other administration . Exemplary polypeptide ligands to their specific binding sites . Hetero 
multiple administrations are described herein and are par bifunctional reagents contain two different functional 
ticularly preferred to maintain continuously high serum and groups . By taking advantage of the differential reactivities of 
tissue levels of kynureninase and conversely low serum and 20 the two different functional groups , cross - linking can be 
tissue levels of kynurenine . Alternatively , continuous intra controlled both selectively and sequentially . The bifunc 
venous infusion sufficient to maintain concentrations in the tional cross - linking reagents can be divided according to the 
blood in the ranges specified for in vivo therapies are specificity of their functional groups , e . g . , amino - , sulfhy 
contemplated . dryl - , guanidine - , indole - , carboxyl - specific groups . Of 
25 these , reagents directed to free amino groups have become 
IV . CONJUGATES especially popular because of their commercial availability , 
ease of synthesis , and the mild reaction conditions under 
Compositions and methods of the present invention which they can be applied . 
involve modified kynureninases , such as by forming conju - A majority of heterobifunctional cross - linking reagents 
gates with heterologous peptide segments or polymers , such 30 contain a primary amine - reactive group and a thiol - reactive 
as polyethylene glycol . In further aspects , the kynureninases group . In another example , heterobifunctional cross - linking 
may be linked to PEG to increase the hydrodynamic radius reagents and methods of using the cross - linking reagents are 
of the enzyme and hence increase the serum persistence . In described ( U . S . Pat . No . 5 , 889 , 155 , specifically incorporated 
certain aspects , the disclosed polypeptide may be conjugated herein by reference in its entirety ) . The cross - linking 
to any targeting agent , such as a ligand having the ability to 35 reagents combine a nucleophilic hydrazide residue with an 
specifically and stably bind to an external receptor or electrophilic maleimide residue , allowing coupling , in one 
binding site on a tumor cell ( U . S . Patent Publ . 2009 / example , of aldehydes to free thiols . The cross - linking 
0304666 ) . reagent can be modified to cross - link various functional 
A . Fusion Proteins groups . 
Certain embodiments of the present invention concern 40 Additionally , any other linking / coupling agents and / or 
fusion proteins . These molecules may have a native or mechanisms known to those of skill in the art may be used 
modified kynureninase linked at the N - or C - terminus to a to combine kynureninase , such as , for example , antibody 
heterologous domain . For example , fusions may also antigen interaction , avidin biotin linkages , amide linkages , 
employ leader sequences from other species to permit the ester linkages , thioester linkages , ether linkages , thioether 
recombinant expression of a protein in a heterologous host . 45 linkages , phosphoester linkages , phosphoramide linkages , 
Another useful fusion includes the addition of a protein anhydride linkages , disulfide linkages , ionic and hydropho 
affinity tag , such as a serum albumin affinity tag or six bic interactions , bispecific antibodies and antibody frag 
histidine residues , or an immunologically active domain , ments , or combinations thereof . 
such as an antibody epitope , preferably cleavable , to facili - It is preferred that a cross - linker having reasonable sta 
tate purification of the fusion protein . Non - limiting affinity 50 bility in blood will be employed . Numerous types of disul 
tags include polyhistidine , chitin binding protein ( CBP ) , fide - bond containing linkers are known that can be success 
maltose binding protein ( MBP ) , and glutathione - S - trans - fully employed to conjugate targeting and therapeutic / 
ferase ( GST ) . preventative agents . Linkers that contain a disulfide bond 
In a particular embodiment , the kynureninase may be that is sterically hindered may prove to give greater stability 
linked to a peptide that increases the in vivo half - life , such 55 in vivo . These linkers are thus one group of linking agents . 
as an XTEN polypeptide ( Schellenberger et al . , 2009 ) , IgG In addition to hindered cross - linkers , non - hindered linkers 
Fc domain , albumin , or albumin binding peptide . also can be employed in accordance herewith . Other useful 
Methods of generating fusion proteins are well known to cross - linkers , not considered to contain or generate a pro 
those of skill in the art . Such proteins can be produced , for tected disulfide , include SATA , SPDP , and 2 - iminothiolane 
example , by de novo synthesis of the complete fusion 60 ( Wawrzynczak and Thorpe , 1987 ) . The use of such cross 
protein , or by attachment of the DNA sequence encoding the linkers is well understood in the art . Another embodiment 
heterologous domain , followed by expression of the intact involves the use of flexible linkers . 
fusion protein . Once chemically conjugated , the peptide generally will be 
Production of fusion proteins that recover the functional purified to separate the conjugate from unconjugated agents 
activities of the parent proteins may be facilitated by con - 65 and from other contaminants . A large number of purification 
necting genes with a bridging DNA segment encoding a techniques are available for use in providing conjugates of 
peptide linker that is spliced between the polypeptides a sufficient degree of purity to render them clinically useful . 
19 
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Purification methods based upon size separation , such as line pH but each has some drawbacks . The thioether formed 
gel filtration , gel permeation , or high performance liquid with the maleimides can be somewhat unstable under alka 
chromatography , will generally be of most use . Other chro - line conditions so there may be some limitation to formu 
matographic techniques , such as Blue - Sepharose separation , lation options with this linker . The carbamothioate linkage 
may also be used . Conventional methods to purify the fusion 5 formed with iodo PEGs is more stable , but free iodine can 
proteins from inclusion bodies may be useful , such as using modify tyrosine residues under some conditions . PEG thiols 
weak detergents , such as sodium N - lauroyl - sarcosine ( SLS ) . form disulfide bonds with protein thiols , but this linkage can 
C . PEGylation also be unstable under alkaline conditions . PEG - vinylsul 
In certain aspects of the invention , methods and compo - fone reactivity is relatively slow compared to maleimide and 
sitions related to PEGylation of kynureninase are disclosed . 10 iodo PEG ; however , the thioether linkage formed is quite 
For example , the kynureninase may be PEGylated in accor - stable . Its slower reaction rate also can make the PEG 
dance with the methods disclosed herein . vinylsulfone reaction easier to control . 
PEGylation is the process of covalent attachment of Site - specific PEGylation at native cysteinyl residues is 
poly ( ethylene glycol ) polymer chains to another molecule , seldom carried out , since these residues are usually in the 
normally a drug or therapeutic protein . PEGylation is rou - 15 form of disulfide bonds or are required for biological activ 
tinely achieved by incubation of a reactive derivative of ity . On the other hand , site - directed mutagenesis can be used 
PEG with the target macromolecule . The covalent attach - to incorporate cysteinyl PEGylation sites for thiol - specific 
ment of PEG to a drug or therapeutic protein can “ mask ” the linkers . The cysteine mutation must be designed such that it 
agent from the host ' s immune system ( reduced immunoge - is accessible to the PEGylation reagent and is still biologi 
nicity and antigenicity ) or increase the hydrodynamic size 20 cally active after PEGylation . 
( size in solution ) of the agent , which prolongs its circulatory Amine - specific modification agents include PEG NHS 
time by reducing renal clearance . PEGylation can also ester , PEG tresylate , PEG aldehyde , PEG isothiocyanate , 
provide water solubility to hydrophobic drugs and proteins . and several others . All react under mild conditions and are 
The first step of the PEGylation is the suitable function - very specific for amino groups . The PEG NHS ester is 
alization of the PEG polymer at one or both terminals . PEGs 25 probably one of the more reactive agents ; however , its high 
that are activated at each terminus with the same reactive reactivity can make the PEGylation reaction difficult to 
moiety are known as “ homobifunctional , " whereas if the control on a large scale . PEG aldehyde forms an imine with 
functional groups present are different , then the PEG deriva - the amino group , which is then reduced to a secondary 
tive is referred as " heterobifunctional ” or “ heterofunc - amine with sodium cyanoborohydride . Unlike sodium boro 
tional . ” The chemically active or activated derivatives of the 30 hydride , sodium cyanoborohydride will not reduce disulfide 
PEG polymer are prepared to attach the PEG to the desired bonds . However , this chemical is highly toxic and must be 
molecule . handled cautiously , particularly at lower pH where it 
The choice of the suitable functional group for the PEG becomes volatile . 
derivative is based on the type of available reactive group on Due to the multiple lysine residues on most proteins , 
the molecule that will be coupled to the PEG . For proteins , 35 site - specific PEGylation can be a challenge . Fortunately , 
typical reactive amino acids include lysine , cysteine , histi - because these reagents react with unprotonated amino 
dine , arginine , aspartic acid , glutamic acid , serine , threonine , groups , it is possible to direct the PEGylation to lower - pK 
and tyrosine . The N - terminal amino group and the C - termi - amino groups by performing the reaction at a lower pH . 
nal carboxylic acid can also be used . Generally the pK of the alpha - amino group is 1 - 2 pH units 
The techniques used to form first generation PEG deriva - 40 lower than the epsilon - amino group of lysine residues . By 
tives are generally reacting the PEG polymer with a group PEGylating the molecule at pH 7 or below , high selectivity 
that is reactive with hydroxyl groups , typically anhydrides , for the N - terminus frequently can be attained . However , this 
acid chlorides , chloroformates , and carbonates . In the sec is only feasible if the N - terminal portion of the protein is not 
ond generation PEGylation chemistry more efficient func required for biological activity . Still , the pharmacokinetic 
tional groups , such as aldehyde , esters , amides , etc . , are 45 benefits from PEGylation frequently outweigh a significant 
made available for conjugation . loss of in vitro bioactivity , resulting in a product with much 
As applications of PEGylation have become more and greater in vivo bioactivity regardless of PEGylation chem 
more advanced and sophisticated , there has been an increase istry . 
in need for heterobifunctional PEGs for conjugation . These There are several parameters to consider when developing 
heterobifunctional PEGs are very useful in linking two 50 a PEGylation procedure . Fortunately , there are usually no 
entities , where a hydrophilic , flexible , and biocompatible more than four or five key parameters . The " design of 
spacer is needed . Preferred end groups for heterobifunc - experiments ” approach to optimization of PEGylation con 
tional PEGs are maleimide , vinyl sulfones , pyridyl disulfide , ditions can be very useful . For thiol - specific PEGylation 
amine , carboxylic acids , and NHS esters . reactions , parameters to consider include : protein concen 
The most common modification agents , or linkers , are 55 tration , PEG - to - protein ratio ( on a molar basis ) , temperature , 
based on methoxy PEG ( mPEG ) molecules . Their activity pH , reaction time , and in some instances , the exclusion of 
depends on adding a protein - modifying group to the alcohol oxygen . ( Oxygen can contribute to intermolecular disulfide 
end . In some instances polyethylene glycol ( PEG diol ) is formation by the protein , which will reduce the yield of the 
used as the precursor molecule . The diol is subsequently PEGylated product . ) The same factors should be considered 
modified at both ends in order to make a hetero - or homo - 60 ( with the exception of oxygen ) for amine - specific modifi 
dimeric PEG - linked molecule . cation except that pH may be even more critical , particularly 
Proteins are generally PEGylated at nucleophilic sites , when targeting the N - terminal amino group . 
such as unprotonated thiols ( cysteinyl residues ) or amino For both amine - and thiol - specific modifications , the 
groups . Examples of cysteinyl - specific modification reaction conditions may affect the stability of the protein . 
reagents include PEG maleimide , PEG iodoacetate , PEG 65 This may limit the temperature , protein concentration , and 
thiols , and PEG vinylsulfone . All four are strongly cysteinyl - pH . In addition , the reactivity of the PEG linker should be 
specific under mild conditions and neutral to slightly alka known before starting the PEGylation reaction . For 
de 
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example , if the PEGylation agent is only 70 percent active , VII . Host Cells 
the amount of PEG used should ensure that only active PEG 
molecules are counted in the protein - to - PEG reaction stoi Host cells may be any that may be transformed to allow 
chiometry . the expression and secretion of kynureninase and conjugates 
5 thereof . The host cells may be bacteria , mammalian cells , 
V . PROTEINS AND PEPTIDES yeast , or filamentous fungi . Various bacteria include 
Escherichia and Bacillus . Yeasts belonging to the genera 
In certain embodiments , the present invention concerns Saccharomyces , Kiuyveromyces , Hansenula , or Pichia 
novel compositions comprising at least one protein or pep would find use as an appropriate host cell . Various species of 
tide , such as a kynureninase . These peptides may be com - 10 filamentous fungi may be used as expression hosts , includ 
prised in a fusion protein or conjugated to an agent as ing the following genera : Aspergillus , Trichoderma , Neuro 
described supra . spora , Penicillium , Cephalosporium , Achlya , Podospora , 
As used herein , a protein or peptide generally refers , but Endothia , Mucor , Cochliobolus , and Pyricularia . Examples of usable host organisms include bacteria , e . g . , is not limited to , a protein of greater than about 200 amino 
acids , up to a full length sequence translated from a gene ; a 15 Escherichia coli MC1061 , derivatives of Bacillus subtilis BRB1 ( Sibakov et al . , 1984 ) , Staphylococcus aureus polypeptide of greater than about 100 amino acids ; and / or a SAI123 ( Lordanescu , 1975 ) or Streptococcus lividans ( Hop peptide of from about 3 to about 100 amino acids . For wood et al . , 1985 ) ; yeasts , e . g . , Saccharomyces cerevisiae 
convenience , the terms protein , " " polypeptide , " and " pep - AH 22 ( Mellor et al . , 1983 ) or Schizosaccharomyces pombe : 
tide ” are used interchangeably herein . 20 and filamentous fungi , e . g . , Aspergillus nidulans , Aspergil 
As used herein , an “ amino acid residue ” refers to any lus awamori ( Ward , 1989 ) , or Trichoderma reesei ( Penttila 
naturally occurring amino acid , any amino acid derivative , et al . , 1987 : Harkki et al . , 1989 ) . 
or any amino acid mimic known in the art . In certain Examples of mammalian host cells include Chinese ham 
embodiments , the residues of the protein or peptide are ster ovary cells ( CHO - K1 ; ATCC CCL61 ) , rat pituitary cells 
sequential , without any non - amino acids interrupting the 25 ( GH1 ; ATCC CCL82 ) , HeLa S3 cells ( ATCC CCL2 . 2 ) , rat 
sequence of amino acid residues . In other embodiments , the hepatoma cells ( H - 4 - II - E ; ATCCCRL 1548 ) , SV40 - trans 
sequence may comprise one or more non - amino acid moi - formed monkey kidney cells ( COS - 1 ; ATCC CRL 1650 ) , 
eties . In particular embodiments , the sequence of residues of and murine embryonic cells ( NIH - 3T3 ; ATCC CRL 1658 ) . 
the protein or peptide may be interrupted by one or more The foregoing being illustrative but not limitative of the 
non - amino acid moieties . 30 many possible host organisms known in the art . In principle , 
Accordingly , the term “ protein or peptide ” encompasses all hosts capable of secretion can be used whether prokary 
amino acid sequences comprising at least one of the 20 otic or eukaryotic . 
common amino acids found in naturally occurring proteins , Mammalian host cells expressing the kynureninase and / or 
or at least one modified or unusual amino acid . their fusion proteins are cultured under conditions typically 
Proteins or peptides may be made by any technique 35 employed to culture the parental cell line . Generally , cells 
known to those of skill in the art , including the expression are cultured in a standard medium containing physiological 
of proteins , polypeptides , or peptides through standard salts and nutrients , such as standard RPMI , MEM , IMEM , or 
molecular biological techniques , the isolation of proteins or DMEM , typically supplemented with 5 % - 10 % serum , such 
peptides from natural sources , or the chemical synthesis of as fetal bovine serum . Culture conditions are also standard , 
proteins or peptides . The nucleotide and protein , polypep - 40 e . g . , cultures are incubated at 37° C . in stationary or roller 
tide , and peptide sequences corresponding to various genes cultures until desired levels of the proteins are achieved . 
have been previously disclosed , and may be found at com 
puterized databases known to those of ordinary skill in the VIII . Protein Purification 
art . One such database is the National Center for Biotech 
nology Information ' s Genbank and GenPept databases 45 Protein purification techniques are well known to those of 
( available on the world wide web at ncbi . nlm . nih . gov / ) . The skill in the art . These techniques involve , at one level , the 
coding regions for known genes may be amplified and / or homogenization and crude fractionation of the cells , tissue , 
expressed using the techniques disclosed herein or as would or organ to polypeptide and non - polypeptide fractions . The 
be known to those of ordinary skill in the art . Alternatively , protein or polypeptide of interest may be further purified 
various commercial preparations of proteins , polypeptides , 50 using chromatographic and electrophoretic techniques to 
and peptides are known to those of skill in the art . achieve partial or complete purification ( or purification to 
homogeneity ) unless otherwise specified . Analytical meth 
VI . Nucleic Acids and Vectors ods particularly suited to the preparation of a pure peptide 
are ion - exchange chromatography , gel exclusion chroma 
In certain aspects of the invention , nucleic acid sequences 55 tography , polyacrylamide gel electrophoresis , affinity chro 
encoding a kynureninase or a fusion protein containing a matography , immunoaffinity chromatography , and isoelec 
kynureninase may be disclosed . Depending on which tric focusing . A particularly efficient method of purifying 
expression system is used , nucleic acid sequences can be peptides is fast - performance liquid chromatography ( FPLC ) 
selected based on conventional methods . For example , if the or even high - performance liquid chromatography ( HPLC ) . 
kynureninase is derived from human kynureninase and 60 A purified protein or peptide is intended to refer to a 
contains multiple codons that are rarely utilized in E . coli , composition , isolatable from other components , wherein the 
then that may interfere with expression . Therefore , the protein or peptide is purified to any degree relative to its 
respective genes or variants thereof may be codon optimized naturally - obtainable state . An isolated or purified protein or 
for E . coli expression . Various vectors may be also used to peptide , therefore , also refers to a protein or peptide free 
express the protein of interest . Exemplary vectors include , 65 from the environment in which it may naturally occur . 
but are not limited , plasmid vectors , viral vectors , transpo - Generally , “ purified ” will refer to a protein or peptide 
son , or liposome - based vectors . composition that has been subjected to fractionation to 
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remove various other components , and which composition physical , and thermal stability . The ligand should be coupled 
substantially retains its expressed biological activity . Where in such a way as to not affect its binding properties . The 
the term “ substantially purified ” is used , this designation ligand should also provide relatively tight binding . It should 
will refer to a composition in which the protein or peptide be possible to elute the substance without destroying the 
forms the major component of the composition , such as 5 sample or the ligand . 
constituting about 50 % , about 60 % , about 70 % , about 80 % , Size exclusion chromatography ( SEC ) is a chromato 
about 90 % , about 95 % , or more of the proteins in the graphic method in which molecules in solution are separated 
composition . based on their size , or in more technical terms , their hydro 
Various techniques suitable for use in protein purification dynamic volume . It is usually applied to large molecules or 
are well known to those of skill in the art . These include , for 10 macromolecular complexes , such as proteins and industrial 
example , precipitation with ammonium sulphate , PEG , anti - polymers . Typically , when an aqueous solution is used to 
bodies and the like , or by heat denaturation , followed by transport the sample through the column , the technique is 
centrifugation ; chromatography steps , such as ion exchange , known as gel filtration chromatography , versus the name gel 
gel filtration , reverse phase , hydroxyapatite , and affinity permeation chromatography , which is used when an organic 
chromatography ; isoelectric focusing ; gel electrophoresis ; 15 solvent is used as a mobile phase . 
and combinations of these and other techniques . As is The underlying principle of SEC is that particles of 
generally known in the art , it is believed that the order of different sizes will elute ( filter ) through a stationary phase at 
conducting the various purification steps may be changed , or different rates . This results in the separation of a solution of 
that certain steps may be omitted , and still result in a suitable particles based on size . Provided that all the particles are 
method for the preparation of a substantially purified protein 20 loaded simultaneously or near simultaneously , particles of 
or peptide . the same size should elute together . Each size exclusion 
Various methods for quantifying the degree of purification column has a range of molecular weights that can be 
of the protein or peptide are known to those of skill in the separated . The exclusion limit defines the molecular weight 
art in light of the present disclosure . These include , for at the upper end of this range and is where molecules are too 
example , determining the specific activity of an active 25 large to be trapped in the stationary phase . The permeation 
fraction , or assessing the amount of polypeptides within a limit defines the molecular weight at the lower end of the 
fraction by SDS / PAGE analysis . A preferred method for range of separation and is where molecules of a small 
assessing the purity of a fraction is to calculate the specific enough size can penetrate into the pores of the stationary 
activity of the fraction , to compare it to the specific activity phase completely and all molecules below this molecular 
of the initial extract , and to thus calculate the degree of 30 mass are so small that they elute as a single band . 
purity therein , assessed by a “ - fold purification number . ” High - performance liquid chromatography ( or high - pres 
The actual units used to represent the amount of activity sure liquid chromatography , HPLC ) is a form of column 
will , of course , be dependent upon the particular assay chromatography used frequently in biochemistry and ana 
technique chosen to follow the purification , and whether or lytical chemistry to separate , identify , and quantify com 
not the expressed protein or peptide exhibits a detectable 35 pounds . HPLC utilizes a column that holds chromatographic 
activity . packing material ( stationary phase ) , a pump that moves the 
There is no general requirement that the protein or peptide mobile phase ( s ) through the column , and a detector that 
will always be provided in its most purified state . Indeed , it shows the retention times of the molecules . Retention time 
is contemplated that less substantially purified products may varies depending on the interactions between the stationary 
have utility in certain embodiments . Partial purification may 40 phase , the molecules being analyzed , and the solvent ( s ) 
be accomplished by using fewer purification steps in com - used . 
bination , or by utilizing different forms of the same general 
purification scheme . For example , it is appreciated that a IX . Pharmaceutical Compositions 
cation - exchange column chromatography performed utiliz 
ing an HPLC apparatus will generally result in a greater 45 It is contemplated that the novel kynureninase can be 
" - fold ” purification than the same technique utilizing a low administered systemically or locally to inhibit tumor cell 
pressure chromatography system . Methods exhibiting a growth and , most preferably , to kill cancer cells in cancer 
lower degree of relative purification may have advantages in patients with locally advanced or metastatic cancers . They 
total recovery of protein product , or in maintaining the can be administered intravenously , intrathecally , and / or 
activity of an expressed protein . 50 intraperitoneally . They can be administered alone or in 
In certain embodiments a protein or peptide may be combination with anti - proliferative drugs . In one embodi 
isolated or purified , for example , a kynureninase , a fusion ment , they are administered to reduce the cancer load in the 
protein containing a kynureninase , or a modified kynureni - patient prior to surgery or other procedures . Alternatively , 
nase post PEGylation . For example , a His tag or an affinity they can be administered after surgery to ensure that any 
epitope may be comprised in such a kynureninase to facili - 55 remaining cancer ( e . g . , cancer that the surgery failed to 
tate purification . Affinity chromatography is a chromato - eliminate ) does not survive . 
graphic procedure that relies on the specific affinity between It is not intended that the present invention be limited by 
a substance to be isolated and a molecule to which it can the particular nature of the therapeutic preparation . For 
specifically bind . This is a receptor - ligand type of interac - example , such compositions can be provided in formulations 
tion . The column material is synthesized by covalently 60 together with physiologically tolerable liquid , gel , or solid 
coupling one of the binding partners to an insoluble matrix . carriers , diluents , and excipients . These therapeutic prepa 
The column material is then able to specifically adsorb the rations can be administered to mammals for veterinary use , 
substance from the solution . Elution occurs by changing the such as with domestic animals , and clinical use in humans 
conditions to those in which binding will not occur ( e . g . , in a manner similar to other therapeutic agents . In general , 
altered pH , ionic strength , temperature , etc . ) . The matrix 65 the dosage required for therapeutic efficacy will vary accord 
should be a substance that does not adsorb molecules to any ing to the type of use and mode of administration , as well as 
significant extent and that has a broad range of chemical , the particularized requirements of individual subjects . 
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Such compositions are typically prepared as liquid solu - hydroxides ; or such organic bases as isopropylamine , trim 
tions or suspensions , as injectables . Suitable diluents and ethylamine , histidine , or procaine . Upon formulation , solu 
excipients are , for example , water , saline , dextrose , glycerol , tions will be administered in a manner compatible with the 
or the like , and combinations thereof . In addition , if desired , dosage formulation and in such amount as is therapeutically 
the compositions may contain minor amounts of auxiliary 5 effective . The formulations are easily administered in a 
substances , such as wetting or emulsifying agents , stabiliz variety of dosage forms , such as formulated for parenteral ing agents , or pH buffering agents . administrations , such as injectable solutions , or aerosols for 
Where clinical applications are contemplated , it may be delivery to the lungs , or formulated for alimentary admin necessary to prepare pharmaceutical compositions compris istrations , such as drug release capsules and the like . ing proteins , antibodies , and drugs in a form appropriate for 10 Further in accordance with certain aspects of the present the intended application . Generally , pharmaceutical compo invention , the composition suitable for administration may sitions may comprise an effective amount of one or more be provided in a pharmaceutically acceptable carrier with or kynureninase or additional agents dissolved or dispersed in 
a pharmaceutically acceptable carrier . The phrases “ phar without an inert diluent . The carrier should be assimilable 
maceutical or pharmacologically acceptable ” refers to 15 and is and includes liquid , semi - solid , i . e . , pastes , or solid carriers . 
molecular entities and compositions that do not produce an Except insofar as any conventional media , agent , diluent , or 
adverse , allergic , or other untoward reaction when admin carrier is detrimental to the recipient or to the therapeutic 
istered to an animal , such as , for example , a human , as effectiveness of a the composition contained therein , its use 
appropriate . The preparation of a pharmaceutical composi in administrable composition for use in practicing the meth 
tion that contains at least one kyureninase isolated by the 20 ods is appropriate . Examples of carriers or diluents include 
method disclosed herein , or additional active ingredient will fats , oils , water , saline solutions , lipids , liposomes , resins , 
be known to those of skill in the art in light of the present binders , fillers , and the like , or combinations thereof . The 
disclosure , as exemplified by Remington ' s Pharmaceutical composition may also comprise various antioxidants to 
Sciences , 18th Ed . , 1990 , incorporated herein by reference . retard oxidation of one or more component . Additionally , the 
Moreover , for animal ( e . g . , human ) administration , it will be 25 prevention of the action of microorganisms can be brought 
understood that preparations should meet sterility , pyroge - about by preservatives , such as various antibacterial and 
nicity , general safety , and purity standards as required by the antifungal agents , including but not limited to parabens ( e . g . , 
FDA Office of Biological Standards . methylparabens , propylparabens ) , chlorobutanol , phenol , 
As used herein , " pharmaceutically acceptable carrier ” sorbic acid , thimerosal or combinations thereof . 
includes any and all solvents , dispersion media , coatings , 30 In accordance with certain aspects of the present inven 
surfactants , antioxidants , preservatives ( e . g . , antibacterial tion , the composition is combined with the carrier in any 
agents , antifungal agents ) , isotonic agents , absorption delay - convenient and practical manner , i . e . , by solution , suspen 
ing agents , salts , preservatives , drugs , drug stabilizers , gels , sion , emulsification , admixture , encapsulation , absorption , 
binders , excipients , disintegration agents , lubricants , sweet and the like . Such procedures are routine for those skilled in 
ening agents , flavoring agents , dyes , such like materials and 35 the art . 
combinations thereof , as would be known to one of ordinary In a specific embodiment of the present invention , the 
skill in the art ( see , for example , Remington ' s Pharmaceu composition is combined or mixed thoroughly with a semi 
tical Sciences , 18th Ed . , 1990 , incorporated herein by ref - solid or solid carrier . The mixing can be carried out in any 
erence ) . Except insofar as any conventional carrier is incom convenient manner , such as grinding . Stabilizing agents can 
patible with the active ingredient , its use in the 40 be also added in the mixing process in order to protect the 
pharmaceutical compositions is contemplated . composition from loss of therapeutic activity , i . e . , denatur 
Certain embodiments of the present invention may com - ation in the stomach . Examples of stabilizers for use in a 
prise different types of carriers depending on whether it is to composition include buffers , amino acids , such as glycine 
be administered in solid , liquid , or aerosol form , and and lysine , carbohydrates , such as dextrose , mannose , galac 
whether it needs to be sterile for the route of administration , 45 tose , fructose , lactose , sucrose , maltose , sorbitol , mannitol , 
such as injection . The compositions can be administered etc . 
intravenously , intradermally , transdermally , intrathecally , In further embodiments , the present invention may con 
intraarterially , intraperitoneally , intranasally , intravaginally , cern the use of a pharmaceutical lipid vehicle composition 
intrarectally , intramuscularly , subcutaneously , mucosally , that includes kynureninases , one or more lipids , and an 
orally , topically , locally , by inhalation ( e . g . , aerosol inhala - 50 aqueous solvent . As used herein , the term " lipid ” will be 
tion ) , by injection , by infusion , by continuous infusion , by defined to include any of a broad range of substances that is 
localized perfusion bathing target cells directly , via a cath characteristically insoluble in water and extractable with an 
eter , via a lavage , in lipid compositions ( e . g . , liposomes ) , or organic solvent . This broad class of compounds is well 
by other methods or any combination of the forgoing as known to those of skill in the art , and as the term “ lipid ” is 
would be known to one of ordinary skill in the art ( see , for 55 used herein , it is not limited to any particular structure . 
example , Remington ' s Pharmaceutical Sciences , 18th Ed . , Examples include compounds that contain long - chain ali 
1990 , incorporated herein by reference ) . phatic hydrocarbons and their derivatives . A lipid may be 
The modified polypeptides may be formulated into a naturally occurring or synthetic ( i . e . , designed or produced 
composition in a free base , neutral , or salt form . Pharma - by man ) . However , a lipid is usually a biological substance . 
ceutically acceptable salts include the acid addition salts , 60 Biological lipids are well known in the art , and include for 
e . g . , those formed with the free amino groups of a proteina - example , neutral fats , phospholipids , phosphoglycerides , 
ceous composition , or which are formed with inorganic steroids , terpenes , lysolipids , glycosphingolipids , glycolip 
acids , such as , for example , hydrochloric or phosphoric i ds , sulphatides , lipids with ether - and ester - linked fatty 
acids , or such organic acids as acetic , oxalic , tartaric , or acids , polymerizable lipids , and combinations thereof . Of 
mandelic acid . Salts formed with the free carboxyl groups 65 course , compounds other than those specifically described 
can also be derived from inorganic bases , such as , for herein that are understood by one of skill in the art as lipids 
example , sodium , potassium , ammonium , calcium , or ferric a re also encompassed by the compositions and methods . 
27 
ma 
US 9 , 975 , 959 B2 
28 
One of ordinary skill in the art would be familiar with the disease that is associated with kynurenine dependency . For 
range of techniques that can be employed for dispersing a example , the disease may be cancer . 
composition in a lipid vehicle . For example , the kynureni - The methods and compositions , including combination 
nase or a fusion protein thereof may be dispersed in a therapies , enhance the therapeutic or protective effect , and / 
solution containing a lipid , dissolved with a lipid , emulsified 5 or increase the therapeutic effect of another anti - cancer or 
with a lipid , mixed with a lipid , combined with a lipid , anti - hyperproliferative therapy . Therapeutic and prophylac 
covalently bonded to a lipid , contained as a suspension in a tic methods and compositions can be provided in a com 
lipid , contained or complexed with a micelle or liposome , or bined amount effective to achieve the desired effect , such as 
otherwise associated with a lipid or lipid structure by any the killing of a cancer cell and / or the inhibition of cellular 
means known to those of ordinary skill in the art . The hyperproliferation . This process may involve administering 
dispersion may or may not result in the formation of a kynureninase and a second therapy . The second therapy 
liposomes . may or may not have a direct cytotoxic effect . For example , 
The actual dosage amount of a composition administered the second therapy may be an agent that upregulates the 
to an animal patient can be determined by physical and 15 immune system without having a direct cytotoxic effect . A 
physiological factors , such as body weight , severity of tissue , tumor , or cell can be exposed to one or more 
condition , the type of disease being treated , previous or compositions or pharmacological formulation ( s ) comprising 
concurrent therapeutic interventions , idiopathy of the one or more of the agents ( e . g . , a kynureninase or an 
patient , and on the route of administration . Depending upon anti - cancer agent ) , or by exposing the tissue , tumor , and / or 
the dosage and the route of administration , the number of 20 cell with two or more distinct compositions or formulations , 
administrations of a preferred dosage and / or an effective wherein one composition provides 1 ) a kynureninase , 2 ) an 
amount may vary according to the response of the subject . anti - cancer agent , or 3 ) both a kynureninase and an anti 
The practitioner responsible for administration will , in any cancer agent . Also , it is contemplated that such a combina 
event , determine the concentration of active ingredient ( s ) in tion therapy can be used in conjunction with chemotherapy , 
a composition and appropriate dose ( s ) for the individual 25 radiotherapy , surgical therapy , or immunotherapy . 
subject . The terms “ contacted ” and “ exposed , ” when applied to a 
In certain embodiments , pharmaceutical compositions cell , are used herein to describe the process by which a 
may comprise , for example , at least about 0 . 1 % of an active therapeutic construct and a chemotherapeutic or radiothera 
compound . In other embodiments , an active compound may peutic agent are delivered to a target cell or are placed in 
comprise between about 2 % to about 75 % of the weight of 30 dire of the weight of 30 direct juxtaposition with the target cell . To achieve cell 
the unit , or between about 25 % to about 60 % , for example , killing , for example , both agents are delivered to a cell in a and any range derivable therein . Naturally , the amount of combined amount effective to kill the cell or prevent it from active compound ( s ) in each therapeutically useful compo 
sition may be prepared in such a way that a suitable dosage 
will be obtained in any given unit dose of the compound . 35 A kynureninase may be administered before , during , after , 
Factors , such as solubility , bioavailability , biological half or in various combinations relative to an anti - cancer treat 
life , route of administration , product shelf life , as well as ment . The administrations may be in intervals ranging from 
other pharmacological considerations , will be contemplated concurrently to minutes to days to weeks . In embodiments 
by one skilled in the art of preparing such pharmaceutical where the kynureninase is provided to a patient separately 
formulations , and as such , a variety of dosages and treatment 40 from an anti - cancer agent , one would generally ensure that 
regimens may be desirable . a significant period of time did not expire between the time 
In other non - limiting examples , a dose may also comprise of each delivery , such that the two compounds would still be 
from about 1 microgram / kg / body weight , about 5 micro - able to exert an advantageously combined effect on the 
gram / kg / body weight , about 10 microgram / kg / body weight , patient . In such instances , it is contemplated that one may 
about 50 microgram / kg / body weight , about 100 microgram / 45 provide a patient with the kynureninase and the anti - cancer 
kg / body weight , about 200 microgram / kg / body weight , therapy within about 12 to 24 or 72 h of each other and , more 
about 350 microgram / kg / body weight , about 500 micro particularly , within about 6 - 12 h of each other . In some 
gram / kg / body weight , about 1 milligram / kg / body weight , situations it may be desirable to extend the time period for 
about 5 milligram / kg / body weight , about 10 milligram / kg ) treatment significantly where several days ( 2 , 3 , 4 , 5 , 6 , or 
body weight , about 50 milligram / kg / body weight , about 100 50 7 ) to several weeks ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , or 8 ) lapse between 
milligram / kg / body weight , about 200 milligram / kg / body respective administrations . 
weight , about 350 milligram / kg / body weight , about 500 In certain embodiments , a course of treatment will last 
milligram / kg / body weight , to about 1000 milligram / kg / body 1 - 90 days or more ( this such range includes intervening 
weight or more per administration , and any range derivable days ) . It is contemplated that one agent may be given on any 
therein . In non - limiting examples of a derivable range from 55 day of day 1 to day 90 ( this such range includes intervening 
the numbers listed herein , a range of about 5 milligram / kg days ) or any combination thereof , and another agent is given 
body weight to about 100 milligram / kg / body weight , about on any day of day 1 to day 90 ( this such range includes 
5 microgram / kg / body weight to about 500 milligram / kg intervening days ) or any combination thereof . Within a 
body weight , etc . , can be administered , based on the num single day ( 24 - hour period ) , the patient may be given one or 
bers described above . 60 multiple administrations of the agent ( s ) . Moreover , after a 
course of treatment , it is contemplated that there is a period 
X . Combination Treatments of time at which no anti - cancer treatment is administered . 
This time period may last 1 - 7 days , and / or 1 - 5 weeks , and / or 
In certain embodiments , the compositions and methods of 1 - 12 months or more ( this such range includes intervening 
the present embodiments involve administration of a 65 days ) , depending on the condition of the patient , such as 
kynureninase in combination with a second or additional their prognosis , strength , health , etc . It is expected that the 
therapy . Such therapy can be applied in the treatment of any treatment cycles would be repeated as necessary . 
dividing 
“ B ” : 
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Various combinations may be employed . For the example purine analogs , such as fludarabine , 6 - mercaptopurine , thia 
below a kynureninase is “ A ” and an anti - cancer therapy is miprine , and thioguanine ; pyrimidine analogs , such as ancit 
abine , azacitidine , 6 - azauridine , carmofur , cytarabine , dide 
oxyuridine , doxifluridine , enocitabine , and floxuridine ; 
5 androgens , such as calusterone , dromostanolone propionate , 
A / B / A B / A / B B / B / A A / A / B A / B / B B / A / A epitiostanol , mepitiostane , and testolactone ; anti - adrenals , 
A / B / B / B B / A / B / B B / B / B / A B / B / A / B A / A / B / B A / B / A / B such as mitotane and trilostane ; folic acid replenisher , such A / B / B / A B / B / A / A B / A / B / A B / A / A / B A / A / A / B B / A / A / A as frolinic acid ; aceglatone ; aldophosphamide glycoside ; A / B / A / A A / A / B / A 
aminolevulinic acid ; eniluracil ; amsacrine ; bestrabucil ; 
10 bisantrene ; edatraxate ; defofamine ; demecolcine ; diazi Administration of any compound or therapy of the present quone ; elformithine ; elliptinium acetate ; an epothilone ; eto 
embodiments to a patient will follow general protocols for glucid ; gallium nitrate ; hydroxyurea ; lentinan ; lonidainine ; 
the administration of such compounds , taking into account maytansinoids , such as maytansine and ansamitocins ; mito 
the toxicity , if any , of the agents . Therefore , in some guazone ; mitoxantrone ; mopidanmol ; nitraerine ; pentosta 
embodiments there is a step of monitoring toxicity that is 15 tin ; phenamet ; pirarubicin ; losoxantrone ; podophyllinic 
attributable to combination therapy . acid ; 2 - ethylhydrazide ; procarbazine ; PSKpolysaccharide 
A . Chemotherapy complex ; razoxane ; rhizoxin ; sizofiran ; spirogermanium ; 
A wide variety of chemotherapeutic agents may be used tenuazonic acid ; triaziquone ; 2 , 2 ' , 2 " - trichlorotriethylamine ; 
in accordance with the present embodiments . The term trichothecenes ( especially T - 2 toxin , verracurin A , roridin A 
" chemotherapy ” refers to the use of drugs to treat cancer . A 20 and anguidine ) ; urethan ; vindesine ; dacarbazine ; manno 
“ chemotherapeutic agent ” is used to connote a compound orm ustine ; mitobronitol ; mitolactol ; pipobroman ; gacytosine ; 
composition that is administered in the treatment of cancer . arabinoside ( " Ara - C " ) ; cyclophosphamide ; taxoids , e . g . , 
These agents or drugs are categorized by their mode of paclitaxel and docetaxel gemcitabine ; 6 - thioguanine ; mer 
activity within a cell , for example , whether and at what stage captopurine ; platinum coordination complexes , such as cis 
they affect the cell cycle . Alternatively , an agent may be 25 platin , oxaliplatin , and carboplatin ; vinblastine ; platinum ; 
characterized based on its ability to directly cross - link DNA , etoposide ( VP - 16 ) ; ifosfamide ; mitoxantrone ; vincristine ; 
to intercalate into DNA , or to induce chromosomal and vinorelbine ; novantrone ; teniposide ; edatrexate ; daunomy 
mitotic aberrations by affecting nucleic acid synthesis . cin ; aminopterin ; xeloda ; ibandronate ; irinotecan ( e . g . , CPT 
Examples of chemotherapeutic agents include alkylating 11 ) ; topoisomerase inhibitor RFS 2000 ; difluorometlhylor 
agents , such as thiotepa and cyclosphosphamide ; alkyl sul - 30 nithine ( DMFO ) ; retinoids , such as retinoic acid ; 
fonates , such as busulfan , improsulfan , and piposulfan ; capecitabine ; carboplatin , procarbazine , plicomycin , gem 
aziridines , such as benzodopa , carboquone , meturedopa , and citabien , navelbine , farnesyl - protein tansferase inhibitors , 
uredopa ; ethylenimines and methylamelamines , including transplatinum , and pharmaceutically acceptable salts , acids , 
altretamine , triethylenemelamine , trietylenephosphoramide , or derivatives of any of the above . 
triethiylenethiophosphoramide , and trimethylolomelamine ; 35 B . Radiotherapy 
acetogenins ( especially bullatacin and bullatacinone ) ; a Other factors that cause DNA damage and have been used 
camptothecin ( including the synthetic analogue topotecan ) ; extensively include what are commonly known as y - rays , 
bryostatin ; callystatin ; CC - 1065 ( including its adozelesin , X - rays , and / or the directed delivery of radioisotopes to 
carzelesin and bizelesin synthetic analogues ) ; cryptophycins tumor cells . Other forms of DNA damaging factors are also 
( particularly cryptophycin 1 and cryptophycin 8 ) ; dolastatin ; 40 contemplated , such as microwaves , proton beam irradiation 
duocarmycin ( including the synthetic analogues , KW - 2189 ( U . S . Pat . Nos . 5 , 760 , 395 and 4 , 870 , 287 ) , and UV - irradia 
and CB1 - TM1 ) ; eleutherobin ; pancratistatin ; a sarcodictyin ; tion . It is most likely that all of these factors affect a broad 
spongistatin ; nitrogen mustards , such as chlorambucil , chlo - range of damage on DNA , on the precursors of DNA , on the 
rnaphazine , cholophosphamide , estramustine , ifosfamide , replication and repair of DNA , and on the assembly and 
mechlorethamine , mechlorethamine oxide hydrochloride , 45 maintenance of chromosomes . Dosage ranges for X - rays 
melphalan , novembichin , phenesterine , prednimustine , tro - range from daily doses of 50 to 200 roentgens for prolonged 
fosfamide , and uracil mustard ; nitrosureas , such as carmus periods of time ( 3 to 4 wk ) , to single doses of 2000 to 6000 
tine , chlorozotocin , fotemustine , lomustine , nimustine , and roentgens . Dosage ranges for radioisotopes vary widely , and 
ranimnustine ; antibiotics , such as the enediyne antibiotics depend on the half - life of the isotope , the strength and type 
( e . g . , calicheamicin , especially calicheamicin gammall and 50 of radiation emitted , and the uptake by the neoplastic cells . 
calicheamicin omegal 1 ) ; dynemicin , including dynemicin C . Immunotherapy 
A ; bisphosphonates , such as clodronate ; an esperamicin ; as The skilled artisan will understand that immunotherapies 
well as neocarzinostatin chromophore and related chro - may be used in combination or in conjunction with methods 
moprotein enediyne antiobiotic chromophores , aclacino - of the embodiments . In the context of cancer treatment , 
mysins , actinomycin , authrarnycin , azaserine , bleomycins , 55 immunotherapeutics , generally , rely on the use of immune 
cactinomycin , carabicin , carminomycin , carzinophilin , effector cells and molecules to target and destroy cancer 
chromomycinis , dactinomycin , daunorubicin , detorubicin , cells . Rituximab ( RITUXAN® ) is such an example . Check 
6 - diazo - 5 - oxo - L - norleucine , doxorubicin ( including mor - point inhibitors , such as , for example , ipilumimab , are 
pholino - doxorubicin , cyanomorpholino - doxorubicin , 2 - pyr - another such example . The immune effector may be , for 
rolino - doxorubicin and deoxydoxorubicin ) , epirubicin , eso - 60 example , an antibody specific for some marker on the 
rubicin , idarubicin , marcellomycin , mitomycins , such as surface of a tumor cell . The antibody alone may serve as an 
mitomycin C , mycophenolic acid , nogalarnycin , olivomy - effector of therapy or it may recruit other cells to actually 
cins , peplomycin , potfiromycin , puromycin , quelamycin , affect cell killing . The antibody also may be conjugated to a 
rodorubicin , streptonigrin , streptozocin , tubercidin , uben - drug or toxin ( chemotherapeutic , radionuclide , ricin A chain , 
imex , zinostatin , and zorubicin ; anti - metabolites , such as 65 cholera toxin , pertussis toxin , etc . ) and serve merely as a 
methotrexate and 5 - fluorouracil ( 5 - FU ) ; folic acid ana - targeting agent . Alternatively , the effector may be a lym 
logues , such as denopterin , pteropterin , and trimetrexate ; phocyte carrying a surface molecule that interacts , either 
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directly or indirectly , with a tumor cell target . Various efficacy of the treatments . Inhibitors of cell adhesion are 
effector cells include cytotoxic T cells and NK cells . contemplated to improve the efficacy of the present embodi 
In one aspect of immunotherapy , the tumor cell must bear ments . Examples of cell adhesion inhibitors are focal adhe 
some marker that is amenable to targeting , i . e . , is not present sion kinase ( FAKS ) inhibitors and Lovastatin . It is further 
on the majority of other cells . Many tumor markers exist and 5 contemplated that other agents that increase the sensitivity 
any of these may be suitable for targeting in the context of of a hyperproliferative cell to apoptosis , such as the antibody 
the present embodiments . Common tumor markers include c225 , could be used in combination with certain aspects of CD20 , carcinoembryonic antigen , tyrosinase ( p97 ) , gp68 , the present embodiments to improve the treatment efficacy . 
TAG - 72 , HMFG , Sialyl Lewis Antigen , MucA , MucB , 
PLAP , laminin receptor , erb B , and p155 . An alternative 10 XI . KITS 
aspect of immunotherapy is to combine anticancer effects 
with immune stimulatory effects . Immune stimulating mol Certain aspects of the present invention may provide kits , 
ecules also exist including : cytokines , such as IL - 2 , IL - 4 , such as therapeutic kits . For example , a kit may comprise 
IL - 12 , GM - CSF , gamma - IFN , chemokines , such as MIP - 1 , one or more pharmaceutical composition as described herein 
MCP - 1 , IL - 8 , and growth factors , such as FLT3 ligand . 15 and optionally instructions for their use . Kits may also 
Examples of immunotherapies currently under investiga comprise one or more devices for accomplishing adminis 
tion or in use are immune adjuvants , e . g . , Mycobacterium tration of such compositions . For example , a subject kit may 
bovis , Plasmodium falciparum , dinitrochlorobenzene , and comprise a pharmaceutical composition and catheter for 
aromatic compounds ( U . S . Pat . Nos . 5 , 801 , 005 and 5 , 739 , accomplishing direct intravenous injection of the composi 
169 ; Hui and Hashimoto , 1998 ; Christodoulides et al . , 20 tion into a cancerous tumor . In other embodiments , a subject 
1998 ) ; cytokine therapy , e . g . , interferons a , ß , and y , IL - 1 , kit may comprise pre - filled ampoules of a kynureninase . 
GM - CSF , and TNF ( Bukowski et al . , 1998 ; Davidson et al . , optionally formulated as a pharmaceutical , or lyophilized , 
1998 ; Hellstrand et al . , 1998 ) ; gene therapy , e . g . , TNF , IL - 1 , for use with a delivery device . 
IL - 2 , and p53 ( Qin et al . , 1998 ; Austin - Ward and Villaseca , Kits may comprise a container with a label . Suitable 
1998 ; U . S . Pat . Nos . 5 , 830 , 880 and 5 , 846 , 945 ) ; and mono - 25 containers include , for example , bottles , vials , and test tubes . 
clonal antibodies , e . g . , anti - CD20 , anti - ganglioside GM2 , The containers may be formed from a variety of materials , 
and anti - p185 ( Hollander , 2012 ; Hanibuchi et al . , 1998 ; U . S . such as glass or plastic . The container may hold a compo 
Pat . No . 5 , 824 , 311 ) . It is contemplated that one or more sition that includes a kynureninase that is effective for 
anti - cancer therapies may be employed with the antibody therapeutic or non - therapeutic applications , such as 
therapies described herein . 30 described above . The label on the container may indicate D . Surgery that the composition is used for a specific therapy or 
Approximately 60 % of persons with cancer will undergo non - therapeutic application , and may also indicate direc 
surgery of some type , which includes preventative , diagnos - tions for either in vivo or in vitro use , such as those 
tic or staging , curative , and palliative surgery . Curative described above . The kit of the invention will typically 
surgery includes resection in which all or part of cancerous 35 comprise the container described above and one or more 
tissue is physically removed , excised , and / or destroyed and other containers comprising materials desirable from a com 
may be used in conjunction with other therapies , such as the mercial and user standpoint , including buffers , diluents , 
treatment of the present embodiments , chemotherapy , radio - filters , needles , syringes , and package inserts with instruc 
therapy , hormonal therapy , gene therapy , immunotherapy , tions for use . 
and / or alternative therapies . Tumor resection refers to physi - 40 
cal removal of at least part of a tumor . In addition to tumor XII . EXAMPLES 
resection , treatment by surgery includes laser surgery , cryo 
surgery , electrosurgery , and microscopically - controlled sur The following examples are included to demonstrate 
gery ( Mohs ' surgery ) . preferred embodiments of the invention . It should be appre 
Upon excision of part or all of cancerous cells , tissue , or 45 ciated by those of skill in the art that the techniques 
tumor , a cavity may be formed in the body . Treatment may disclosed in the examples which follow represent techniques 
be accomplished by perfusion , direct injection , or local discovered by the inventor to function well in the practice of 
application of the area with an additional anti - cancer the invention , and thus can be considered to constitute 
therapy . Such treatment may be repeated , for example , every preferred modes for its practice . However , those of skill in 
1 , 2 , 3 , 4 , 5 , 6 , or 7 days , or every 1 , 2 , 3 , 4 , and 5 weeks 50 the art should , in light of the present disclosure , appreciate 
or every 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , or 12 months . These that many changes can be made in the specific embodiments 
treatments may be of varying dosages as well . which are disclosed and still obtain a like or similar result 
E . Other Agents without departing from the spirit and scope of the invention . 
It is contemplated that other agents may be used in 
combination with certain aspects of the present embodi - 55 Example 1 Gene Construction , Expression , and 
ments to improve the therapeutic efficacy of treatment . Purification of Kynureninase from Psuedomonas 
These additional agents include agents that affect the fluorescens 
upregulation of cell surface receptors and GAP junctions , 
cytostatic and differentiation agents , inhibitors of cell adhe A gene for expression of the kynureninase enzyme from 
sion , agents that increase the sensitivity of the hyperprolif - 60 Pseudomonas fluorescens ( Pf - KYNU ) was constructed by 
erative cells to apoptotic inducers , or other biological agents . overlap extension polymerase chain reaction ( PCR ) of four 
Increases in intercellular signaling by elevating the number codon optimized gene blocks designed using DNA - Works 
of GAP junctions would increase the anti - hyperproliferative software ( Hoover and Lubkowski , 2002 ) . The full - length 
effects on the neighboring hyperproliferative cell popula - gene includes an N - terminal Xbal restriction enzyme site 
tion . In other embodiments , cytostatic or differentiation 65 ( nucleotides 1 - 6 ) , an optimized ribosome binding site ( RBS ; 
agents can be used in combination with certain aspects of the nucleotides 29 - 55 ) , a start codon ( nucleotides 56 - 58 ) , an 
present embodiments to improve the anti - hyperproliferative N - terminal His , tag ( nucleotides 59 - 91 ) , an E . coli codon 
33 
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optimized Pf - KYNU gene ( nucleotides 92 - 1336 ) , a stop continued shaking overnight at 37° C . Cells were then 
codon ( nucleotides 1337 - 1342 ) , and a C - terminal BamHI harvested by centrifugation and re - suspended in lysis buffer 
restriction enzyme site ( nucleotides 1342 - 1347 ) ( see , SEQ consisting of 50 mM sodium phosphate , pH 7 . 4 , 300 mm 
ID NO : 1 ) . The aforementioned restriction enzyme sites NaCl , 0 . 5 mM pyridoxyl phosphate ( PLP ) , 1 mM phenyl 
were used to clone the assembled gene into a PET - 28a + 5 methylsulfonylfluoride , and 1 ug / mL DNase . Lysis was 
vector ( Novagen ) . This construct was then used to transform achieved by French press and the lysate was cleared of 
BL21 ( DE3 ) E . coli for expression . Cells were grown at 37° particulates by centrifuging at 20 , 000xg for 1 h at 4° C . The 
C . with shaking at 210 rpm in Terrific Broth ( TB ) media with supernatant was then filtered through a 5 um syringe filter 
50 mg / L of kanamycin . Expression was induced when an and applied to a Ni -NTA / agarose column ( Qiagen ) pre 
OD600 ~ 1 . 0 was reached by adding IPTG ( 0 . 5 mM final 10 equilibrated in 50 mM sodium phosphate , pH 7 . 4 , 300 mM 
concentration ) with continued shaking overnight at 37° C . NaCl , and 0 . 1 mM PLP buffer . After loading the lysate onto 
Cells were then harvested by centrifugation and re - sus - the column , the resin was washed with 5 column volumes 
pended in lysis buffer consisting of 50 mM sodium phos ( CV ) of 50 mM sodium phosphate , pH 7 . 4 , 300 mM NaC1 , 
phate , pH 7 . 4 , 300 mM NaC1 , 0 . 5 mM pyridoxyl phosphate and 0 . 1 mM PLP with 30 mM imidazole . Next , the flow rate 
( PLP ) , 1 mM phenylmethylsulfonylfluoride , and 1 ug / mL 15 was set to slowly wash the column overnight with 100 CV 
DNase . Lysis was achieved by French press and the lysate of endotoxin - free PBS ( Corning ) buffer with 0 . 1 mM PLP 
was cleared of particulates by centrifuging at 20 , 000xg for and 1 % V / v TRITON® X114 . This overnight wash removes 
1 h at 4° C . The supernatant was then filtered through a 5 um lipopolysaccharide ( LPS or endotoxin ) that is a typical 
syringe filter and applied to a Ni - NTA / agarose column contaminant in bacterial expression of enzymes . The washed 
( Qiagen ) pre - equilibrated in a buffer composed of 50 mM 20 enzyme was then eluted in 5 CV of endotoxin free PBS with 
sodium phosphate , 300 mM NaCl , and 0 . 1 mM PLP at pH 0 . 1 mM PLP with 250 mM imidazole and the resin was 
7 . 4 . After loading the lysate onto the column , the resin was rinsed with a second 5 CV portions of endotoxin free PBS 
washed with 5 column volumes ( CV ) of 50 mM sodium with 0 . 1 mM PLP . At this point , enzyme was buffer 
phosphate , pH 7 . 4 , 300 mM NaCl , and 0 . 1 mM PLP with 30 exchanged into fresh PBS to remove imidazole , 10 % glyc 
mM imidazole . Next , the flow rate was set to slowly wash 25 erol was added and aliquots were flash frozen in liquid 
the column overnight with 100 CV of endotoxin - free PBS nitrogen for storage at - 80° C . Alternatively , enzyme could 
( Corning ) buffer with 0 . 1 mM PLP and 1 % V / v TRITON be buffer exchanged into freshly made , sterile 100 mm 
X114 . This overnight wash removes lipopolysaccharide sodium phosphate , pH 8 . 4 , to both remove imidazole and 
( LPS or endotoxin ) that is a typical contaminant of bacterial prepare it for PEGylation ( see , Example 4 ) . Enzyme purities 
expression systems . The washed enzyme was then eluted in 30 were typically > 95 % as assessed by SDS - PAGE analysis 
5 CV of endotoxin - free PBS with 0 . 1 mM PLP with 250 mM and typical yields averaged around 20 mg / L of liquid 
imidazole , and the resin was rinsed with a second 5 CV culture . Protein quantities were assessed by measuring 
portion of endotoxin free PBS with 0 . 1 mM PLP . At this Abs2go mm and using the calculated enzyme extinction coef 
point , enzyme was buffer exchanged into fresh PBS to ficient of 76 , 040 M - ' cm - ? . 
remove imidazole , 10 % glycerol was added and aliquots 35 
were flash frozen in liquid nitrogen for storage at - 80° C . Example 3 — Gene Construction , Expression , and 
Alternatively , enzyme was immediately buffer exchanged Purification of Kynureninase from Mus musculus 
into freshly made , sterile 100 mM sodium phosphate , pH 
8 . 4 , to both remove imidazole and prepare it for PEGylation A gene for expression of the kynureninase enzyme from 
( see , Example 4 ) . Enzyme purities were typically > 95 % 40 Mus musculus ( m - KYNU ) was obtained by overlap exten 
based on SDS - PAGE analysis and typical yields averaged sion polymerase chain reaction ( PCR ) of three codon opti 
around 75 mg / L of culture . Protein quantities were assessed mized gene blocks designed using DNA - Works software 
by measuring Abs280 nm and using the calculated enzyme ( Hoover et al . , 2002 ) . The full - length gene included an 
extinction coefficient of 63 , 745 M - ? cm - . N - terminal Xbal restriction enzyme site ( nucleotides 1 - 6 ) , 
45 an optimized RBS ( nucleotides 29 - 58 ) , a start codon 
Example 2 — Gene Construction , Expression , and ( nucleotides 59 - 61 ) , an N - terminal His , tag ( nucleotides 
Purification of Kynureninase from Homo sapiens 62 - 94 ) , an E . coli codon optimized m - KYNU gene ( nucleo 
tides 95 - 1483 ) , a stop codon ( nucleotides 1484 - 1486 ) , and a 
A gene for expression of the kynureninase enzyme from C - terminal BamHI restriction enzyme site ( nucleotides 
Homo sapiens ( h - KYNU ) was obtained by overlap exten - 50 1487 - 1492 ) ( see , SEQ ID NO : 3 ) . The aforementioned 
sion polymerase chain reaction ( PCR ) of four codon opti - restriction enzyme sites were used to clone the assembled 
mized gene blocks designed using DNA - Works software gene into a PET - 28a + vector ( Novagen ) . This construct was 
( Hoover and Lubkowski , 2002 ) . The full - length gene then used to transform BL21 ( DE3 ) E . coli for expression . 
includes an N - terminal Xbal restriction enzyme site ( nucleo - Cells were grown at 37° C . shaking at 210 rpm in Terrific 
tides 1 - 6 ) , an optimized RBS ( nucleotides 28 - 60 ) , a start 55 Broth ( TB ) media with 50 mg / L of kanamycin . Expression 
codon ( nucleotides 61 - 63 ) , an N - terminal His , tag ( nucleo was induced when an OD600 ~ 1 . 0 was reached by adding 0 . 5 
tides 64 - 96 ) , an E . coli codon optimized h - KYNU gene mM IPTG and continued overnight at 37° C . Cells were 
( nucleotides 97 - 1488 ) , a stop codon ( nucleotides 1489 - harvested by centrifugation and re - suspended in lysis buffer 
1491 ) , and a C - terminal BamHI restriction enzyme site consisting of 50 mM sodium phosphate , pH 7 . 4 , 300 mm 
( nucleotides 1492 - 1497 ) ( see , SEQ ID NO : 2 ) . The afore - 60 NaCl , 0 . 5 mM pyridoxyl phosphate ( PLP ) , 1 mM phenyl 
mentioned restriction enzyme sites were used to clone the methylsulfonylfluoride , and 1 ug / mL DNase . Lysis was 
assembled gene into a pET - 28a + vector ( Novagen ) . This achieved by French press and the lysate cleared of particu 
construct was then used to transform BL21 ( DE3 ) E . coli for lates by centrifuging at 20 , 000xg for 1 h at 4° C . The 
expression . Cells were grown at 37° C . with shaking at 210 supernatant was filtered through a 5 um syringe filter and 
rpm in Terrific Broth ( TB ) media with 50 mg / L of kanamy - 65 applied to a Ni -NTA / agarose column ( Qiagen ) pre - equili 
cin . Expression was induced when an OD600 ~ 1 . 0 was brated in 50 mM sodium phosphate , pH 7 . 4 , 300 mM NaCl , 
reached by adding IPTG ( 0 . 5 mM final concentration ) with and 0 . 1 mM PLP buffer . After loading the lysate onto the 
35 
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column , the resin was washed with 5 column volumes ( CV ) nomenex ) equilibrated with PBS and retention times com 
of 50 mM sodium phosphate , pH 7 . 4 , 300 mM NaCl , and 0 . 1 pared to a MW standard solution ( BioRad ) . Endotoxin levels 
mM PLP with 30 mM imidazole . Next the flow rate was set were quantified using the Chromo - LAL kinetic chromogenic 
to slowly wash overnight with 100 CV of endotoxin - free endotoxin testing kit ( Associates of Cape Cod , Inc . ) . 
PBS ( Corning ) buffer with 0 . 1 mM PLP and 1 % v / v TRI - 5 
TON® X114 . This overnight wash removed lipopolysac Example 6 — Assay for Measuring Kinetic 
charide ( LPS or endotoxin ) that is a typical contaminant in Parameters of Kynureninase 
bacterial expression of enzymes . The washed enzyme was 
eluted in 5 CV of endotoxin - free PBS with 0 . 1 mM PLP with The kinetic parameters of Pf - KYNU and h - KYNU , as 
250 mM imidazole and the resin rinsed with a second 5 CV 10 well as of their PEGylated versions as described in 
portion of endotoxin - free PBS with 0 . 1 mM PLP . At this Examples 4 and 5 , were quantified by a spectrophotometric 
point , enzyme was buffer exchanged into fresh PBS to assay , in which the decay in the maximum absorbance of the 
remove imidazole , 10 % glycerol added and aliquots flash enzyme substrate , L - kynurenine , was monitored as a func 
frozen in liquid nitrogen for storage at - 80° C . tion of time . L - kynurenine solutions were prepared in a PBS 
15 buffer , pH 7 . 4 , to result in final concentrations ranging from 
Example 4 - Pharmacological Preparation of 8 UM to 250 UM . L - Kynurenine has an extinction coefficient 
Kynureninase from Pseudomonas fluorescens of 4 , 500 M - cm - l with a amar at 365 nm while the products 
of the kynureninase reaction , L - anthranilic acid and L - ala 
To improve the circulation time of the enzyme in vivo , the nine , do not appreciably absorb at 365 nm . Reactions were 
hydrodynamic radius of KYNU enzymes was increased by 20 initiated by adding and rapidly mixing enzyme solutions 
functionalizing surface reactive groups in the protein by ( ~ 20 nM final ) with the substrate solutions and monitoring 
conjugation to PEG . In one embodiment , Pf - KYNU was the loss of substrate KYN at 25° C . by measuring Abs 265 mm 
functionalized by reaction of surface lysine residues with over time . The resulting data was processed and fitted to the 
Methoxyl PEG Succinimidyl Carbonate 5000 MW Michaelis - Menten equation for determining kinetic con 
( NANOCS ) . The purified , endotoxin - free enzyme was thor - 25 stants . The kinetics of PEGylated Pf - KYNU enzyme was 
oughly buffer exchanged into freshly prepared 100 mm measured in an identical manner . For the non - PEGylated 
sodium phosphate , pH 8 . 4 , and concentrated to 10 mg / mL . enzyme , kcal / Ky = 1 . 0x10 M s - , and for the PEGylated 
The resulting solution was added directly to a 100 : 1 molar form , k Kv = 1 . 3x10 M ' s - - . Kinetic parameters for the 
excess of solid PEG reagent and allowed to react at room hydrolysis of 3 - hydroxy - L - kynurenic acid were also deter 
temperature for 1 h ( FIG . 1 ) . Un - reacted PEG was removed 30 mined as described here . 
from solution by thorough buffer exchange into fresh , endo 
toxin - free PBS in a 100 kDa cut off centrifugal filtration Example 7 — In Vitro Stability of Kynureninase 
device ( AMICON® ) . The apparent molecular mass of the 
enzyme was then checked on a size exclusion HPLC column To measure the in vitro stability of Pf - KYNU , the enzyme 
( Phenomenex ) in PBS . A MW standard solution from Bio - 35 was added to either PBS buffer or pooled human serum to a 
Rad was used to generate a standard curve and enzyme final concentration of 10 uM and incubated at 37° C . 
retention times compared to those of the protein standards . Portions of 10 uL each were taken out at time points and 
Based on the standard curve , the non - PEGylated enzyme has added to 990 uL of a 250 JM solution of L - kynurenine / PBS . 
an apparent mass of 40 kDa , which is close to that of the The initial rate of reaction was monitored by measuring the 
mass of one monomer of Pf - KYNU . The PEGylated version 40 decay of absorbance at 365 nm over time as described in 
of the enzyme was seen to have an apparent mass of 1 , 300 Example 3 . Enzyme stability was determined by comparing 
kDa , i . e . substantially larger than the unmodified enzyme . the initial rate of L - kynurenine catalysis at each time point 
Endotoxin levels were quantified using the Chromo - LAL and comparing it to the rate at time = 0 . The resulting data 
kinetic chromogenic endotoxin testing kit ( Associates of was plotted as % activity vs . time and fitted to an exponential 
Cape Cod , Inc . ) . Enzyme washed in the manner described 45 equation to determine the half - life ( T12 ) . The Pf - KYNU 
above typically resulted in endotoxin levels 0 . 19 + 0 . 07 enzyme was found to have a T12 = 34 . 3 hours in PBS and a 
EU / mg of purified Pf - KYNU . T12 = 2 . 4 hours in pooled human serum ( FIG . 2 ) . 
Example 5 — Pharmacological Preparation of 
Kynureninase from Homo sapiens 
Example 8 - Assay for Quantifying Kynurenine and 
Tryptophan Levels In Vivo 50 
To improve circulatory residence time of the human In vivo levels of L - kynurenine , tryptophan , kynureninic 
enzyme in vivo , the hydrodynamic radius of h - KYNU was acid , 3 - hydroxy - L - kynurenine and L - anthranlilic acid ( one 
increased by functionalizing surface reactive groups in the of the products of kynureninase catalysis ) were quantified 
protein by conjugation to PEG . In one embodiment , 55 and monitored by HPLC . Upon necropsy of the mice , 
h - KYNU was functionalized by reaction of surface lysine samples of blood , the tumor , the spleen , and the liver were 
residues with Methoxyl PEG Succinimidyl Carbonate 5000 removed . Blood samples were centrifuged to separate whole 
MW ( NANOCS ) . The purified , endotoxin - free enzyme was blood from serum . Tissue samples were first homogenized , 
thoroughly buffer exchanged into freshly prepared 100 mM and then centrifuged to remove the solid portion . To each 
sodium phosphate , pH 8 . 4 , and concentrated to 10 mg / mL . 60 liquid portion was added a 1 : 10 v / v portion of 100 % 
The resulting solution was added directly to a 100 : 1 molar trichloroacetic acid to precipitate macromolecules . Solids 
excess of solid PEG reagent and allowed to react at room were again removed by centrifuging and the supernatants 
temperature for 1 h . Un - reacted PEG was removed from were passed through a 0 . 45 um syringe filter . The treated 
solution by thorough buffer exchange into fresh , endotoxin - supernatants were applied directly to a HPLC ( Shimadzu ) 
free PBS in a 100 kDa cut off centrifugal filtration device 65 and separated on a standard analytical C - 18 column using a 
( AMICON® ) . The apparent molecular mass of the enzyme gradient starting from 0 % solution B to 100 % solution B 
was determined using a size exclusion HPLC column ( Phe - where solution A is H , 0 + 0 . 1 % trifluoroacetic acid and 
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solution B is acetonitrile + 0 . 1 % trifluoroacetic acid . The full lian kynureninase linked to a heterologous amino acid 
absorbance range from 190 nm to 900 nm was continually sequence . For example , the native or modified kynureninase 
collected to monitor all possible molecules and fluorescence may be linked to a single - chain variable fragment ( scFv ) 
spectroscopy ( Ex = 365 nm , Em = 480 nm ) was simultane antibody that binds the Cytotoxic T - Lymphocyte Antigen 4 
ously collected to specifically monitor kynurenine levels . 5 ( CTLA - 4 ) receptor , Programmed Cell Death 1 ( PD - 1 ) , or 
Concentrations and retention times were determined using Programmed Cell Death Ligand 1 ( PD - L1 ) . A blockade of 
standard solutions made from the pure molecules ( Sigma ) . CTLA - 4 , PD - 1 , or PD - L1 by an antagonizing antibody or 
antibody fragment allows the inhibitory T - cell signal to be 
Example 9 — Efficacy of PEG - Pf - KYNU in the reversed allowing CD28 to stimulate T - cell activation . In 
Autologous B16 Mouse Melanoma Model 10 this embodiment a native or modified kynureninase - anti 
CTLA4 - , anti - PD - 1 - , or anti - PD - L1 - scFv fusion protein 
B6 - WT mice ( n = 20 ) were each inoculated with 2 . 5x105 would act to remove both inhibitory protein : protein inter 
B16 murine melanoma cells by subcutaneous flank injec - action signaling and inhibitory kynurenine signaling . This 
tion . After allowing tumors to establish for 10 days ( tumor embodiment of a native or modified kynureninase - scFv 
mean = 20 mm ? ) the mice were split into two groups of n = 10 15 fusion protein would be expected to potently upregulate 
each . The control group was then treated with 20 mg / kg of T - cell activation and promote robust anti - tumoral responses . 
heat inactivated PEG - Pf - KYNU by intra - tumoral injection 
every three days until tumors reached 350 mm² in size . The Example 12 — Chimeric Antigen Receptor 
experimental group was treated in an identical manner Constructs for Delivery of Kynureninase to T Cells 
except with 20 mg / kg of active PEG - Pf - KYNU by intra - 20 
tumoral injection every three days until tumors reached an In some aspects , the present invention also contemplates 
endpoint of 350 mm2 in size . The growth rates of B16 a lentiviral vector suitable for transfection of T cells with 
melanoma tumors was significantly retarded in the treatment chimeric antigen receptor ( CAR ) constructs such that a 
group administered active PEG - Pf - KYNU compared to the modified bacterial or mammalian kynureninase would be 
identically treated heat - inactivated PEG - Pf - KYNU group 25 co - expressed in addition to the CAR construct . CAR con 
( FIG . 3 ) resulting in a significant life - span extension ( FIG . structs are proteins containing an extracellular antigen bind 
4 ) . Lymphocytes isolated from control and experimental ing domain fused to a transmembrane and cytoplasmic 
treatment groups were assessed with panels of antibodies signaling domain from a CD3 - chain and often a CD28 
( i . e . , anti - CD45 , CD4 , Nk1 . 1 , CD25 , FoxP3 , CD8 , gran - molecule ( Ahmed et al . , 2010 ) . The antigen binding domain 
zyme B , IFNY , CTLA4 , CD11c , CD11b , F4 / 80 , GR - 1 , and 30 may be an scFv designed to bind an antigen expressed by a 
Ly6 - C ) which revealed that the population of circulating tumor cell with examples being HER2 expressed by glio 
CD4 + CD25 + FoxP3 + regulatory T - cells was significantly blastoma or osteosarcoma , CD19 or CD20 expressed by 
lower in the group treated with active PEG - Pf - KYNU various B - cell malignancies , or GD2 expressed by neuro 
( 4 . 8 + 0 . 8 % vs . 8 . 6 + 0 . 8 % ) . In addition , the population of blastoma ( Lipowska - Bhalla et al . , 2012 ) or any other rel 
tumor infiltrating CD8 + T - cells expressing granzyme B and 35 evant target . In this embodiment the lentiviral vector , deliv 
interferon y was significantly higher in mice treated with ering an appropriate CAR construct to a T cell , would in 
active enzyme ( 26 : 19 % vs . 4 : 2 % ) ( FIGS . 5A - B ) . addition co - express a native or modified bacterial or mam 
malian kynureninase in the cytosol . The T cell containing 
Example 10 — Kynureninase - scFv Fusion Proteins this CAR / kynureninase construct would have the dual abil 
for Tumor Targeting 40 ity to 1 ) bind to specific tumor cells and 2 ) to degrade KYN , 
preventing KYN induction of a regulatory phenotype and or 
In some aspects , the present invention also contemplates apoptosis . In another embodiment a T cell would express a 
polypeptides comprising the modified bacterial or mamma - CAR construct that binds a CD19 + or CD20 + diffuse large 
lian kynureninase linked to a heterologous amino acid B - cell lymphoma while co - expressing a kynureninase to 
sequence . For example , the native or modified kynureninase 45 degrade the high concentrations of KYN often produced by 
may be linked to a single - chain variable fragment ( scFv ) this tumor type ( Yoshikawa et al . , 2010 ; de Jong et al . , 2011 ; 
antibody that binds specific cell surface tumor antigens . In Yao et al . , 2011 ) . 
this embodiment an scFv - kynureninase fusion protein with 
the scFv portion of the protein having specific affinity for a Example 13 — Genetic Selection for Kynureninase 
known tumor antigen , preferably a tumor specific antigen 50 Activity 
that internalizes at a slower rate , e . g . , MUC - 1 , would allow 
the kynureninase portion of the fusion protein to be deliv The amino acid L - tryptophan ( L - Trp ) is synthesized from 
ered to the tumor cell and degrade KYN . One example the pentose derived precursor , chorismate , by expression of 
would be a scFv - kynureninase fusion protein where the scFv the trp biosynthetic genes . In bacteria such as E . coli the trp 
portion targets and binds to the human epidermal growth 55 biosynthetic genes are organized in an operon composed of 
factor receptor 2 ( HER2 ) that is upregulated in certain types five genes ; trpE , trpD , trpC , trpB , and trpA . The TrpE and 
of breast cancer . TrpD proteins are components of the anthranilate synthase 
In this embodiment a native or modified kynureninase complex that catalyzes the first step in the conversion of 
anti - HER2 - scFV fusion protein would act to target and chorismate and L - glutamine to anthranilic acid and L - glu 
concentrate kynureninase directly to the tumor surface and 60 tamate . Anthranilic acid is then subsequently converted to 
act to degrade tumor - produced KYN . L - Trp by the action of TrpC , TrpA , and TrpB . Cells lacking 
a functional anthranilate synthase gene are auxotrophic for 
Example 11 — Kynureninase - Anti - CTLA4 - scFv L - Trp and cannot grow in minimal media without trypto 
Fusion Proteins phan . The inventors postulated that since kynurenine can be 
65 transported into the cytosol of many organisms , cells 
In some aspects , the present invention also contemplates expressing recombinant L - kynureninase enzymes display 
polypeptides comprising the modified bacterial or mamma ing a sufficiently high catalytic activity should be able to 
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convert cytosolic L - kynurenine to anthranilic acid and the optimized gene blocks designed using the DNA - Works 
latter then enables the synthesis of L - Trp . By contrast , cells software ( Hoover and Lubkowski , 2002 ) . The full - length 
that do not express the enzyme or express variants with low gene includes an N - terminal Ncol restriction enzyme site , an 
catalytic activity should display either no growth or very optimized RBS , an N - terminal Hise tag , E . coli codon 
slow growth , respectively , on minimal media with L - kynure - 5 optimized Mu - KYNU gene , a stop codon and a C - terminal 
nine . EcoRI restriction enzyme site . The aforementioned restric 
E . coli trpE and trp deletion mutants were obtained from tion enzyme sites were used to clone the assembled gene into 
Genetic Resources at Yale CGSC . Strain genotypes were a PET - 28a + vector ( Novagen ) . This construct was then used 
( F - A ( araD - araB ) 567 , AlacZ4787 ( : : rrnB - 3 ) , à - , AtrpE772 : : to transform BL21 ( DE3 ) E . coli for expression . Cells were 
kan , rph - 1 , A ( rhaD - rhaB ) 568 , hsdR514 ) and ( F - , A ( araD - 10 grown at 37° C . with shaking at 210 rpm in Terrific Broth 
araB ) 567 , AlacZ4787 ( : : rrnB - 3 ) , N - , AtrpD771 : : kan , rph - 1 , ( TB ) media with 50 mg / L of kanamycin . Expression was 
A ( rhaD - rhaB ) 568 , hsdR514 ) , respectively . Cells were plated induced when an OD600 ~ 1 . 0 was reached by adding IPTG 
on M9 minimal media plates . Filter paper disks soaked in ( 0 . 5 mM final concentration ) with continued shaking over 
either L - Trp , L - Kyn , anthranilic acid , or buffer were then night at 37° C . Cells were then harvested by centrifugation 
placed on the plates followed by incubation at 37° C . E . 15 and re - suspended in lysis buffer consisting of 50 mM 
coli - AtrpD cells only grew in the presence of L - Trp , how sodium phosphate , pH 7 . 4 , 300 mM NaCl , 0 . 5 mm pyri 
ever E . coli - AtrpE could also grow in the presence of doxyl phosphate ( PLP ) , 1 mM phenylmethylsulfonylfluo 
anthranilic acid but not buffer or L - Kyn , demonstrating that ride , and 1 ug / mL DNase . Lysis was achieved by French 
trpC , trpA , and trpB were expressed , allowing rescue of the press and the lysate was cleared of particulates by centri 
L - Trp auxotrophy with anthranilic acid as an intermediate 20 fuging at 20 , 000xg for 1 h at 4° C . The supernatant was then 
metabolite ( FIG . 6 ) . Furthermore , E . coli - AtrpE cells trans - filtered through a 5 um syringe filter and applied to a 
formed with a plasmid harboring the Pf - KYNU gene grew Ni - NTA / agarose column ( Qiagen ) pre - equilibrated in 50 
robustly on M9 minimal media plates in the presence of mM sodium phosphate , pH 7 . 4 , 300 mM NaCl , and 0 . 1 mm 
L - Kyn . PLP buffer . After loading the lysate onto the column , the 
25 resin was washed with 5 column volumes ( CV ) of 50 mM 
Example 14 Gene Construction , Expression and sodium phosphate , pH 7 . 4 , 300 mM NaCl , and 0 . 1 mM PLP 
Purification of Bacterial Kynureninases Displaying with 30 mM imidazole . The washed enzyme was then eluted 
High Catalytic Activity Towards Kynurenine and in 5 CV of PBS with 0 . 1 mM PLP with 250 mM imidazole . 
Identity to the Human Kynureninase At this point , enzyme was buffer exchanged into fresh PBS 
30 to remove imidazole , 10 % glycerol was added and aliquots 
Similar to other eukaryotic kynureninases the Homo sapi - were flash frozen in liquid nitrogen for storage at - 80° C . 
ens enzyme is highly selective towards the hydrolysis of Enzyme purities were typically > 95 % based on SDS - PAGE 
3 ' - OH kynurenine and has about 1 , 000 - fold lower catalytic analysis and typical yields averaged around 75 mg / L of 
activity towards kynurenine . Because of its poor catalytic culture . Protein quantities were assessed by measuring 
activity towards kynurenine , the human enzyme is not 35 Abs280 mm and using the calculated enzyme extinction coef 
suitable for therapeutic purposes . Administration of PEGy - ficient of 78 , 185 M - ' cm - 1 . 
lated Pf - KYNU ( Example 9 ) , Mu - KYNU ( Example 22 and 
Example 23 ) , or Cp - KYNU ( Example 17 ) ( all of which TABLE 1 
display high catalytic activity towards kynurenine instead of 
3 ' - OH kynurenine ) resulted in tumor growth retardation as 40 Percent identities of eubacterial kynureninase enzymes as compared to Homo sapiens kynureninase . 
shown in Example 9 ( FIG . 3 ) . However , administration of 
PEGylated human kynureninase at similar or higher dosing Species SEQ ID NO % Identity 
had no effect on the growth of B16 melanoma tumors ( n = 4 ) . 
Arenitalea lutea 44 . 1 However , as shown in Example 20 , engineering of h - KYNU Belliella baltica DSM 15883 43 . 3 
can improve the L - kynurenine degrading activity of the 45 Bizion Bizionia argentinensis 42 . 9 
human enzyme . Such engineered h - KYNU variants may Candidatus Entotheonella sp . TSY2 44 . 9 
result in tumor growth retardation as seen with PEGylated Candidatus Koribacter versatilis Ellin345 43 . 3 
Cecembia lonarensis Pf - KYNU ( Example 9 ) , Mu - KYNU ( Example 22 and Chlamydia pecorum PV3056 / 3 38 . 2 Example 23 ) , and Cp - KYNU ( Example 17 ) . Chlamydophila caviae GPIC 40 . 8 
The Pf - KYNU displays low sequence identity to its 50 Corallococcus coralloides DSM 2259 43 
human counterpart ( 24 % amino acid identity ) . Due to its low Cyclobacterium marinum DSM 74 44 . 5 43 . 5 Cystobacter fuscus sequence identity to the human protein , Pf - KYNU may elicit Echinicola vietnamensis DSM 17526 44 . 5 adverse immune responses in patients as well as the pro Flavobacteria bacterium BBFL7 43 . 4 
duction of neutralizing antibodies . Therefore it is important Flexibacter litoralis DSM 6794 47 . 5 
45 . 7 to discover kynureninase enzymes that display high catalytic 55 Formosa sp . AK20 
47 . 1 Fulvivirga imtechensis activity and selectivity towards kynurenine and have a Kangiella aquimarina 44 . 1 higher degree of amino acid identity to the Homo sapiens Kangiella koreensis DSM 16069 44 . 3 
kynureninase . The inventors identified a number of bacterial Lacinutrix sp . 5H - 3 - 7 - 4 44 . 2 
enzymes that display > 38 % amino acid identity to the Homo Mariniradius saccharolyticus 44 . 5 
Mucilaginibacter paludis 43 . 9 sapiens kynureninase and also high kynurenine hydrolysis 60 Myroides odoratimimus 42 . 2 activity . The sequences of these enzymes are provided as Myxococcus fulvus HW - 1 44 . 5 
SEQ ID NOs : 13 - 52 . The percent identities of these enzymes Myxococcus stipitatus DSM 14675 44 . 4 
45 . 1 as compared to Homo sapiens kynureninase are provided in Myxococcus xanthus DK 1622 
Nafulsella turpanensis 48 . 2 Table 1 . As a representative example , a gene for expression Niastella koreensis GR20 - 10 44 . 8 of the kynureninase enzyme from Mucilaginibacter paludis 65 Nonlabens dokdonensis DSW - 6 
( Mu - KYNU ) ( SEQ ID NO : 33 ) was constructed by overlap Pedobacter agri 
extension polymerase chain reaction ( PCR ) of two codon 
vai Aw
a 
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TABLE 1 - continued using E . coli - codon optimized gene blocks . The full - length 
gene includes an N - terminal Ncol restriction enzyme site 
Percent identities of eubacterial kynureninase enzymes ( nucleotides 1 - 6 ) , a start codon ( nucleotides 3 - 5 ) , an N - ter as compared to Homo sapiens kynureninase . 
minal His tag ( nucleotides 6 - 35 ) , an E . coli codon opti 
Species SEQ ID NO % Identity 5 mized Cp - KYNU gene ( nucleotides 36 - 1295 ) , a stop codon 
( nucleotides 1296 - 1298 ) , and a C - terminal EcoRI restriction Pedobacter sp . BAL39 42 . 1 enzyme site ( nucleotides 1299 - 1304 ) ( SEQ ID NO : 53 ) . The Pedobacter sp . 148 44 . 1 
Rhodonellum psychrophilum 45 . 4 aforementioned restriction enzyme sites were used to clone 
Salinispora arenicola 39 . 1 the assembled gene into a pET - 28a + vector ( Novagen ) . This Saprospira grandis str . Lewin 43 . 2 construct was then used to transform BL21 ( DE3 ) E . coli for Stigmatella aurantiaca DW4 / 3 - 1 
Xanthomonas axonopodis expression . Cells were grown at 37° C . with shaking at 210 
Psychroflexus gondwanensis rpm in Terrific Broth ( TB ) media with 50 mg / L of kanamy 
Lewinella cohaerens 45 . 6 cin . Expression was induced when an OD600 ~ 1 . 0 was 
Lewinella persica 44 . 9 reached by adding IPTG ( 0 . 5 mM final concentration ) with 
Pontibacter roseus 44 . 8 15 continued shaking overnight at 16° C . Cells were then 
harvested by centrifugation and re - suspended in lysis buffer 
consisting of 50 mM sodium phosphate , pH 7 . 4 , 300 mm 
Example 15 — Kinetic Parameters of NaCl , 0 . 5 mM pyridoxyl phosphate ( PLP ) , 1 mM phenyl Mucilaginibacter paludis Kynureninase methylsulfonylfluoride , and 1 ug / mL DNase . Lysis was 
( Mu - KYNU ) 20 achieved by French press and the lysate was cleared of 
particulates by centrifuging at 20 , 000xg for 1 h at 4° C . The The kinetic parameters of Mu - KYNU were quantified by supernatant was then filtered through a 5 um syringe filter a spectrophotometric assay , in which the decay in the and applied to a Ni - NTA / agarose column ( Qiagen ) pre maximum absorbance of the enzyme substrate , L - kynure equilibrated in 50 mM sodium phosphate , pH 7 . 4 , 300 MM nine , was monitored as a function of time . L - Kynurenine , 
solutions were prepared in a PBS buffer , pH 7 . 4 , to result in in 25 NaCl , and 0 . 1 mM PLP buffer . After loading the lysate onto 
final concentrations ranging from 16 uM to 500 UM . the column , the resin was washed with 10 column volumes 
L - Kynurenine has an extinction coefficient of 4 , 500 ( CV ) of 50 mM sodium phosphate , pH 7 . 4 , 300 mM Naci , 
M - ' cm - 1 with a m at 365 nm while the products of the and 0 . 1 mM PLP with 30 mM imidazole . The washed 
kynureninase reaction , L - anthranilic acid and L - alanine , do enzyme was then eluted with 5 CV of PBS containing 0 . 1 
not appreciably absorb at 365 nm . Reactions were initiated 30 mM PLP and 250 mM imidazole . The eluted enzyme was 
by adding and rapidly mixing enzyme solutions ( ~ 20 nM buffer exchanged into fresh PBS to remove imidazole , 10 % 
final concentration ) with the substrate solutions and moni - glycerol was added , and aliquots were flash frozen in liquid 
toring the loss of substrate at 25° C . by measuring Abs265 nm nitrogen for storage at - 80° C . 
over time . The resulting data were processed and fitted to the 
Michaelis - Menten equation for determining kinetic con - 35 Example 18 – Kinetic Parameters of Chlamydophila 
stants . Mu - KYNU was determined to have a k / Kw = 1 . 2x pecorum Kynureninase ( Cp - KYNU ) 
10 M - s - 1 . 
The kinetic parameters of Cp - KYNU ( SEQ ID NO : 57 ) 
Example 16 — In Vitro Stability of Mucilaginibacter were quantified by a spectrophotometric assay , in which the 
paludis Kynureninase ( Mu - KYNU ) 40 decay in the maximum absorbance of the enzyme substrate , 
L - kynurenine , was monitored as a function of time . 
To measure the in vitro stability of Mu - KYNU , the L - Kynurenine solutions were prepared in PBS buffer , pH 
enzyme was added to either PBS buffer or pooled human 7 . 4 , to result in final concentrations ranging from 16 uM to 
serum to a final concentration of 10 uM and incubated at 37° 500 uM . L - Kynurenine has an extinction coefficient of 4 , 500 
C . Portions of 10 uL each were taken out at time points and 45 M - ' cm - l with a hor at 365 nm while the products of the 
added to 990 uL of a 250 uM solution of L - kynurenine / PBS . kynureninase reaction , anthranilate and L - alanine , do not 
The initial rate of reaction was monitored by measuring the appreciably absorb at 365 nm . Reactions were initiated by 
decay of absorbance at 365 nm over time as described in adding and rapidly mixing enzyme solutions ( 200 nM final 
Example 3 . Enzyme stability was determined by comparing concentrations ) with the substrate solutions and monitoring 
the initial rate of L - kynurenine catalysis at each time point 50 the loss of substrate at 25° C . by measuring Abs 365 m over 
and comparing it to the rate at time = 0 . The resulting data time . The resulting data were processed and fitted to the 
were plotted as percent activity vs . time and fitted to a Michaelis - Menten equation for determining kinetic con 
bi - phasic decay model ( Stone et al . , 2010 ) to determine the stants . Cp - KYNU was determined to have a kcal / Ky = 3x104 
half - lives ( T . ) . The activity of Mu - KYNU enzyme in PBS M - ' s - . 
was found have a ' T1 / 2 = 6 h with an amplitude of 74 % 55 
remaining activity and a subsequent ? T1 / 2 = 150 h ( FIG . 7 ) . Example 19 — Pharmacological Preparation of 
The stability of Mu - KYNU enzyme in pooled human serum Kynureninase from Mucilaginibacter paludis 
was determined to have a ' T12 = 5 h with an amplitude of 
30 % remaining activity and a subsequent 2T 1 / 2 = 73 h ( FIG . To improve the circulation time of the enzyme in vivo , the 
7 ) . 60 hydrodynamic radius of Mu - KYNU was increased by func 
tionalizing surface reactive groups in the protein by conju 
Example 17 — Gene Construction , Expression , and gation to PEG . In one embodiment , Mu - KYNU was PEGY 
Purification of Kynureninase from Chlamydophila lated by reaction of surface lysine residues with Methoxyl 
??????? PEG Succinimidyl Carbonate 5000 MW ( NANOCS ) . The 
65 purified Mu - KYNU , was determined to contain very low 
A gene for expression of the kynureninase enzyme from endotoxin levels ( < 20 EU / mg ) as described below . It was 
Chlamydophila pecorum ( Cp - KYNU ) was synthesized thoroughly buffer exchanged into freshly prepared 100 mM 
44 
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sodium phosphate buffer , pH 8 . 4 , and concentrated to quently purified to near homogeneity as described in 
greater than 1 mg / mL . The resultant solution was added Example 2 and assessed in detail for their steady - state 
directly to a 100 : 1 molar excess of solid PEG reagent and kinetic parameters . This approach yielded numerous vari 
allowed to react at room temperature for 1 h with stirring . ants with significant improvements in catalysis of L - Kyn as 
Un - reacted PEG was removed from solution by thorough 5 compared to WT h - KYNU . Table 2 shows h - KYNU variants 
buffer exchange into fresh , endotoxin - free PBS in a 100 kDa with a 22 fold improvement in kcal / Ky . 
cutoff centrifugal filtration device ( Amicon ) . The apparent 
molecular mass of the enzyme was then checked on a size TABLE 2 
exclusion HPLC column ( Phenomenex ) in PBS using a MW 
standard solution from BioRad to generate a standard curve , 10 Kinetics of h - KYNU variants displaying > 
and enzyme retention times were compared to those of the 2 fold greater k / Ky than WT h - KYNU 
protein standards . Endotoxin levels were quantified using Fold 
the Chromo - LAL kinetic chromogenic endotoxin testing kit SEQ change 
( Associates of Cape Cod , Inc . ) . ID kcal / KM from 
NO : Variant ( s - ' mM - ) WT 
Example 20Enhanced L - Kynurenine Degradation 8 WT h - KYNU 0 . 1 in an Engineered Human Kynureninase Variant 58 A436T 1 . 4 
59 A99F / G112A / F306Y / V339A / I405L / S408N 
60 A991 / 1131V / F249W 0 . 4 The h - KYNU enzyme is highly selective towards the 61 A991 / 1131V / F249W / E259P 0 . 6 hydrolysis of 3 ' - OH kynurenine and has about 1 , 000 fold 20 62 A991 / 1131V / F249W / E259P / F306L 0 . 9 
lower catalytic activity towards L - kynurenine . Because of 63 A99S / F306L 1 . 7 
its poor catalytic activity towards L - kynurenine , the wild 64 A99S / F306L / A436T 2 . 4 24 
65 A99S / T138S / F306L / A436T type human enzyme is not suitable for therapeutic purposes . 66 A99V / G112A / F306Y / L337V / 1405L / S408N 2 . 1 To engineer improved L - kynurenine degrading activity into 67 A99V / G112A / F306Y / L337V / 1 . 4 
h - KYNU , a saturation mutagenesis library was constructed 25 V3391 / 1405F / S408N 
by overlap extension polymerase chain reaction ( PCR ) using 68 A99V / G112A / F306Y / V339A / 1405L / S408N 
69 A99V / G112A / T138S / V339A / 1405F the h - KYNU gene and a pair of oligonucleotides designed to 70 F3061 / L337V / V3391 / 1405F / S408T 
introduce mutations of the codon corresponding to amino 71 F71L / A991 / E259P 
acid F306 . F306 is located within the active site of h - KYNU 72 F71L / A991 / 1131V / E259P / A282P 
where it appears to play a role in substrate binding . The F306 30 73 F71L / A991 / 1131V / E259P / V303S 0 . 3 
74 F71L / A991 /1131V / F249W / L322P saturation library was screened for activity using the micro 75 F71L / E259P / L322P titer plate kynureninase assay of Example 6 . More than a 76 F71L / F249W / E259P / V303S 
dozen clones displayed significantly higher activity than 77 G112A / F306Y / L337V / 1405L 2 . 0 
wild - type h - KYNU and were selected for further analysis . 78 G112A / F306Y / V339M / 1405L 1 . 6 
79 G112A / F306Y / V339S / 1405L Sequencing of these clones revealed that two amino acid 35 1 . 5 80 G112S / F306L / V339T / S408T 1 . 6 substitutions at position F306 resulted in increased 81 G112S / F306Y / V339T / 1405L 
L - kynurenine degrading activity , namely h - KYNU - F306M 82 1110L 
( SEQ ID NO : 55 ) and h - KYNU - F306L ( SEQ ID NO : 56 ) . 83 1110L / F306L 
84 1131M / F249W / S274G 0 . 8 These variants were then purified to homogeneity and a 85 1131V / F249W 
detailed kinetic analysis revealed a 2 - fold and 5 - fold 40 86 T138S 
increase in kcal / Ky for L - kynurenine for h - KYNU - F306M 87 L59M / G112S / F306Y / V339A / 1405L / S408N 
and h - KYNU - F306L , respectively , as compared to wild 88 H41R / Q175L / A436T 0 . 4 
89 T138S / A436T 0 . 3 type h - KYNU . 90 F71L / A991 / 6112A / T138S / F306Y / L337V / 1 . 4 To further engineer improved L - kynurenine degrading V3391 / 1405L / S408N / A436T 
activity into h - KYNU , a series of libraries were constructed 45 91 F306Y 0 . 2 
by either error prone PCR methods of the entire h - KYNU 92 F71L / A991 / S167T / E259P 0 . 9 
93 A991 / G112A / F306Y / 1405L / S408N / A436T 1 . 2 gene or oligonucleotide - directed saturation mutagenesis of 
codons corresponding to amino acid positions that were 
selected from structural and phylogenetic analyses ( Cole and 
Gaucher , 2011 ) that potentially contribute to enhanced activ - 50 Example 21 - Comparison of Pf - KYNU , Anti - PD1 , 
ity and / or substrate selectivity . These positions include resi and Anti - CTLA - 4 Therapies in the Autologous B16 
dues H41 , L59 , F71 , A98 , A99 , G101 , H102 , 1110 , G112 , Mouse Melanoma Model 
M120 , K121 , D122 , 1131 , N135 , A136 , T138 , H142 , F148 , 
F149 , K157 , S167 , A171 , 0175 , Q229 , N232 , G248 , F249 , The PEGylated Pseudomonas fluorescence kynureninase The PEGUA 
E259 , W272 , S274 , A282 , 1285 , G287 , A288 , P300 , V303 , 55 ( PEG - Pf - KYNU ) was evaluated in the B16 melanoma 
F306 , L320 , L322 , S332 , N333 , P334 , L337 , V339 , T404 , mouse model in a side - by - side comparison with the anti 
1405 , S408 , and A436 . These libraries were analyzed in a PD1 ( clone RMP1 - 14 , BioXCell # BE0146 ) or anti - CTLA - 4 
two - stage process . First , after each library was constructed , ( clone UC10 - 4F10 - 11 , BioXCell # BE0032 ) immune check 
the resulting plasmids were transformed into E . coli - Atrpe point inhibitor antibodies . Fifty thousand B16 cells were 
cells and plated on M9 minimal media plates in the presence 60 implanted in the flank of C57BL / 6J mice ( Day 0 , n = 8 mice 
of L - Kyn to select for variants that enabled the rescue of the each group ) . Once palpable tumors developed ( Day 10 ) , the 
L - Trp auxotrophy in this strain as described in Example 13 . animals were treated with either 250 ug anti - PD1 , 100 ug 
Second , the largest growing colonies were selected and anti - CTLA - 4 ( 200 ug 1st dose as per Holmgaard et al . 
subsequently evaluated for catalytic activity using a micro - ( 2013 ) ) , or 500 ug of PEG - Pf - KYNU at the times shown 
titer plate kynureninase assay as described in Example 6 . 65 ( FIG . 8 ) . Heat - inactivated PEG - Pf - KYNU was used as a 
Clones displaying greater apparent activity than controls control . Administration of PEG - Pf - KYNU resulted in sig 
were sequenced to identify mutations , and were subse - nificant tumor growth retardation and extended survival in a 
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manner indistinguishable from that observed with the anti moter were able to grow in M9 - KYN liquid media , whereas 
PD1 or anti - CTLA - 4 checkpoint inhibitor antibodies ( FIG . E . coli AtrpE cells not harboring a kynureninase enzyme 
8 ) for PEG - Pf - KYNU vs . inactivated enzyme or PBS only . were unable to grow in M9 - KYN media , demonstrating the 
necessity of an active kynureninase enzyme for E . coli AtrpE 
Example 22 — Efficacy of Mu - KYNU or Pf - KYNU 5 cells for growth in M9 - KYN media . Similarly , in media 
and Anti - PD1 Combination Therapy in the lacking kynurenine , E . coli AtrpE cells harboring h - KYNU , 
Autologous B16 Mouse Melanoma Model Mu - KYNU , or Pf - KYNU were unable to grow . Specifically , 
following inoculation of 10 + E . coli AtrpE cells harboring the 
The PEGylated enzymes ( PEG - Pf - KYNU and PEG - Mu higher activity Pf - KYNU into 25 mL of M9 - KYN liquid 
KYNU ) were evaluated in B16 melanoma allografts in 10 media at 37° C . with shaking at 220 rpm , the culture reached 
combination with the anti - PD1 immune checkpoint inhibitor saturation at an OD600 = 2 after 18 hours . In contrast , inocu 
antibody ( Curran et al . , 2010 ) . Four groups of C57BL / 6J lation of the same number ( 104 ) of E . coli AtrpE cells 
mice ( 10 per group ) were implanted with 50 , 000 B16 cells harboring Mu - KYNU ( 4 - fold lower catalytic activity ) 
( Day ( ) and tumors were allowed to develop . Once palpable reached saturation ( OD600 = 2 ) within 18 - 24 hours . Under the 
tumors developed ( Day 10 ) , the animals were treated with 15 same conditions , inoculation of a culture with the same 
250 ug anti - PD1 by IP injection ( clone RMP1 - 14 , BioXCell number of cells , but expressing instead the low activity 
# BE0146 ) on days 10 , 13 , and 16 either with or without 500 h - KYNU , reached saturation ( OD600 = 2 ) in > 48 hours . 
ug PEG - Pf - KYNU or 500 ug PEG - Mu - KYNU s . c . near the A generalized genetic selection process employing the 
tumor site . Mice received a total of six doses of KYNU M9 - KYN media to enable isolation of more active kynureni 
between days 10 and 25 . One group was given PBS injec - 20 nase variants from less active kynureninase variants was 
tions i . p . as a control for PD - 1 . Tumor growth was drasti - devised . In the generalized genetic selection , an initial 
cally impaired or even reversed in all treatment arms com inoculum of 104 - 101° E . coli AtrpE cells harboring a library 
pared to PBS control ( FIG . 9A ) . Importantly , additive effects of mutated kynureninase variants were scraped off of LB 
were observed with anti - PD1 in combination with KYNU agar + 0 . 1 mg / mL ampicillin plates and inoculated into 25 mL 
resulting in complete remission of 60 % of the tumors with 25 M9 - KYN media . The number of cells utilized for the initial 
PEG - Pf - KYNU / anti - PD1 treatment and 20 % of the tumors inoculum routinely was 10 - fold the number of the estimated 
with PEG - Mu - KYNU / anti - PD1 treatment ( FIG . 9B ) . Cor number of variants for a given library of kynureninase . The 
responding Kaplan - Meier plots are provided in FIG . 9C . initial inoculum was washed 3 times by pelleting by cen 
trifugation at 3000xg for 5 minutes , discarding the super 
Example 23 — Efficacy of PEG - Mu - KYNU 30 natant , and then resuspending in 1 mL of sterile PBS , 
Therapies in the Autologous B16 Mouse Melanoma pH = 7 . 4 . After inoculation in 25 mL M9 - KYN media , the 
Model cells were grown under the same conditions as stated in the 
preceding paragraph to an OD600 > 1 . 0 and < 2 . 0 ( passage 1 
The PEGylated Mucilaginibacter paludis kynureninase culture ) . Cells from 1 mL culture were washed by pelleting 
( PEG - Mu - KYNU ) was evaluated in the B16 melanoma 35 by centrifugation at 3000xg for 5 minutes , discarding the 
mouse model . Allografts were initiated by implanting supernatant , and then resuspending in 1 mL of sterile PBS , 
50 , 000 B16 cells in the flanks of C57BL / 6J mice ( Day 0 , pH = 7 . 4 . This wash process was repeated 3 times . Subse 
n = 9 mice per group ) . Once palpable tumors developed ( Day quently a number of cells equal to 20 % of the number of 
10 ) , the animals were treated with 500 ug of PEG - Mu - cells that had been used to inoculate the passage 1 culture , 
KYNU by subcutaneous injection near the tumor site every 40 were used to inoculate 25 mL of fresh M9 - KYN media . The 
three days for a total of 6 doses . An identical treatment cells were then allowed to grow to an OD600 > 1 . 0 and < 2 . 0 
regimen with heat - inactivated PEG - Mu - KYNU was used as as above . For this and every subsequent round of passage , 
a control . Administration of PEG - Mu - KYNU resulted in cells from the previous round equal to 20 % of the number of 
tumor growth retardation ( FIG . 10A ) with an extended cells that had been used as inoculum for the previous 
median survival time of 25 days compared to 22 days for the 45 passage were grown in selection media to an OD600 > 1 . 0 and 
heat - inactivated PEG - Mu - KYNU control ( FIG . 10B ) . < 2 . 0 . Multiple rounds of passage were performed as 
required . 104 cells from the final round of selection were 
Example 24Development and Verification of a plated on LB agar + 0 . 1 mg /mL ampicillin plates for further 
Competitive Genetic Selection for Enhanced analysis . For instance , for an error - prone library with a 
Kynureninase Activity 50 calculated size = 1 . 0x10 ' , the initial inoculum would utilize 
1x108 cells , and rounds 2 - 6 thereafter would utilize 2x107 , 
A genetic selection method utilizing a defined culture 4x106 , 8x10 % , 1 . 6x10 % , and 3 . 2x104 , cells from their previ 
media was devised to enable the isolation of E . coli clones ous rounds , respectively , and then 104 cells from the sixth 
expressing kynureninase variants displaying increased activ round of selection would be plated on LB agar + 0 . 1 mg / mL 
ity from a large excess of clones expressing less active 55 ampicillin plates for further analysis . 
kynureninase variants in combinatorial libraries . The The genetic selection process above was validated by 
defined culture media , dubbed M9 - KYN media , contained demonstrating successful enrichment of cells expressing 
M9 minimal salts , 2 mM magnesium sulfate , 0 . 1 mM higher activity kynureninase variants from a 100 or 10 , 000 
calcium chloride , 2 % glucose , 10 uM IPTG , ampicillin , 100 fold excess of cells expressing lower activity kynureninase 
uM Kynurenine , and water . As described in Example 13 , an 60 variants . 104 E . coli AtrpE cells expressing Pf - KYNU were 
E . coli AtrpE deletion mutant was utilized for genetic mixed with 10 % E . coli AtrpE cells expressing the less active 
selection experiments . The E . coli AtrpE strain was obtained Mu - KYNU . These cells had been grown up overnight in LB 
from Genetic Resources at Yale CGSC and had the genotype media + 0 . 1 mg / mL ampicillin , and they were washed 3 times 
( F - , A?araD - araB ) 567 , AlacZ4787 ( : : rrnB - 3 ) , à , AtrpE772 : : by pelleting by centrifugation at 3000xg for 5 minutes , 
kan , rph - 1 , A ( rhaD - rhaB ) 568 , hsdR514 ) . E . coli AtrpE cells 65 discarding the supernatant , and then resuspending in 1 mL 
expressing either h - KYNU , Mu - KYNU , or Pf - KYNU under of sterile PBS , pH = 7 . 4 before being inoculated into 25 mL 
the transcriptional control of the IPTG inducible tac pro - of M9 - KYN liquid media and grown at 37° C . with shaking 
US 9 , 975 , 959 B2 
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at 220 rpm to an OD600 > 1 . 0 and < 2 . 0 . For the second , third , apparent to those skilled in the art are deemed to be within 
fourth , fifth , and sixth rounds of selection , the inocula the spirit , scope and concept of the invention as defined by 
comprised 2x107 , 4x10 " , 8x10 % , 1 . 6x109 , and then 3 . 2x104 the appended claims . 
of washed cells from the prior culture , respectively . After six 
rounds of growth on selective media , 104 cells were plated 5 REFERENCES 
onto agar plates with LB media + 0 . 1 mg / mL ampicillin and 
plasmid DNA was extracted from 5 colonies and subjected The following references , to the extent that they provide 
to DNA sequencing . 4 / 5 plasmids encoded Pf - KYNU and exemplary procedural or other details supplementary to 
1 / 5 encoded Mu - KYNU indicating an enrichment of 8000 - those set forth herein , are specifically incorporated herein by 
fold . In a separate experiment 108 E . coli AtrpE cells 1 reference . 
expressing the h - KYNU F71L / A991 / G112A / T138S / F306Y / U . S . Pat . No . 4 , 870 , 287 
L337V / 3391 / 1405L / S408N / A436T variant ( SEQ ID NO : U . S . Pat . No . 5 , 739 , 169 
90 ) displaying 14 times greater activity than wild - type U . S . Pat . No . 5 , 760 , 395 
h - KYNU were mixed with 104 E . coli AtrpE cells encoding - U . S . Pat . No . 5 , 801 , 005 
wild - type Mu - KYNU ( 370 fold greater activity than wild U . S . Pat . No . 5 , 824 , 311 
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SEQUENCE LISTING 




< 210 > SEQ ID NO 1 
211 > LENGTH : 1347 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 




< 400 > SEQUENCE : 1 
tctagaaata attttgttta actttaagga aaacattaaa ataaggaggt agcaaatggg 60 
cggtcatcat caccaccatc atgggagcgg caccacccgc aacgattgcc tggcgctgga 120 
tgcgcaggat agcctggcac cgctgcgtca gcagtttgcg ctgccggaag gtgttattta 180 
tctggatggc aacagcctgg gtgcgcgtcc ggttgcggcg ctggcgcgtg cgcaggcggt 240 
gattgcggaa gaatggggca acggcctgat tcgcagctgg aacagcgcgg gctggcgcga 300 
tctgagcgaa cgcctgggca accgcctggc gaccctgatt ggcgcgcgcg atggcgaagt 360 
ggtggtgacc gataccacca gcattaacct gtttaaagtg ctgagcgcgg cgctgcgcgt 420 
gcaggcgacc cgcagcccgg aacgccgcgt gattgtgacc gaaaccagca actttccgac 480 
cgatctgtat attgcggaag gcctggcgga tatgctgcag cagggctata Ccctgcgcct 540 
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ggtggatagc ccggaagaac tgccgcaggo gattgatcag gataccgcgg tggtgatgct 600 
gacccatgtg aactataaaa ccggctatat gcatgatatg caggcgctga ccgcgctgag 660 
ccatgaatgc ggcgcgctgg cgatttggga tctggcgcat agcgcgggcg cggtgccggt 720 
ggatctgcat caggcgggcg cggattatgc gattggctgc acctataaat atctgaacgg 780 
cggcccgggc agccaggcgt ttgtgtgggt gagcccgcag ctgtgcgatc tggtgccgca 840 
900 gccgctgtct ggttggtttg gccatagccg ccagtttgcg atggaaccgc gctatgaacc 
gagcaacggc attgcgcgct atctgtgcgg cacccagccg attaccagcc tggcgatggt 960 
ggaatgcggc ctggatgtgt ttgcgcagac cgatatggcg agcctgcgcc gcaaaagcct 1020 
ggcgctgacc gatctgttta ttgaactggt ggaacagcgc tgcgcggcgc atgaactgac 1080 
cctggtgacc ccgcgcgaac atgcgaaacg cggcagccat gtgagctttg aacatccgga 1140 
aggctatgcg gtgattcagg cgctgattga tcgcggcgtg attggcgatt atcgcgaacc 1200 
gcgcattatg cgctttggct ttaccccgct gtataccacc tttaccgaag tgtgggatge 1260 
ggtgcagatt ctgggcgaaa ttctggatcg caaaacctgg gcgcaggcgc agtttcaggt 1320 
gcgccatagc gtgacctagt aggatec 1347 
A 
A 
< 210 > SEQ ID NO 2 
< 211 > LENGTH : 1497 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polynucleotide 
NN HAHAA A 
A 
< 400 > SEQUENCE : 2 
tctagaaata attttgttta actttaagga caaatcagga cacagttaag gaggtaaaat 60 
atgggcggtc atcatcacca ccatcatggg agcggcgaac cgagctccct tgaacttccg 120 
gccgataccg tgcaacggat agcggcggaa ttgaaatgtc acccgaccga cgaacgcgtc 180 
gcgttacatc tggatgagga agacaagctg cgtcacttcc gcgagtgctt ttacattccg 240 
aaaattcagg atctgccgcc agtggacttg agcctggtca acaaagacga gaacgccato 300 
tacttcctgg gcaatagcct gggcctgcaa ccaaagatgg tgaaaaccta tcttgaggag 360 
gagcttgaca aatgggcgaa gatcgcggcc tacggccatg aagtcggcaa gcgtccctgg 420 
attaccggcg atgagtcaat cgttggettg atgaaggata tcgtcggcgc gaacgagaaa 480 
gaaattgcgc tgatgaacgc gctgaccgtg aatctgcatc tgctgatgct gtcattcttt 540 
aagcccaccc cgaagcgcta caaaatcctg ctggaagcga aagcgtttcc cagcgatcat 600 
tatgcgatag aaagccagct gcaactgcac ggcctgaata tcgaggagag catgcgtatg 660 
ataaaaccgc gcgaaggtga ggagaccctg cggattgagg acatcctgga ggtgatcgag 720 
aaggagggcg acagtatcgc ggtgatactt ttcagcggcg tgcatttcta cacgggccaa 780 
cacttcaata tcccggccat taccaaagcc ggccaggcga aagggtgcta tgtaggettt 840 
gatctggcgc atgcagtggg caacgtcgaa ctgtatcttc atgattgggg cgttgatttt 900 
gcgtgctggt gcagctataa gtatctgaat gccggggccg gtgggattgc gggagccttt 960 
attcatgaga aacacgcgca taccattaaa ccggcgctgg ttggctggtt tgggcacgaa 1020 
ctgagcaccc gcttcaagat ggataacaaa ctgcaattga ttccgggcgt gtgcggcttt 1080 
cgtattagca accccccgat tctgctggtc tgcagcctgc acgcgtctct ggagattttc 1140 
aagcaggcga ccatgaaagc gctgcgtaag aaaagtgtgc ttctgacggg ctacctggag 1200 
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tacctgataa agcacaacta cggcaaggat aaggeggcca cgaagaagcc ggttgtgaac 1260 
attatcaccc cgtctcatgt ggaagaacgt ggctgccaac tgacgataac gttcagcgtg 1320 
ccaaacaagg acgtgttcca agagctggag aagcgtggcg tggtgtgtga taaacgtaat 1380 
ccgaatggca ttcgtgtggc gcctgtgccg ctgtacaaca gcttccacga cgtgtataag 1440 
ttcaccaacc tgctgacgag cattctggac agtgcggaaa ccaaaaacta gggatcc 1497 
< 210 > SEQ ID NO 3 
< 211 > LENGTH : 1492 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polynucleotide 
< 400 > SEQUENCE : 3 
tctagaaata attttgttta actttaagaa cacggtcggg aatataagga ggtaaaatat 60 
gggcggtcat catcaccacc atcatgggag cggcgagccg agcccgctgg aactgccggt 120 
tgacgcggta cgtcgtattg cggcagaact gaactgtgac ccgaccgatg aacgtgtggc 180 
gctgcgtctc gacgaagagg acaagctctctcacttccgt aactgcttct atatccctaa 240 
aatgcgtgac ctgccgagca togatctgtc tctggtttct gaagacgacg acgcgattta 300 
cttcctgggt aactctctgg gtctgcagcc aaaaatggtt cgtacctacc tggaggaaga 360 
gctggacaaa tgggcgaaaa tgggtgccta cggccatgat gtgggcaaac gcccgtggat 420 
cgtcggcgac gaaagcattg tgtctctcat gaaggacatt gttggtgcac acgagaaaga 480 
aattgcgctg atgaatgctc tgaccatcaa cctgcacctg ctgctcctgt ctttcttcaa 540 
gccgaccccg aagcgtcata aaatcctgct cgaggotaaa gcgttcccgt ctgatcacta 600 
cgcgatcgaa tctcaaatcc aactgcacgg tctggacgtt gagaagtcta tgcgtatggt 660 
taagccgcgt gaaggcgagg agaccctccg tatggaagac atcctcgaag ttatcgaaga 720 
agaaggtgac tctatcgcag ttattctgtt ctctggcctg cacttttaca ccggtcaact 780 
gttcaatatc ccggcaatca ccaaagcggg ccacgcgaaa ggttgcttcg ttggtttcga 840 
cctggcccat gcggttggta acgtggagct gcgcctccac gactggggtg ttgactttgc 900 
gtgctggtgc tcttacaaat acctgaactc tggtgcgggt ggtctcgcgg gtgcgttcgt 960 
ccacgaaaaa cacgcgcaca ccgttaaacc ggcgctggtt ggctggttog gccacgacct 1020 
ctctacgcgt ttcaacatgg acaacaaact ccagctgate ccaggcgcca acggtttccg 1080 
tatctctaac ccgccgatcc tcctggtttg ctctctgcac gcgtctctcg aggttttcca 1140 
gcaggcgacc atgaccgccc tgcgccgtaa atctattctc ctgacgggtt atctggaata 1200 
catgotgaag cactaccact ctaaagacaa cacggaaaac aaaggtccga tcgttaacat 1260 
catcaccccg tctcgtgcgg aagaacgtgg ctgccaactg accctgacct tctctattcc 1320 
gaaaaaatct gttttcaaag aactggagaa acgtggtgtt gtttgcgaca aacgtgaacc 1380 
ggacggtatc cgcgttgctc cggtcccgct gtacaactct ttccatgacg tttataagtt 1440 
cattcgtctg ctcacctcca tcctggactc tagcgaacgc tcctaaggat cc 1492 
< 210 > SEQ ID NO 4 
< 211 > LENGTH : 1251 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Pseudomonas fluorescens 
< 400 > SEQUENCE : 4 
atgaccaccc gcaacgattg cctggcgctg gatgcgcagg atagcctggc accgctgcgt 60 
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cagcagtttg cgctgccgga aggtgttatt tatctggatg gcaacagcct gggtgcgcgt 120 
ccggttgcgg cgctggcgcg tgcgcaggcg gtgattgcgg aagaatgggg caacggcctg 180 
attcgcagct ggaacagcgc gggctggcgc gatctgagcg aacgcctggg caaccgcctg 240 
300 gcgaccctga ttggcgcgcg cgatggcgaa gtggtggtga ccgataccac cagcattaac 
ctgtttaaag tgctgagcgc ggcgctgcgc gtgcaggcga cccgcagccc ggaacgccgc 360 
gtgattgtga ccgaaaccag caactttccg accgatctgt atattgcgga aggcctggcg 420 
gatatgctgc agcagggcta taccctgcgc ctggtggata gcccggaaga actgccgcag 480 
gcgattgatc aggataccgc ggtggtgatg ctgacccatg tgaactataa aaccggctat 540 
atgcatgata tgcaggcgct gaccgcgctg agccatgaat goggcgcgct ggcgatttgg 600 
gatctggcgc atagcgcggg cgcggtgccg gtggatctgc atcaggcggg cgcggattat 660 
gcgattggct gcacctataa atatctgaac ggcggcccgg gcagccaggc gtttgtgtgg 720 
gtgagcccgc agctgtgcga tctggtgccg cagccgctgt ctggttggtt tggccatage 780 
cgccagtttg cgatggaacc gcgctatgaa ccgagcaacg gcattgcgcg ctatctgtgc 840 
ggcacccagc cgattaccag cctggcgatg gtggaatgcg gcctggatgt gtttgcgcag 900 
accgatatgg cgagcctgcg ccgcaaaagc ctggcgctga ccgatctgtt tattgaactg 960 
gtggaacagc gctgcgcggc gcatgaactg accctggtga ccccgcgcga acatgcgaaa 1020 
cgcggcagcc atgtgagctt tgaacatccg gaaggctatg cggtgattca ggcgctgatt 1080 
gatcgcggcg tgattggcga ttatcgcgaa ccgcgcatta tgcgctttgg ctttaccccg 1140 
ctgtatacca cctttaccga agtgtgggat gcggtgcaga ttctgggcga aattctggat 1200 
cgcaaaacct gggcgcaggc gcagtttcag gtgcgccata gcgtgaccta g 1251 
< 210 > SEQ ID NO 5 
< 211 > LENGTH : 1398 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Homo sapiens 
< 400 > SEQUENCE : 5 
atggaaccga gctcccttga acttccggcc gataccgtgc aacggatagc ggcggaattg 60 
aaatgtcacc cgaccgacga acgcgtcgcg ttacatctgg atgaggaaga caagctgcgt 120 
cacttccgcg agtgctttta cattccgaaa attcaggatc tgccgccagt ggacttgagc 180 
ctggtcaaca aagacgagaa cgccatctac ttcctgggca atagcctggg cctgcaacca 240 
aagatggtga aaacctatct tgaggaggag cttgacaaat gggcgaagat cgcggcctac 300 
ggccatgaag toggcaagcg tccctggatt accggcgatg agtcaatcgt tggcttgatg 360 
420 aaggatatcg toggcgcgaa cgagaaagaa attgcgctga tgaacgcgct gaccgtgaat 
ctgcatctgc tgatgctgtc attctttaag cccaccccga agcgctacaa aatcctgctg 480 
gaagcgaaag cgtttcccag cgatcattat gcgatagaaa gccagctgca actgcacggc 540 
ctgaatatcg aggagagcat gcgtatgata aaaccgcgcg aaggtgagga gaccctgcgg 600 
attgaggaca tcctggaggt gatcgagaag gagggcgaca gtatcgcggt gatacttttc 660 
agcggcgtgc atttctacac gggccaacac ttcaatatcc cggccattac caaagccggc 720 
caggcgaaag ggtgctatgt aggctttgat ctggcgcatg cagtgggcaa cgtcgaactg 780 
tatcttcatg attggggcgt tgattttgcg tgctggtgca gctataagta tctgaatgcc 840 
ggggccggtg ggattgcggg agcctttatt catgagaaac acgcgcatac cattaaaccg 900 
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gcgctggttg gctggtttgg gcacgaactg agcacccgct tcaagatgga taacaaactg 960 
caattgattc cgggcgtgtg cggetttcgt attagcaacc ccccgattct gctggtctgc 1020 
agcctgcacg cgtctctgga gattttcaag caggcgacca tgaaagcgct gcgtaagaaa 1080 
agtgtgcttc tgacgggcta cctggagtac ctgataaagc acaactacgg caaggataag 1140 
goggccacga agaagccggt tgtgaacatt atcaccccgt ctcatgtgga agaacgtggc 1200 
tgccaactga cgataacgtt cagcgtgcca aacaaggacg tgttccaaga gctggagaag 1260 
cgtggcgtgg tgtgtgataa acgtaatccg aatggcattc gtgtggcgcc tgtgccgctg 1320 
tacaacagct tccacgacgt gtataagttc accaacctgc tgacgagcat tctggacagt 1380 
gcggaaacca aaaactag 1398 
< 210 > SEQ ID NO 6 
< 211 > LENGTH : 1395 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Mus musculus 
< 400 > SEQUENCE : 6 
atggagccga gcccgctgga actgccggtt gacgcggtac gtcgtattgc ggcagaactg 60 
aactgtgacc cgaccgatga acgtgtggcg ctgcgtctcg acgaagagga caagctctct 120 . cacttccgta actgcttcta tatccctaaa atgcgtgacc tgccgagcat cgatctgtct 180 ctggtttctg aagacgacga cgcgatttac ttcctgggta actctctggg tctgcagcca 240
aaaatggttc gtacctacct ggaggaagag ctggacaaat gggcgaaaat gggtgcctac 300 
ggccatgatg tgggcaaacg cccgtggatc gtcggcgacg aaagcattgt gtctctcatg 360 
aaggacattg ttggtgcaca cgagaaagaa attgcgctga tgaatgctct gaccatcaac 420 
ctgcacctgc tgctcctgtc tttcttcaag ccgaccccga agcgtcataa aatcctgctc 480 
gaggotaaag cgttcccgtc tgatcactac gcgatcgaat ctcaaatcca actgcacggt 540 
ctggacgttg agaagtctat gcgtatggtt aagccgcgtg aaggcgagga gaccctccgt 600 
atggaagaca tcctcgaagt tatcgaagaa gaaggtgact ctatcgcagt tattctgttc 660 
tctggcctgc acttttacac cggtcaactg ttcaatatcc cggcaatcac caaagcgggc 720 
cacgcgaaag gttgcttcgt tggtttcgac ctggcccatg cggttggtaa cgtggagctg 780 
cgcctccacg actggggtgt tgactttgcg tgctggtgct cttacaaata cctgaactct 840 
ggtgcgggtg gtctcgcggg tgcgttcgtc cacgaaaaac acgcgcacac cgttaaaccg 900 
gcgctggttg gctggttcgg ccacgacctc tctacgcgtt tcaacatgga caacaaacto 960 
cagctgatcc caggcgccaa cggtttccgt atctctaacc cgccgatcct cctggtttgc 1020 
tctctgcacg cgtctctcga ggttttccag caggcgacca tgaccgccct gcgccgtaaa 1080 
totattctcc tgacgggtta tctggaatac atgctgaagc actaccactc taaagacaac 1140 
acggaaaaca aaggtccgat cgttaacatc atcaccccgt ctcgtgcgga agaacgtggc 1200 
tgccaactga ccctgacctt ctctattccg aaaaaatctg ttttcaaaga actggagaaa 1260 
cgtggtgttg tttgcgacaa acgtgaaccg gacggtatcc gcgttgctcc ggtcccgctg 1320 
tacaactctt tccatgacgt ttataagtto attcgtctgc tcacctccat cctggactct 1380 
agcgaacgct cctaa 1395 
< 210 > SEQ ID NO 7 
< 211 > LENGTH : 416 
< 212 > TYPE : PRT 
13 > ORGANISM : Pseudomonas fluorescens < 2 
US 9 , 975 , 959 B2 
59 
- continued 
< 400 > SEQUENCE : 7 
Met Thr Thr Arg Asn Asp Cys Leu Ala Leu Asp Ala Gin Asp Ser Leu 
Ala Pro Leu Arg Gin Gin Phe Ala Leu Pro Glu Gly Val Ile Tyr Leu 
20 25 
Asp Gly Asn Ser Leu Gly Ala Arg Pro Val Ala Ala Leu Ala Arg Ala 
40 
Gin Ala Val Ile Ala Glu Glu Trp Gly Asn Gly Leu Ile Arg Ser Trp 
Asn Ser Ala Gly Trp Arg Asp Leu Ser Glu Arg Leu Gly Asn Arg Leu 
70 75 
Ala Thr Leu Ile Gly Ala Arg Asp Gly Glu Val Val Val Thr Asp Thr 
Thr Ser Ile Asn Leu Phe Lys Val Leu Ser Ala Ala Leu Ara Val Gln 
100 105 
Ala Thr Arq Ser Pro Glu Arq Arq Val Ile Val Thr Glu Thr Ser Asn 
120 
Phe Pro Thr Asp Leu Tyr Ile Ala Glu Gly Leu Ala Asp Met Leu Gin 
Gin Gly Tyr Thr Leu Arg Leu Val Asp Ser Pro Glu Glu Leu Pro Gin 
150 155 
Ala Ile Asp Gin Asp Thr Ala Val Val Met Leu Thr His Val Asn Tyr mmmmm Lys Thr Gly Tyr Met His Asp Met Gin Ala Leu Thr Ala Leu Ser His 180 185 Glu Cys Gly Ala Leu Ala Ile Trp Asp Leu Ala His Ser Ala Gly Ala 200 
mamm 
mmmmmmmmm mmmm mmm Val Pro Val Asp Leu His Gin Ala Gly Ala Asp Tyr Ala Ile Gly Cys Thr Tyr Lys Tyr Leu Asn Gly Gly Pro Gly Ser Gin Ala Phe Val Trp 230 235 Val Ser Pro Gin Leu Cys Asp Leu Val Pro Gin Pro Leu Ser Gly Trp Phe Gly His Ser Arg Gin Phe Ala Met Glu Pro Arg Tyr Glu Pro Ser 260 265 Asn Gly Ile Ala Arg Tyr Leu Cys Gly Thr Gin Pro Ile Thr Ser Leu 280 Ala Met Val Glu Cys Gly Leu Asp Val Phe Ala Gln Thr Asp Met Ala Ser Leu Arg Arg Lys Ser Leu Ala Leu Thr Asp Leu Phe Ile Glu Leu 310 315 Val Glu Gln Arg Cys Ala Ala His Glu Leu Thr Leu Val Thr Pro Arq Glu His Ala Lys Arg Gly Ser His Val Ser Phe Glu His Pro Glu Gly 340 345 Tyr Ala Val Ile Gin Ala Leu Ile Asp Arg Gly Val Ile Gly Asp Tyr 360 Arg Glu Pro Arg Ile Met Arg Phe Gly Phe Thr Pro Leu Tyr Thr Thr Phe Thr Glu Val Trp Asp Ala Val Gin Ile Leu Gly Glu Ile Leu Asp 390 395 400 
Arg Lys Thr Trp Ala Gln Ala Gln Phe Gin Val Arg His Ser Val Thr 
US 9 , 975 , 959 B2 
- continued 
405 410 415 
1 
< 210 > SEQ ID NO 8 
< 211 > LENGTH : 465 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Homo sapiens 
2 
3 
< 400 > SEQUENCE : 8 m 
8 Met Glu Pro Ser Ser Leu Glu Leu Pro Ala Asp Thr Val Gin Arg Ile 15 Ala Ala Glu Leu Lys Cys His Pro Thr Asp Glu Arg Val Ala Leu His
30 & 
Leu Asp Glu Glu Asp Lys Leu Arg His Phe Arg Glu Cys Phe Tyr Ile 
40 45 
& Pro Lys Ile Gin Asp Leu Pro Pro Val Asp Leu Ser Leu Val Asn Lys &
Asp Glu Asn Ala Ile Tyr Phe Leu Gly Asn Ser Leu Gly Leu Gin Pro 
75 J RSEPR2
Lys Met Val Lys Thr Tyr Leu Glu Glu Glu Leu Asp Lys Trp Ala Lys 
95 
Ile Ala Ala Tyr Gly His Glu Val Gly Lys Arg Pro Trp Ile Thr Gly 
110 
Asp Glu Ser Ile Val Gly Leu Met Lys Asp Ile Val Gly Ala Asn Glu 
120 125 
Lys Glu Ile Ala Leu Met Asn Ala Leu Thr Val Asn Leu His Leu Leu 
Met Leu Ser Phe Phe Lys Pro Thr Pro Lys Arg Tyr Lys Ile Leu Leu 
155 
Glu Ala Lys Ala Phe Pro Ser Asp His Tyr Ala Ile Glu Ser Gin Leu 
175 
Gin Leu His Gly Leu Asn Ile Glu Glu Ser Met Arq Met Ile Lys Pro 
190 | mmmmm mmmm Arg Glu Gly Glu Glu Thr Leu Arg Ile Glu Asp Ile Leu Glu Val Ile 200 
sm mmmm 
mm 5
mmmmm mmmmm mmmm mmmmm mmmmmm 205 Glu Lys Glu Gly Asp Ser Ile Ala Val Ile Leu Phe Ser Gly Val His Phe Tyr Thr Gly Gin His Phe Asn Ile Pro Ala Ile Thr Lys Ala Gly 235 Gin Ala Lys Gly Cys Tyr Val Gly Phe Asp Leu Ala His Ala Val Gly | 245 255 mmmm mm Asn Val Glu Leu Tyr Leu His Asp Trp Gly Val Asp Phe Ala Cys Trp 270 | Cys Ser Tyr Lys Tyr Leu Asn Ala Gly Ala Gly Gly Ile Ala Gly Ala 280 285 Phe Ile His Glu Lys His Ala His Thr Ile Lys Pro Ala Leu Val Gly Trp Phe Gly His Glu Leu Ser Thr Arg Phe Lys Met Asp Asn Lys Leu 315 Gin Leu Ile Pro Gly Val Cys Gly Phe Arg Ile Ser Asn Pro Pro Ile 335 Leu Leu Val Cys Ser Leu His Ala Ser Leu Glu Ile Phe Lys Gin Ala 350 Thr Met Lys Ala Leu Arq Lys Lys Ser Val Leu Leu Thr Gly Tyr Leu 360 365 
US 9 , 975 , 959 B2 
63 . 64 
- continued 
Glu Tyr Leu Ile Lys His Asn Tyr Gly Lys Asp Lys Ala Ala Thr Lys 
370 375 380 TES | 
Lys Pro Val Val Asn Ile Ile Thr Pro Ser His Val Glu Glu Arg Gly 
385 390 395 
3
? 
E Cys Gin Leu Thr Ile Thr Phe Ser Val Pro Asn Lys Asp Val Phe Gln 
415 
?





Ile Arq Val Ala Pro Val Pro Leu Tyr Asn Ser Phe His Asp Val Tyr 
435 440 445 gg Lys Phe Thr Asn Leu Leu Thr Ser Ile Leu Asp Ser Ala Glu Thr Lys 
450 455 460 
Asn 
465 
< 210 > SEQ ID NO 9 
< 211 > LENGTH : 464 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Mus musculus 
< 400 > SEQUENCE : 9 
m Met Glu Pro Ser Pro Leu Glu Leu Pro Val Asp Ala Val Ara Arq Ile 
a 
Ala Ala Glu Leu Asn Cys Asp Pro Thr Asp Glu Arg Val Ala Leu Arg 
5 SEA Leu Asp Glu Glu Asp Lys Leu Ser His Phe Arg Asn Cys Phe Tyr Ile 
Pro Lys Met Arg Asp Leu Pro Ser Ile Asp Leu Ser Leu Val Ser Glu 
50 
Asp Asp Asp Ala Ile Tyr Phe Leu Gly Asn Ser Leu Gly Leu Gin Pro 
70 75 2 
Lys Met Val Arg Thr Tyr Leu Glu Glu Glu Leu Asp Lys Trp Ala Lys 
Met Gly Ala Tyr Gly His Asp Val Gly Lys Arg Pro Trp Ile Val Gly 
Asp Glu Ser Ile Val Ser Leu Met Lys Asp Ile Val Gly Ala His Glu 
Lys Glu Ile Ala Leu Met Asn Ala Leu Thr Ile Asn Leu His Leu Leu 
130 mmm Leu Leu Ser Phe Phe Lys Pro Thr Pro Lys Arg His Lys Ile Leu Leu 150 155 Glu Ala Lys Ala Phe Pro Ser Asp His Tyr Ala Ile Glu Ser Gin Ile 
mmm mmmm 
?mmmm mmm mmmmm 
mm 
8mm mmmm Gin Leu His Gly Leu Asp Val Glu Lys Ser Met Arg Met Val Lys Pro Arg Glu Gly Glu Glu Thr Leu Arg Met Glu Asp Ile Leu Glu Val Ile Glu Glu Glu Gly Asp Ser Ile Ala Val Ile Leu Phe Ser Gly Leu His 210 mm Phe Tyr Thr Gly Gln Leu Phe Asn Ile Pro Ala Ile Thr Lys Ala Gly 230 235 His Ala Lys Gly Cys Phe Val Gly Phe Asp Leu Ala His Ala Val Gly Asn Val Glu Leu Arg Leu His Asp Trp Gly Val Asp Phe Ala Cys Trp 




Cys Ser Tyr Lys Tyr Leu Asn Ser Gly Ala Gly Gly Leu Ala Gly Ala 









Trp Phe Gly His Asp Leu Ser Thr Arg Phe Asn Met Asp Asn Lys Leu 
310 315 320 
Gin Leu Ile Pro Gly Ala Asn Gly Phe Arg Ile Ser Asn Pro Pro Ile 
Leu Leu Val Cys Ser Leu His Ala Ser Leu Glu Val Phe Gin Gin Ala 
345 
Thr Met Thr Ala Leu Arg Arg Lys Ser Ile Leu Leu Thr Gly Tyr Leu 
355 360 365 ?? mmmmm Glu Tyr Met Leu Lys His Tyr His Ser Lys Asp Asn Thr Glu Asn Lys 375 380 Gly Pro Ile Val Asn Ile Ile Thr Pro Ser Arg Ala Glu Glu Arg Gly 390 395 400 Cys Gin Leu Thr Leu Thr Phe Ser Ile Pro Lys Lys Ser Val Phe Lys mmmm Glu Leu Glu Lys Arg Gly Val Val Cys Asp Lys Arg Glu Pro Asp Gly 425 Ile Arq Val Ala Pro Val Pro Leu Tyr Asn Ser Phe His Asp Val Tyr 435 440 445 Lys Phe Ile Arg Leu Leu Thr Ser Ile Leu Asp Ser Ser Glu Arg Ser 450 455 460 ?
< 210 > SEQ ID NO 10 
< 211 > LENGTH : 466 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Pongo abelii 
< 400 > SEOUENCE : 10 
Met Glu Pro Ser Ser Leu Glu Leu Pro Ala Asp Thr Val Gin Arg Ile 
15 66 E 3 Ala Ala Glu Leu Lys Cys His Pro Thr Asp Glu Arg Val Ala Leu His 30 &g 
Leu Asp Glu Glu Asp Lys Leu Arg His Phe Arg Glu Tyr Phe Tyr Ile 
35 40 
Pro Lys Ile Arg Asp Leu Pro Pro Val Asp Phe Ile Ile Ser Glu Ser 
55 mem Lys Asp Glu Asn Ala Ile Tyr Phe Leu Gly Asn Ser Leu Gly Leu Gln 65 70 & Pro Lys Met Val Lys Thr Tyr Leu Glu Glu Glu Leu Asp Lys Trp Ala 95 . am mmm Lys Ile Ala Ala Tyr Gly His Glu Val Gly Lys Arg Pro Trp Ile Thr 110 Gly Asp Glu Ser Ile Val Gly Leu Met Lys Asp Ile Val Gly Ala Asn 115 120 Glu Lys Glu Ile Ala Leu Met Asn Ala Leu Thr Val Asn Leu His Leu 135 Leu Met Leu Ser Phe Phe Lys Pro Thr Pro Lys Arg Tyr Lys Ile Leu 145 150 160 | 1 | Leu Glu Ala Lys Ala Phe Pro Ser Asp His Tyr Ala Ile Glu Ser Gin 175 Leu Gin Leu His Gly Leu Asn Ile Glu Glu Ser Met Arg Met Val Lys 
US 9 , 975 , 959 B2 
- continued 
180 190 
Pro Arg Glu Gly Glu Glu Thr Leu Arg Thr Glu Asp Ile Leu Glu Val 
195 200 
18 ?
? IT Ile Glu Lys Glu Gly Asp Ser Ile Ala Val Ile Leu Phe Ser Gly Val 215 
& His Phe Tyr Thr Gly Gln His Phe Asn Ile Pro Ala Ile Thr Lys Ala 
225 






Pg E: EEE 8 Gly Asn Val Glu Leu Tyr Leu His Asp Trp Gly Val Asp Phe Ala Cys 270 Trp Cys Ser Tyr Lys Tyr Leu Asn Ala Gly Ala Gly Gly Ile Ala Gly 275 280 
Ala Phe Val His Glu Lys His Ala His Thr Ile Lys Pro Ala Leu Val 
295 
Gly Trp Phe Gly His Glu Leu Ser Thr Arg Phe Lys Met Asp Asn Lys 
305 
Leu Gin Leu Ile Pro Gly Val Cys Gly Phe Arg Ile Ser Asn Pro Pro Ag 
Ile Leu Leu Val Cys Ser Leu His Ala Ser Leu Glu Ile Phe Lys Gin 
350 mmmm mmmm mmmm Ala Thr Met Lys Ala Leu Arg Lys Lys Ser Ile Leu Leu Thr Gly Tyr 355 360 Leu Glu Tyr Leu Ile Lys His Ser Tyr Gly Lys Asp Lys Ala Ala Thr 375 Lys Lys Pro Val Val Asn Ile Ile Thr Pro Ser His Ile Glu Glu Arq 385 Gly cys Gin Leu Thr Ile Thr Phe Ser Val Pro Asn Lys Asp Val Phe Gin Glu Leu Glu Lys Arg Gly Val Val Cys Asp Lys Arg Asn Pro Asn 430 Gly Ile Arg Val Ala Pro Val Pro Leu Tyr Asn Ser Phe His Asp Val 435 440 Tyr Lys Phe Thr Asn Leu Leu Thr Ser Ile Leu Asp Ser Ala Glu Thr 455 ?? | Thr Asn 465 < 210 > SEQ ID No 11 
< 211 > LENGTH : 465 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Macaca fascicularis 
< 400 > SEOUENCE : 11 
Met Glu Pro Ser Pro Leu Glu Leu Pro Ala Asp Thr Val Gin Arg Ile 
Ala Thr Glu Leu Lys Cys His Pro Thr Asp Glu Arg Val Ala Leu His 
Leu Asp Glu Val Asp Lys Leu Arg His Phe Arg Glu Cys Phe Tyr Ile a gº8 & dJRPro Lys Ile Gin Asp Leu Pro Pro Val Asp Leu Ser Leu Val Asn Lys gs Tie Sin Asp Lee Lite Pro val asp sel Sie " 55 60
? Asp Glu Asn Ala Ile Tyr Phe Leu Gly Asn Ser Leu Gly Leu Gin Pro 
65 70 75 80 ?
US 9 , 975 , 959 B2 
| 70 
- continued 
Lys Met Val Lys Thr Tyr Leu Glu Glu Glu Leu Asp Lys Trp Ala Lys 
95 90 | 
Ile Ala Ala Tyr Gly His Glu Val Gly Lys Arg Pro Trp Ile Thr Gly 
110 ?? Asp Glu Ser Ile Val Gly Leu Met Lys Asp Ile Val Gly Ala Asn Glu 120 1 1 
Lys Glu Ile Ala Leu Met Asn Ala Leu Thr Val Asn Leu His Leu Leu 
135 140 
Leu Leu Ser Phe Phe Lys Pro Thr Pro Lys Arg Tyr Lys Ile Leu Leu 
145 155 160 
Glu Ala Lys Ala Phe Pro Ser Asp His Tyr Ala Ile Glu Ser Gin Leu 
170 175 
Gln Leu His Gly Leu Asn Ile Glu Glu Ser Met Arg Met Ile Lys Pro 
190 
Arg Glu Gly Glu Glu Thr Leu Arg Ile Glu Asp Ile Leu Glu Val Ile 
| 195 200 
Glu Lys Glu Gly Asp Ser Ile Ala Val Ile Leu Phe Ser Gly Val His 
215 220 
Phe Tyr Thr Gly Gin His Phe Asn Ile Pro Ala Ile Thr Lys Ala Gly 
225 235 240 
Gin Ala Lys Gly Cys Tyr Val Gly Phe Asp Leu Ala His Ala Val Gly 
| 245 250 255 
Asn Val Glu Leu Tyr Leu His Asp Trp Gly Val Asp Phe Ala Cys Trp 
270 | 
Cys Ser Tyr Lys Tyr Leu Asn Ala Gly Ala Gly Gly Ile Ala Gly Ala 
275 280 
Phe Ile His Glu Lys His Ala His Thr Ile Lys Pro Ala Leu Val Gly 
295 300 8 mmmmmm mmm Trp Phe Gly His Glu Leu Ser Thr Arg Phe Lys Met Asp Asn Lys Leu 305 315 320 mmmmmm mmmmmmm Gin Leu Ile Pro Gly Val Cys Gly Phe Arg Ile Ser Asn Pro Pro Ile 330 335 Leu Leu Val Cys Ser Leu His Ala Ser Leu Glu Ile Phe Lys Gln Ala 350 Thr Met Lys Ala Leu Arg Lys Lys Ser Ile Leu Leu Thr Gly Tyr Leu 355 360 Glu Tyr Leu Ile Lys His Lys Tyr Gly Lys Asp Lys Ala Ala Thr Glu 375 380 Lys Pro Ile Val Asn Ile Ile Thr Pro Ser His Ile Glu Glu Arg Gly 385 395 400 Cys Gin Leu Thr Ile Thr Phe Ser Val Pro Asn Lys Asp Val Phe Gin 410 415 Glu Leu Glu Lys Arg Gly Val Val Cys Asp Lys Arg Asn Pro Asn Gly 430 Ile Arg Val Ala Pro Val Pro Leu Tyr Asn Ser Phe His Asp Val Tyr 435 440 Lys Phe Thr Asn Leu Leu Thr Ser Ile Leu Asp Ser Ala Glu Thr Thr 450 455 460 ?Asn 465 < 210 > SEQ ID NO 12 < 211 > LENGTH : 465 < 212 > TYPE : PRT 
US 9 , 975 , 959 B2 
- continued 
< 213 > ORGANISM : Pan troglodytes 
< 400 > SEQUENCE : 12 
Met Glu Pro Ser Ser Val Glu Leu Pro Ala Asp Thr Val Gin Arg Ile 
101 . 
Ala Ala Glu Leu Lys Cys His Pro Thr Asp Glu Arg Val Ala Leu His 
20 
Leu Asp Glu Glu Asp Lys Leu Arg His Phe Arg Glu Cys Phe Tyr Ile 
35 40 
Pro Lys Ile Gin Asp Leu Pro Pro Val Asp Leu Ser Leu Val Asn Lys 
55 RR Asp Glu Asn Ala Ile Tyr Phe Leu Gly Asn Ser Leu Gly Leu Gin Pro 75 65 
Lys Met Val Lys Thr Tyr Leu Glu Glu Glu Leu Asp Lys Trp Ala Lys 
90 
Ile Ala Ala Tyr Gly His Glu Val Gly Lys Arg Pro Trp Ile Thr Gly 
100 
Asp Glu Ser Ile Val Gly Leu Met Lys Asp Ile Val Gly Ala Asn Glu 
120 115 
Lys Glu Ile Ala Leu Met Asn Ala Leu Thr Val Asn Leu His Leu Leu 
135 
Met Leu Ser Phe Phe Lys Pro Thr Pro Lys Arg Tyr Lys Ile Leu Leu 
145 155 
Glu Ala Lys Ala Phe Pro Ser Asp His Tyr Ala Ile Glu Ser Gin Leu 
170 
Gln Leu His Gly Leu Asn Ile Glu Glu Ser Met Arg Met Ile Lys Pro 
180 
Arg Glu Gly Glu Glu Thr Leu Arg Ile Glu Asp Ile Leu Glu Val Ile 
195 200 mmmmm mmmmm mmmmmm mmmmmmm mmmm Glu Lys Glu Gly Asp Ser Ile Ala Val Ile Leu Phe Ser Gly Val His 215 mmmm 
m 
mm 
?8mmmmmm mmmm mmmm mmmmmmm Phe Tyr Thr Gly Gln His Phe Asn Ile Pro Ala Ile Thr Lys Ala Gly 225 235 Gin Ala Lys Gly Cys Tyr Val Gly Phe Asp Leu Ala His Ala Val Gly 250 Asn Val Glu Leu Tyr Leu His Asp Trp Gly Val Asp Phe Ala Cys Trp 260 Cys Ser Tyr Lys Tyr Leu Asn Ala Gly Ala Gly Gly Ile Ala Gly Ala 275 280 Phe Ile His Glu Lys His Ala His Thr Ile Lys Pro Ala Leu Val Gly 295 Trp Phe Gly His Glu Leu Ser Thr Arg Phe Lys Met Asp Asn Lys Leu 305 315 Gin Leu Ile Pro Gly Val Cys Gly Phe Arg Ile Ser Asn Pro Pro Ile 330 Leu Leu Val Cys Ser Leu His Ala Ser Leu Glu Ile Phe Lys Gln Ala 340 Thr Met Lys Ala Leu Arg Lys Lys Ser Val Leu Leu Thr Gly Tyr Leu 355 360 Glu Tyr Leu Ile Lys His Asn Tyr Gly Lys Asp Lys Ala Ala Thr Lys 375 380 Lys Pro Val Val Asn Ile Ile Thr Pro Ser His Val Glu Glu Arg Gly 385 395 400 




Cys Gln Leu Thr Ile Thr Phe Ser Val Pro Asn Lys Asp Val Phe Gin 
| 415 415 | 2 Ep Glu Leu Glu Lys Arg Gly Val Val Cys Asp Lys Arg Asn Pro Asn Gly 420 425 430 Ile Arq Val Ala Pro Val Pro Leu Tyr Asn Ser Phe His Asp Val Tyr 
435 440 445 m gg ? 3 Lys Phe Thr Asn Leu Leu Thr Ser Ile Leu Asp Ser Ala Glu Thr Thr 
450 455 460 
Asn 
465 
< 210 > SEQ ID NO 13 
< 211 > LENGTH : 431 
< 212 > TYPE : PRT 
213 > ORGANISM : Arenitalea lutea 
< 400 > SEQUENCE : 13 
Met Leu Glu Thr Glu Asn Ile Arg Thr Leu Ser Asp Tyr Lys Leu Gly 
15 
Leu Asp Tyr Ala Leu Asp Gin Asp Arg Lys Asp Glu Leu Lys Ser Tyr 
30 20 
Arg Asn Gin Phe His Ile Pro Lys Asp Lys Gin Gly Asp Ala Trp Ile 
5 
Tyr Met Thr Gly Asn Ser Leu Gly Leu Gin Pro Lys Gin Thr Lys Ala & ?
Tyr Val Asn Gin Glu Leu Asn Asp Trp Ala Asn Leu Gly Val Glu Gly 
Ee 
His Phe Glu Ala Lys Asn Pro Trp Leu Ala Tyr His Glu Phe Leu Thr 
95 mmm & Glu Ser Met Ala Lys Val Val Gly Ala Lys Pro Ile Glu Val Val Val 100 110 Met Asn Thr Leu Thr Ala Asn Leu His Phe Met Met Val Ser Phe Tyr mmmmmm mmmm Lys Pro Thr Lys Thr Arg Tyr Lys Ile Leu Ile Glu Ser Asp Ala Phe Pro Ser Asp Lys Tyr Ala Val Glu Ser Gin Leu Arg His His Gly Phe Asp Asp Lys Glu Gly Val Val Leu Trp Lys Pro Arg Pro Gly Glu Glu 175 Leu Leu Asn Tyr Asp Asp Leu Glu Thr Ile Leu Glu Thr Gin Gly Asp 180 190 Glu Ile Ala Leu Ile Met Ile Gly Gly Val Asn Tyr Tyr Thr Gly Gin Tyr Phe Asp Leu Lys Arg Ile Thr Gin Leu Gly His Lys Gin Gly cys Asn Val Gly Phe Asp Cys Ala His Gly Ala Gly Asn Val Ala Leu Asn Leu His Asp Ser Gly Ala Asp Phe Ala Val Trp Cys Thr Tyr Lys Tyr 255 mm Leu Asn Ser Gly Pro Gly Ser Leu Ala Gly Cys Phe Val His Glu Arq 260 270 His Ala Tyr Arg Lys Asp Leu Asn Arg Phe Thr Gly Trp Trp Ser His 
Asn Lys Gin Thr Arg Phe Asn Met Arg Gly Glu Phe Asp Gin Leu Pro ?
US 9 , 975 , 959 B2 
75 
- continued 
Gly Ala Glu Gly Trp Gin Leu Ser Asn Pro Pro Ile Leu Ser Met Ala 
315 310 
Ala Ile Lys Ala Ser Leu Asp Leu Phe Asn Glu Val Gly Met Asp Lys 
? 3 Leu Ile Asn Lys Ser Lys Lys Leu Thr Gly Tyr Phe Glu Tyr Leu Leu 
340 345 350 
Lys Gin Leu Gly Glu Asp Thr Ile Arg Ile Ile Thr Pro Lys Arg Ser 
355 360 
?
Glu Glu Arg Gly Cys Gin Leu Ser Ile Gin Val Lys Asn Ala Asp Lys 
370 
Ser Leu His Asn Lys Leu Thr Glu Val Gly Ile Ile Ser Asp Trp Arg 
390 395 
3 & Glu Pro Asp Val Ile Arg Cys Ala Pro Val Pro Leu Tyr Asn Ser Phe 
| | Glu Asp Val Tyr Arg Leu Val Glu Lys Leu Lys Gly Ile Leu Lys 
| 425 430 420 
< 210 > SEQ ID NO 14 
< 211 > LENGTH : 429 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Belliella Baltica DSM 15883 
< 400 > SEOUENCE : 14 
Met Ser Asn Gin Ile Asn Phe Glu Tyr Ser Leu Asp Phe Ala Gln Lys Met ser Asn Gin Ile Asn Phe Glu Tyr ser Leu Aøp 
Met Asp Glu Lys Asp Pro Leu Lys Ser Phe Arg Ser Lys Phe Phe Phe 
30 20 25 
Pro Lys Val Glu Asp Lys Glu Ala Ile Tyr Phe Cys Gly Asn Ser Leu 
& J
8 3
& 4? 40 Gly Leu Gin Pro Lys Thr Thr Gln Asn Tyr Ile Gln Lys Glu Leu Ser & 
Asn Trp Ala Glu Met Ala Val Asp Gly His Phe His Gly Glu Asp Ala 
70 75 PE E Trp Tyr His Ile Arg Lys Lys Ser Lys Pro Ala Leu Ala Glu Ile Val 
Gly Ala His Glu His Glu Val Val Ala Met Asn Asn Leu Thr Ser Asn 
100 105 110 
Leu His Phe Leu Met Val Ser Phe Tyr Arg Pro Asn Ala Lys Arg Phe 
120 
Lys Ile Ile Thr Glu Ala Gly Ala Phe Pro Ser Asp Met Tyr Met Leu 
mm * ammmmm mmm mmm . mmm Glu Thr Gin Val Lys Phe His Gly Leu Asp Pro Asn Lys Ala Ile Val 150 155 Glu Leu Ala Pro Arg Asp Gly Glu His Thr Leu Arg Thr Glu Asp Ile Leu Gin Ser Ile Lys Glu Gin Gly Glu Glu Leu Ala Leu Val Met Met 180 185 190 Ala Gly Leu Gln Tyr Tyr Thr Gly Gin Val Phe Asp Met Lys Ala Ile 200 Ala Gin Ala Val Lys Asp Glu Gly Ala Phe Val Gly Phe Asp Leu Ala His Ala Ala Gly Asn Val Pro Leu Ala Leu His Asp Trp Gly Val Asp 230 235 240 | Phe Ala Thr Trp Cys Ser Tyr Lys Tyr Met Asn Ser Gly Pro Gly Asn 
US 9 , 975 , 959 B2 
- continued 
245 250 255 
? Val Ser Gly Ile Phe Val His Glu Asn His Ala Glu Lys Pro Asp Met 
260 265 270 
? Ile Arg Phe Ala Gly Trp Trp Gly His Asp Glu Gly Glu Arg Phe Lys 
280 
Met Glu Lys Gly Phe Lys Pro Met Phe Gly Ala Asp Gly Trp Gin Leu 
295 300 
Ala Asn Ser Asn Val Leu Ala Leu Ala Ala His Gln Ala Ser Leu Asp 
305 310 Egg Ile Phe Gin Gin Ala Gly Ile Lys Thr Leu Arg Glu Lys Ser Glu Thr 
325 335 5 6





Eegg3mm Gly Val Leu Glu Ile Ile Thr Pro Lys Asn Ile Asn Glu Arg Gly Cys 360 Gin Leu Ser Leu Leu Val His Lys Gly Gly Lys Ala Val Phe Asp Glu 375 380 Sg Phe Tyr Lys Asn Gly Ile Val Gly Asp Trp Arg Asn Pro Asn Val Ile 385 1390 Arg Ile Ala Pro Thr Pro Leu Tyr Asn Ser Tyr Glu Asp Val Phe Arg 405 415 1?8? | | Phe Ala Lys Ile Leu Glu Gin Ser Leu Gin Lys Phe Ala 
420 425 ?
< 210 > SEO ID NO 15 
< 211 > LENGTH : 422 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Bizionia argentinensis 
< 400 > SEQUENCE : 15 
? 
? Met Ser Asn Phe Lys Thr Gly Ile Asp Phe Ala Lys Glu Gin Asp Glu ?
E Asn Asp Thr Leu Ser Cys Tyr Arg Asn Gln Phe His Ile Pro Lys Asp 
20 25 
Lys Gin Gly Asn Asp Met Ile Tyr Leu Cys Gly Asn Ser Leu Gly Leu 
35 | 40 1 
&SET A &R ?3 J 45 Gin Pro Lys Ala Thr Lys Asp Tyr Ile Asn Gin Glu Leu Glu Asp Trp 250 Ala Asn Leu Gly Val Glu Gly His Thr His Ala Lys Asn Pro Trp Leu 65 80 Gly Tyr His Glu Phe Leu Thr Asp Ser Met Ala Lys Val Val Gly Ala 
& ? Lys Pro Ile Glu Val Val Val Met Asn Thr Leu Thr Ala Asn Leu His 
100 105 
5 
mmmm mm Phe Met Met Val Ser Phe Tyr Lys Pro Thr Ile Glu Arg Tyr Lys Ile 115 120 125 Ile Ile Glu Ala Asp Ala Phe Pro Ser Asp Lys Tyr Ala Val Glu Ser 130 Gin Leu Arg His His Gly Tyr Asp Asp Lys Glu Gly Leu Leu Leu Trp 145 160 Lys Ala Arg Glu Gly Glu Glu Leu Leu Arg Tyr Glu Asp Leu Glu Ala 175 165 Ile Leu Lys Glu His Gly Asp Asp Val Ala Leu Val Met Ile Gly Gly 180 185 Lys Glu His Gly Asp Asp val Ala Leu val met Ile Gly Gly ??
US 9 , 975 , 959 B2 
80 
- continued 
? Val Asn Tyr Tyr Thr Gly Gin Phe Phe Asp Leu Lys Arg Ile Thr Glu 
195 200 | 
Leu Gly His Lys His Gly Cys Met Val Gly Phe Asp Cys Ala His Gly 
215 am Ala Gly Asn Val Glu Leu Asn Leu His Asp Ser Gly Ala Asp Phe Ala 230 240 
? Val Trp Cys Thr Tyr Lys Tyr Leu Asn Ser Gly Pro Gly Ser Leu Gly 
245 | 250 255 
Gly Cys Phe Val His Glu Arg His Ala His Asn Lys Arg Leu Asn Arg 
265 270 








Asp Glu Phe Asp Ala Ile Pro Gly Ala Glu Gly Trp Gin Leu Ser Asn 
295 
Pro Pro Ile Leu Ser Met Ala Ala Ile Lys Ala Ser Leu Asp Ile Phe 
310 320 
Glu Glu Ile Gly Met Lys Lys Leu Asn Glu Lys Ser Arg Ala Leu Thr 
325 330 335 mmmm mmm Ala Tyr Phe Glu Phe Leu Leu Lys Gin Val Gly Asp Asp Ser Ile Arg 345 350 OR Ile Ile Thr Pro Glu Asn Pro Asp Glu Arg Gly Cys Gin Leu Ser Ile 355 360 Gin Val Lys Asn Ala Asp Arg Ser Leu His Asp Lys Leu Thr Asp Ala 375 Gly Val Ile Ser Asp Trp Arg Glu Pro Asp Val Ile Arg Cys Ala Pro 390 400 Ile Pro Leu Tyr Asn Ser Tyr Gln Asp Val Tyr His Met Val Glu Arq 405 410 415 Leu Lys Asn Ile Leu Glu 420 < 210 > SEQ ID NO 16 
< 211 > LENGTH : 431 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Candidatus Entotheonella sp . TSY2 vv 
< 400 > SEQUENCE : 16 
Met Thr Ala Phe His Ala His Phe Gin Pro Thr Arg Glu Ala Ala Leu 
. 
| 
Ala Leu Asp Ala Ser Asp Glu Leu Ala Pro Tyr Arg Asp Gin Phe Cys 2
Leu Pro Gin Thr Gin Gly Gin Pro Val Val Tyr Leu Cys Gly His Ser 
35 45 
Leu Gly Leu Gln Pro Lys Thr Val Arg Glu Tyr Ile Asp Glu Glu Leu &
Gin Asp Trp Ala Ala Leu Gly Val Glu Gly His Phe His Ala Arg Arg 
70 80 
Pro Trp Leu Ser Tyr His Glu Ile Leu Thr Ala Gin Thr Ala Arg Leu mmm Ala Gly Ala Lys Pro Ala Glu Val Val Val Met Asn Ser Leu Thr Val &Asn Met His Leu Met Leu Val Ser Phe Tyr Arg Pro Thr Pro Glu Arg 115 125 
Phe Lys Ile Leu Ile Glu Ala Asp Ala Phe Pro Ser Asp Arg Tyr Ala 
?
US 9 , 975 , 959 B2 
m - continued 
? Ala Glu Ser His Leu Arg Trp His Gly Tyr Asp Pro Gin Asp Ala Leu 
145 150 3 
Leu Thr Leu Gin Pro Arg Pro Gly Glu Ala Ala Val Arg Gin Glu Asp 
165 175 
&
Ile Ala Ala Phe Leu His Arg Glu Gly Glu Thr Ile Ala Leu Val Trp 






Leu Gly Gly Val Asn Tyr Tyr Thr Gly Gin Val Phe Asp Met Ala Glu 
195 205 
Ile Thr Ala Ile Gly His Ala Gin Gly cys Val Val Gly Phe Asp Leu 
215 
E Ala His Ala Ala Gly Asn Ile Ile Leu Gin Leu His Asp Trp Asp Val 
225 230 
Asp Cys Ala Val Trp Cys Ser Tyr Lys Tyr Leu Asn Ala Gly Pro Gly 
245 255 
Ala Ala Ala Gly Cys Phe Val His Glu Arg Tyr Ala Gin Arg Pro Asp 
265 270 




275 285 , gn &EHGin Met Pro Ala Gly Phe Asp Pro Ile Pro Gly Ala Glu Gly Trp Gin 
295 mmmm mmmmm mmmmm gmmmmm mmmmmmmm Ile Ser Asn Pro Pro Ile Phe Gin Leu Ala Ala Leu Lys Ala Ser Met 305 310 320 mmmmmm Asp Ile Phe Asp Arg Ala Gly Met Met Arg Leu Arg Ala Lys Ser Glu 325 335 Arg Leu Thr Gly Tyr Leu Glu Tyr Leu Leu Arg Asp Arg Ala Leu Pro 345 350 EGly Val Ser Leu Ile Thr Pro Asp Asp Pro Ala Gin Arg Gly Ala Gin 355 365 J Leu Ser Leu Gin Ile Lys Gin His Gly Cys Ala Leu His Gin Arg Leu 375 EH S Ala Glu Ala His Ile Ile Cys Asp Trp Arg Glu Pro Asp Val Ile Arg 385 390 400 & Val Ala Pro Val Pro Leu Tyr Asn Thr Phe Leu Asp Val Leu Thr Phe 405 415 Val Asn Ala Leu Asp Thr Ala His Arg Glu Val Leu Val Ser Ser 420 425 430 .< 210 > SEQ ID NO 17 < 211 > LENGTH : 424 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Candidatus Koribacter versatilis Ellin345 
< 400 > SEQUENCE : 17 
? Met Ala Ala Ala Ala Phe Asp Thr Thr Glu Asn Phe Ala Ile Glu Met 
15 
Asp Ala Arg Asp Pro Met Ser Arg Phe Arg Gly Arg Phe His Ile Pro 
20 25 am 
?g3? LEEPro Ala Pro Asp Gly Ser Ala Ser Val Tyr Leu Val Gly His Ser Leu 
35 40 mms Gly Leu Gin Pro Lys Thr Val Arg Ala Tyr Leu Glu Gin Glu Leu Lys R && DE
? 
mmm Asp Trp Glu Thr Leu Gly Val Glu Gly His Phe Arg Gly Lys His Pro 70 80 Trp Met Pro Tyr His Arq Leu Leu Thr Glu Gin Thr Ala Arq Leu Val 
US 9 , 975 , 959 B2 
8 . 3 84 
- continued 
85 90 95 
Cys Ala Gin Pro Ser Glu Val Val Val Met Asn Ser Leu Thr Val Asn 
105 110 
Leu His Leu Met Met Val Ser Phe Tyr Arg Pro Thr Arg Glu Arg His 
120 
?
Asn Ile Leu Ile Glu Gly Ser Ala Phe Pro Ser Asp Gln Tyr Ala Val RET Gin Ser Gin Ile Lys Phe His Gly Phe Asp Pro Ala Ser Ser Leu Leu 145 155 Glu Leu Cys Pro Arg Val Gly Glu Ala Thr Met Arg Asp Glu Asp Ile 170 175 
Leu Glu Leu Ile Glu Arg Glu Gly Gin Ser Ile Ala Leu Ile Leu Leu 
185 190 
3
? Gly Gly Val Asn Tyr Ala Thr Gly Gin Ala Phe Asp Met Ala Glu Ile 
200 
Thr Lys Ala Gly His Ala Gin Gly cys Val Val Ala Phe Asp Cys Ala 
His Ala Ala Gly Asn Leu Glu Leu Lys Leu His Glu Trp Asp Val Asp 
225 235 
Trp Ala Ala Trp Cys Ser Tyr Lys Tyr Leu Asn Gly Gly Pro Gly Cys 
250 255 
mmmmm mmmmmmm Ile Gly Gly Cys Phe Val His Glu Arg Tyr Ala Arg Asp Phe Glu Leu 265 270 mmmmmmmmm 
m
mmmmmm mmmmmmm mmmmmm mmmm 3 mmmmmm Pro Arg Phe Ala Gly Trp Trp Gly His Asp Gin Glu Thr Arg Phe Lys 280 Met Gly Pro Glu Phe His Pro Met Ala Gly Ala Glu Gly Trp Gin Leu Ser Asn Pro Ser Ile Leu Thr Met Ala Ala Leu Arg Ala Ser Met Glu 305 315 Ile Phe Asp Glu Ala Gly Ile Gly Lys Leu Arg Gin Arg Ser Ile Ala 330 335 Leu Thr Gly Tyr Leu Glu Phe Leu Leu Asp Gin Gin Lys Ser Ala Arg 345 350 Phe Glu Ile Ile Thr Pro Arg Glu Pro Glu Arg Arg Gly Ala Gin Leu 360 Ser Ile Arg Val Ala Ala Gly Asn Arg Ser Val Cys Asp Arg Leu Val Glu Glu Gly Ala Leu Cys Asp Trp Arg Glu Pro Asp Ile Leu Arg Val 385 395 & Ala Pro Val Pro Leu Tyr Cys Ser Tyr Arg Asp Cys Tyr Arg Phe Val 410 415 ? Gln Arg Phe Val Ala Asn Leu Asn 
420 
< 210 > SEQ ID NO 18 
< 211 > LENGTH : 428 
< 212 > TYPE : PRT 
< 213 > ORGANISM : cecembia lonarensis 
< 400 > SEQUENCE : 18 
Met Ser Asn Asn Gln Tyr Glu Phe Ser Glu Ser Phe Ala Ara Gln Met 
101 15 
Asp Val Gin Asp Thr Leu Ser Gly Phe Arg Asp Arg Phe Tyr Phe Pro 
20 30 25 
US 9 , 975 , 959 B2 
85 86 
- continued 
Gin Ile Asn Gly Lys Glu Ala Ile Tyr Phe cys Gly Asn Ser Leu Gly 
45 | 35 | 40 5
Leu Gln Pro Lys Thr Val Ala Thr Tyr Ile Asn Lys Glu Leu Asp Asn EST 
Trp Ala Lys Leu Gly Val Asp Gly His Phe Tyr Gly Glu Asp Ala Trp 
65 
Tyr His Val Arg Lys Lys Ser Lys Pro Ala Leu Ser Ala Ile Val Gly 
95 
Ala His Glu His Glu Val Val Ala Met Asn Asn Leu Thr Ser Asn Leu 
105 110 
His Phe Leu Met Val Ser Phe Tyr Cys Pro Asp Gin Thr Arg Tyr Lys 
115 120 125 
Ile Ile Thr Glu Ala Gly Ala Phe Pro Ser Asp Met Tyr Met Leu Glu 
Thr Gin Val Lys Phe His Gly Leu Asp Pro Glu Lys Cys Ile Val Glu 
145 160 
Leu Ser Pro Arg Ala Gly Glu Tyr Thr Leu Arg Thr Glu Asp Ile Leu 
175 
Met Ala Ile Glu Ala Asn Lys Glu Asn Leu Ala Leu Val Met Met Ala 
185 190 
Gly Leu Gin Tyr Tyr Thr Gly Gin Val Phe Asp Met Lys Ala Ile Thr 
195 200 205 mmmm Ala Ala Ala His Gin Val Gly Ala Arg Ala Gly Phe Asp Leu Ala His 
mea
mmmm mmmm smmmmmmmm mam mmmmm mmmm mmmmm mmmm Ala Val Gly Asn Ala Lys Leu Glu Leu His Asp Trp Gly Val Asp Phe 225 240 mm 8?mmm mmmmmmm Ala Thr Trp Cys Ser Tyr Lys Tyr Leu Asn Ser Gly Pro Gly Asn Ile 255 Ser Gly Ile Phe Val His Glu Arg His Ala Glu Asn Gin Glu Leu Pro 265 270 Arg Phe Ala Gly Trp Trp Gly His Asp Glu Gly Glu Arg Phe Arg Met 275 280 285 Glu Lys Gly Phe Lys Pro Met Tyr Gly Ala Asp Gly Trp Gin Leu Ala Asn Ser Asn Val Leu Ala Leu Ala Ala His Gin Ala Ser Leu Asp Ile 305 320 Phe Glu Glu Ala Gly Met Asp Arg Leu Arg Ala Lys Ser Glu Leu Leu 335 Thr Gly Tyr Leu Glu Phe Leu Ile Glu Lys Ile Ser Gly Asp Ser Gly 345 350 Val Leu Glu Ile Ile Thr Pro Lys Ile Pro Asn Glu Arg Gly cys Gin 355 360 365 Leu Ser Leu Leu Ile His Lys Gly Gly Lys Ser Val Phe Asp Glu Phe Tyr Lys His Gly Val Val Gly Asp Trp Arg Asn Pro Asn Val Ile Arg 385 390 400 Leu Ala Pro Thr Pro Leu Tyr Asn Ser Phe Ile Asp Ile Tyr Gln Phe 405 415 Ala Lys Ile Leu Glu Gin Ser Leu Gin Lys Phe Ala 420 425 < 210 > SEQ ID NO 19 < 211 > LENGTH : 421 
< 212 > TYPE : PRT 
US 9 , 975 , 959 B2 
87 88 
- continued 
< 213 > ORGANISM : Chlamydia pecorum PV3056 / 3 
< 400 > SEQUENCE : 19 
Met Ile Glu Lys Leu Lys Gin Tyr His Asp Glu Ala Ile Ser Leu Asp 
10 15 
Ser Leu Asp Pro Leu Gln Lys Phe Lys Glu Cys Phe Thr Leu Pro Lys 
| 
|238& &30 
Glu Pro Gly Ala Leu Tyr Phe cys Ser Asn Ser Leu Gly Leu Pro Ala 
40 
Lys Ala Ala Ser Gin Lys Leu Glu Glu Gin Leu Gin Arg Trp Ser Glu 
Leu Gly Ala Arg Gly Trp Phe Glu Gly Glu Gly Asn Trp Tyr Asn Ser 
65 70 & 
Leu Glu Glu Ser Ile Val Arg Pro Leu Ser Lys Ile Leu Gly Ala Glu 
901 95 
Ser Asn Glu Val Thr Leu Met Asn Ser Leu Thr Val Asn Leu His Met 
110 
Leu Leu Ile Ser Phe Tyr Arg Pro Thr Lys Thr Arg Tyr Lys Ile Leu 
120 
Ile Asp Gly Pro Ala Phe Pro Ser Asp Leu Tyr Ala Ile Lys Ser His 
Leu Arg Phe His Lys Lys Glu Glu Gly Leu Ile Leu Ile Glu Pro Arg 
145 150 
Pro Gly Glu His Leu Val Gin Glu Glu Asp Phe Leu Arg Val Ile Lys 
170 175 
Ile Gin Gly Glu Glu Ile Ala Leu Val Phe Leu Asn cys Val Asn Phe 
190 
Leu Ser Gly Gin Val Leu Lys Val Asp Glu Ile Thr Arg Tyr Ala Lys 
200 
Glu Ala Gly Cys Cys Val Gly Tyr Asp Leu Ala His Ala Ala Gly Asn mmm Ile Pro Leu Ser Leu His Asp Leu Gly Gly Asp Phe Ala Val Gly Cys 225 230 Ser Tyr Lys Tyr Leu Cys Gly Gly Pro Gly Gly Pro Gly Ile Ala Tyr 250 255 Val His Ala Ser His His His Gin Gin Phe Val Arq Phe Ser Gl 270 Trp Gly Asn Asp Pro Asn Thr Arg Phe Tyr Phe Pro Lys Glu Phe Val 280 
Pro Tyr Gly Gly Ala Ser Ser Trp Gin Val Ser Thr Pro Ser Ile Leu 
Ala Lys Leu Pro Leu Ile Ala Ala Leu Glu Val Phe Glu Glu Ala Gly 
305 310 
Met Glu Asn Ile Arg Glu Lys Ser Lys Lys Gin Thr Ala Phe Leu Tyr 
330 335 
Thr Leu Leu Glu Asn Ala Arg Gly Thr His Phe Asp Met Ile Thr Pro 
350 
Lys Glu Pro Glu Leu Arg Gly cys Gin Leu Ser Leu Arg Ile Lys Cys 
360 
Ser Arg Ser Glu Glu Ile Leu Arg Lys Leu Glu Arg Leu Gly Ile Thr 
Cys Asp Phe Arg Ser Pro Asn Ile Leu Arg Val Thr Pro Ser Pro Leu 
385 390 
?
US 9 , 975 , 959 B2 
89 
- continued 
Tyr Thr Ser Phe Tyr Glu Ile Tyr Arg Phe Ala Tyr Thr Phe Leu Glu 
405 410 415 
Val Leu Lys Thr Ile 
420 
< 210 > SEQ ID NO 20 
< 211 > LENGTH : 425 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Chlamydophila caviae GPIC 
< 400 > SEOUENCE : 20 
Met Asn Glu Ile Leu Lys His Tyr Gln Lys Lys Ala Ala Gln Leu Asp 
10 15 
Glu Gin Asp Ser Leu Lys His Leu Arg Ala Arg Phe Ala Leu Pro Lys 
25 30 no S 
° Asp Pro Asn Ala Ile Tyr Phe Cys Asn Asn Ser Leu Gly Leu Pro Ala 
40 
Val Gly Ala Phe Thr Lys Ile Glu Glu Leu Leu Gin Arg Trp Ser Asp ?




Phe Asp Asn Pro Leu Arg Gin Pro Leu Ser Lys Ile Leu Gly Ala Glu 
90 95 
3 Tyr Glu Glu Val Val Val Met Asn Ser Leu Thr Met Asn Leu His Leu 
105 110 
Leu Leu Val Ser Phe Tyr Arg Pro Thr Asp Thr Arg Tyr Lys Ile Leu 
120 
Ile Glu Gly Pro Thr Phe Pro Ser Asp Leu Tyr Ala Ile Lys Ser Gin ?
3 Leu Ser Phe His Gly Lys Asn Pro Asp Asp Ala Leu Ile Ile Leu Glu 
145 155 
Pro Arg Ala Gly Glu Asp Leu Leu Arg Tyr Glu Asp Phe Gin Gin Thr 
170 175 
Leu Glu Glu Gin G 3 Glu Ser Ile Ala Leu Val Phe Met Asn Cys Val 
185 190 
Asn Phe Leu Thr Gly Gin Val Leu Glu Val Glu Ala Ile Thr Asn Leu 
200 mmmmmmm Ala Lys Glu Lys Gly Cys Val Val Gly Cys Asp Leu Ala His Ala Ala 3Gly Asn Ile Pro Leu Lys Leu His Glu Trp Gly Val Asp Phe Ala Leu 225 235 Gly cys Ser Tyr Lys Tyr Leu Cys Gly Gly Pro Gly Gly Pro Gly Ile 250 255 Ala Phe Val His Lys Ser His His Asn Glu Gin Leu Pro Arq Phe Ser 265 270 Gly Trp Trp Gly Asn Asp Pro Glu Thr Arg Phe Gin Met Gin Leu Gin 280 Pro Glu Phe Ile Pro Tyr Ser Gly Ala Tyr Ser Trp Gin Val Ser Thr Pro Ser Ile Val Ser Leu Met Pro Leu Leu Ala Thr Leu Glu Val Phe 305 315 Glu Glu Ala Gly Met Glu Arg Val Arg His Lys Ser Lys Gin Met Thr 330 335 Ala Phe Leu Leu Glu Leu Leu Glu Leu Ala Pro Pro Ser Cys Phe Glu 345 350 ?
US 9 , 975 , 959 B2 
- continued 
Ile Tie The Pro Arg Asp Pro as Lee ang diy sat Gin Leu ser Ile Im Ile Ile Thr Pro Arg Asp Pro Glu Leu Arg Gly Ser Gin Leu Ser Ile 355 360 365Arg Ile Gin Gin His Ser Glu Glu Val Leu Gin Lys Leu Glu Ala Gin 375 380 ?&JSR 83&
? Arg Ile Thr cys Asp Ser Arg Pro Pro Asp Ile Ile Arg Val Thr Ala 
390 395 400 
1 
Thr Pro Leu Tyr Asn Thr Phe Ser Glu Ile Tyr Lys Phe Thr cys Lys 
410 415 
1 
Leu Phe Glu Val Leu Glu Ile Lys Ser 
425 420 
< 210 > SEQ ID NO 21 
< 211 > LENGTH : 425 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Corallococcus coralloides DSM 2259 
< 400 > SEQUENCE : 21 
Met Thr Ala Pro Val Tyr Glu Asn Thr Asp Val Phe Ala Tyr Gly Leu 
15 
Asp Ala Ala Asp Pro Leu Arg Pro Leu Arg Asp Glu Phe Leu Phe Pro 
20 25 30 
Pro Ala Pro Ser Gly Ala Pro Ala Ile Tyr Leu Ala Gly Asn Ser Leu 
35 40 45 
Gly Leu Gin Pro Arg Lys Ala Arg Lys Tyr Val Gin Met Glu Met Glu 
&
RT R &E33 3? Asp Trp Glu Arg Leu Gly Val Glu Gly His Val His Gly Arg His Pro 80 Trp Leu Pro Tyr His Glu Gln Leu Thr Asp Met Val Ala Ara Val Val 85 95 
Gly Ala Gln Pro Ile Glu Val Val Val Met Asn Thr Leu Ser Val Asn 
100 105 110 
Leu His Leu Met Met Val Ser Phe Tyr Arg Pro Thr Arg Glu Arg Phe 
115 120 125 
Lys Ile Leu Ile Glu Gly Gly Ala Phe Pro Ser Asp Gin Tyr Ala Val 
Ala Ser Gin Ala Arg Phe His Gly Tyr Asp Pro Lys Glu Ala Ile Val 
160 mmm gmmmmmm mmmm smmm smmmm mmmmmm mmmmm mmmm Arg Leu Met Pro Arg Glu Gly Glu Asp Thr Leu Arg Ser Glu Asp Ile 165 175 Leu Glu Ala Ile Glu Arg His Gly Lys Glu Leu Ala Leu Val Met Leu 180 185 190 Gly Ser Val Asn Tyr Leu Thr Gly Gin Ala Phe Asp Leu Arg Glu Ile 195 200 205 ?Thr Arg Val Ala His Ala Gin Gly Cys Lys Val Gly Phe Asp Leu Ala His Ala Ala Gly Asn Leu Lys Leu Ser Leu His Asp Asp Gly Pro Asp 240 Phe Ala Val Trp Cys Ser Tyr Lys Tyr Leu Asn Gly Gly Pro Gly Ser 255 Eng Leu Gly Gly Val Phe Val His Glu Arg His Ala His Ser Pro Gln Leu 260 265 270 Pro Arg Phe Glu Gly Trp Trp Gly His Asn Lys Ala Thr Arg Phe Glu 275 280 285 Met Gly Pro Thr Phe Asp Pro Leu Pro Gly Ala Glu Gly Trp Gin Leu &
US 9 , 975 , 959 B2 
8 94 
- continued 
| g 290 300 
18 3
Ser Asn Pro Pro Ile Phe Gin Leu Ala Ala Leu Arg Ser Ser Leu Glu 
310 315 320 
E
: ggLeu Phe Asp Lys Ala Thr Met Ala Ala Leu Arg Thr Lys Ser Asp Gln 325 
Leu Thr Gly Tyr Leu Glu Phe Leu Leu Asp Arg Leu Pro Ala Gly Tyr 
340 345 350 
? Val Ser Ile Thr Thr Pro Arg Asp Leu Lys Gin Arg Gly Ala Gin Leu 
355 365 
E Ser Leu Arg Phe Lys Gly Glu Pro Lys Arg Leu Leu Gin Arg Leu Ser 
370 380 mm ? Ala Ala Gly Ile Ile Cys Asp Phe Arg Glu Pro Asp Ile Ile Arg Ala 390 395 400 3? & ESE Ala Pro Thr Pro Leu Tyr Asn Thr Tyr Leu Asp Val Phe Arg Phe Val 405 Lys Ala Leu Glu Ala His Ala Leu Glu 420 425 
< 210 > SEQ ID NO 22 
< 211 > LENGTH : 426 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Cyclobacterium marinum DSM 745 
< 400 > SEQUENCE : 22 





Asp Leu Ala Asp Pro Leu Ser Thr Tyr Arg Glu Lys Phe Tyr Ile Pro 
20 am 
Glu Lys Asn Gly Gin Pro Leu Ile Tyr Phe Cys Gly Asn Ser Leu Gly 
40 
Leu Gin Pro Arg Ser Val Asn Ala Tyr Leu Lys Gin Glu Leu Glu Lys 
8 
me Trp Ala Asp Lys Gly Val Asp Gly His Phe Glu Gly Lys Val Pro Trp 70 3 & gg
Ile Asp Ala Arg Lys Pro Ser Lys Arg Leu Ile Ala Pro Leu Val Gly 
Ala Asn Glu Gin Glu Val Val Ala Met Asn Ser Leu Ser Val Asn Leu 
100 
His Leu Leu Met Val Ser Phe Tyr Gin Pro Lys Gly Lys Lys Phe Lys 
120 
Ile Leu Thr Glu Ala Gly Ala Phe Pro Ser Asp Gln Tyr Ile Leu Glu 
mmamgammmm mmm mmm mmmmm ?? Ser Gin Val Lys Phe His Gly Leu Leu Pro Asp Glu Ala Ile Leu Glu 150 Met Ala Pro Arg Pro Asn Glu His Leu Leu Arg Thr Glu Asp Ile Leu mmmm Gin Lys Ile Glu Asp His Lys Asp Glu Leu Ala Leu Ile Met Leu Ser 180 Gly Leu Gin Tyr Tyr Thr Gly Gin Leu Phe Asp Leu Glu Ala Ile Ser 200 Ser Ala Ala Asn Lys Gin Gly Ile Thr Ile Gly Phe Asp Leu Ala His ?Ala Ile Gly Asn Val Pro Leu Arg Leu His Asp Trp Gly Val Asp Phe 230 
US 9 , 975 , 959 B2 
95 96 
- continued 
& 3 Ala Thr Trp Cys Ser Tyr Lys Tyr Leu Asn Ser Gly Pro Gly Asn Val 
255 8 
Ser Gly Ile Phe Val His Glu Lys His Ser Asp Asn Ala Leu Leu Pro 
265 270 
2
Arg Phe Ala Gly Trp Trp Gly His Asp Glu Lys Glu Arg Phe Lys Met 
280 
?°FEE 
Lys Lys Gly Phe Lys His Met Pro Gly Ala Asp Gly Trp Leu Leu Ser 
295 
Asn Asp Asn Val Leu Gly Leu Ala Ala His Gin Ala Ser Leu Glu Leu 
305 310 320 ? 
Phe Ala Glu Ala Gly Leu Asp Lys Leu Arg Lys Lys Ser Ile Gin Leu 
Thr Asn Tyr Leu Glu Phe Ala Ile His Glu Thr Ile Lys Asp Ser Glu 
345 350 
?
Leu Leu Glu Ile Ile Thr Pro Leu Lys Pro Thr Glu Arg Gly cys Gin 
355 360 
&?
E Leu Ser Leu Leu Ile His Lys Lys Gly Lys Glu Val Phe Asp Tyr Trp 
375 
? I Ile Asp Asn Gly Val Val Ala Asp Trp Arg Asn Pro Asn Val Ile Arg 
385 390 400 
& ? Leu Ala Pro Thr Pro Met Tyr Asn Thr Phe Gln Asp Val Phe Glu Phe 
415 
Ser Arg Ile Leu Lys Asn Ser Leu Glu Ala 
420 425 
?
< 210 > SEQ ID NO 23 
< 211 > LENGTH : 426 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Cystobacter fuscus 
mm mmm 
mmmmm mm mmmmm 
< 400 > SEQUENCE : 23 
Met Ser Gly Glu Ala Val Arg Phe Glu Pro Gly Glu Ala Phe Ala Arg ?
. 15 
Arq Met Asp Ala Glu Asp Pro Leu Ara Ser Phe Art Glu Glu Phe Leu 
? &
rg TEE So Phe Pro Val His Gly Asp Gly His Glu Leu Tyr Leu Leu Gly Asn Ser 35 45 40 ? Leu Gly Leu Gin Pro Arg Lys Ala Lys Glu Tyr Val Leu Ala Ala Met 55 
Glu Asp Trp Ala Arg Leu Gly Val Asp Gly His Phe Lys Gly Ser Pro 
70 8 
Pro Trp Met Glu Phe His Val Gly Leu Gly Glu Gin Met Ala Arg Val 
85 95 
Val Gly Ala Arg Pro Glu Glu Val Val Val Met Asn Thr Leu Thr Val 
AI JAsn Leu His Leu Met Met Val Ser Phe Tyr Arg Pro Thr Pro Glu Arq 115 120 125 Ser Lys Ile Leu Met Glu Ala Ser Ala Phe Pro Ser Asp Gin Tyr Ala 
135 E BE6
Val Ala Ala Gin Val Arg His His Gly Tyr Ser Pro Glu Gln Thr Val 
150 
Ile Pro Leu Ala Pro Arg Pro Gly Glu His Thr Leu Arg His Glu Asp 
165 175 
Ile Leu Asp Thr Leu Glu Arg His Gly Lys Glu Ile Ala Leu Val Leu 
US 9 , 975 , 959 B2 
97 98 
- continued 
? Leu Gly Asn Val Asn Tyr Leu Thr Gly Gin Ala Phe Asp Met Ala Ala 
195 200 
Ile Thr Arg Ala Ala His Gin Arg Gly cys Arg Val Gly Phe Asp Leu °?
I EE
SERGR mm Ala His Ala Ala Gly Asn Leu Arg Leu Ser Leu His Glu Asp Gly Pro 240 Asp Phe Ala Val Trp Cys Thr Tyr Lys Tyr Leu Asn Gly Gly Pro Gly 255 &Aga
Ala Leu Gly Gly Val Phe Ile His Glu Arg His Leu Arg Asp Ala Ser 
265 
Leu His Arg Leu Pro Gly Trp Trp Gly Asn Asp Arg Gly Thr Arg Phe 
275 280 
Gin Met Lys Pro Asp Phe Glu Pro Ala Pro Gly Ala Glu Gly Trp Val 
8? Leu Ser Asn Pro Pro Ile Ile Gln Met Ala Ala Leu Arq Ala Ser Leu 320 mmmm mmmmm mmm mmmmm mm Glu Leu Phe Asp Arq Ala Thr Met Pro Ala Leu Arq Ala Lys Ser Glu 335 Lys Leu Thr Gly Tyr Leu Glu Phe Leu Ile Asp Arg Leu Pro Glu Gly 345 Phe Val His Ser Leu Thr Pro Arg Asp Pro Gly Gin Arg Gly Ala His 355 360 Leu Ser Leu Arg Phe Thr Lys Asp Pro Gln Arg Met Yeu Glu Thr Leu Arg Ala Glu Gly Ile His Cys Asp Phe Arg Tyr Pro Asp Ile Ile Arg 385 400 Ala Ala Pro Val Pro Leu Tyr Asn Ser Phe Leu Asp Val His Arq Phe 405 415 Val Ser Val Leu Glu Arg Tyr Ala Arg Gly 420 425 
< 210 > SEQ ID NO 24 
< 211 > LENGTH : 426 
12 > TYPE : PRT 
13 > ORGANISM : Echinicola vietnamengig DSM 17526 
v 2 
v 2 
< 400 > SEQUENCE : 24 
Met Ser Ser Tyr Arg Tyr Ser Leu Ala Phe Ala Gin Glu Arg Asp Arg 
Glu Asp Pro Leu Arg Lys Phe Gin Ser Arg Phe His Phe Pro Lys Val 
20 25 
3 Asn Gly Glu Ala Ala Ile Tyr Phe cys Gly Asn Ser Leu Gly Leu Gin 
40 mmm smmmm Pro Lys Ala Val Arg Glu His Leu Asp Arg Asp Leu Glu Ser Trp Ala 55 







Ser Lys Ala Val Asp Gly His Phe Glu Gly Asp Ala Pro Trp Phe Ser 
70 
g d
Val His Glu Arq Ser Lys Ala Ala Leu Ala Glu Ile Val Gly Ala Lys 
95 
m
8? Lys His Glu Val Val Ala Met Gl ? Ser Leu Thr Thr Asn Leu His Ala 100 105 Lys His Glu val val Ala Met Gly Leu Leu Val Ser Phe Tyr Gin Pro Asn Gly Lys Arg Asn Lys Ile Leu 120 Thr Glu Ala Gly Ala Phe Pro Ser Asp Met Tyr Ala Leu Glu Ser Gin 




Val Lys Tyr His Gly Leu Asp Pro Asp Glu Ala Ile Val Glu Val Gly 
160 
E &
1 Pro Arq Pro Gly Glu His Thr Ile Arq Thr Glu Asp Ile Leu Gln Ala 
165 175 
Ile Ser Lys His Gin Asp Glu Leu Ala Cys Val Met Met Ala Gly Leu 
180 190 | 
Gin Tyr Tyr Thr Gly Gin Val Phe Asp Met Lys Ala Ile Ala Ser Ala 
195 200 205 
Ala His Ala Val Gly Ala Thr Val Gly Phe Asp Leu Ala His Ala Ala 
Gly Asn Ala Pro Leu His Leu His Asp Trp Gly Val Asp Phe Ala Ala RB
Trp Cys Ser Tyr Lys Tyr Leu Asn Ser Gly Pro Gly Asn Val Ala Gly 
245 255 
&
Ile Phe Val His Glu Arg His Gly Asn Asn Pro Ala Leu Asn Arg Phe 
260 270 
PR 33 Ala Gly Trp Trp Gly His Asp Glu Lys Val Arg Phe Lys Met Glu Lys 275 280 285 mmmmmm mmmm mmmm mmmmmm mmmmm mmmm 3 mmGly Phe Val Pro Met Tyr Gly Ala Asp Gly Trp Gin Asn Ser Asn Gly Asn Val Leu Gly Met Ala Ala His Gin Ala Ser Leu Asp Ile Phe Gln Glu Ala Gly Met Val His Leu Arg Lys Lys Ser Val Gin Leu Thr Gly 325 335 Phe Leu Ala Phe Leu Ile Arg Glu Ile Ser Gly Glu Ser Gly Val Leu 340 350 3 Glu Val Ile Thr Pro Asn Ala Glu Ala Glu Arg Gly Cys Gin Leu Ser 355 360 365 Leu Leu Ile His Lys Gly Gly Lys Ala Val Phe Asp Glu Phe Tyr Gin Asn Gly Ile Val Gly Asp Trp Arg Asn Pro Asn Val Ile Arg Ile Ala ? Pro Thr Pro Leu Tyr Asn Ser Phe Glu Asp Val Phe Arg Phe Ala Lys 405 415 ?Ile Leu Glu Gin Ser Leu Ser Lys Phe Ala 420 425 < 210 > SEQ ID NO 25 < 211 > LENGTH : 420 1 < 212 > TYPE : PRT 
< 213 > ORGANISM : Flavobacteria bacterium BBFL7 
< 400 > SEQUENCE : 25 
Met Glu Phe Asn Thr Thr Arg Asp Tyr Ala Leu Gin Leu Asp Gin Glu 
10 
? Asp Ser Leu Ser Ara Phe Ara Glu Ser Phe His Ile Pro Lys His Thr 
25 
Lya His The 
& 
Asp Gly Thr Asp Ser Ile Tyr Leu Cys Gly Asn Ser Leu Gly Leu Gin 
Pro Arg Gin Thr Lys Thr Phe Leu Asn Gin Glu Leu Asp Asp Trp Ala 
55 50 
Lys Leu Gly Val Glu Gly His Phe His Ala Glu Asn Pro Trp Met Pro 
65 75 ? 
US 9 , 975 , 959 B2 
101 101 1 102 
- continued 
Tyr His Glu Phe Leu Thr Glu Thr Thr Ala Gin Val Val Gly Ala Lys 
95 
| 
Pro His Glu Val Val Ile Met Asn Thr Leu Thr Thr Asn Leu His Leu 
105 110 
Met Met Val Ser Phe Tyr Gin Pro Lys Gly Lys Arg Thr Lys Ile Ile 
120 125 
Ile Glu Ala Asp Ala Phe Pro Ser Asp Arg Tyr Ala Val Ala Ser Gin 
135 
Val Gin Phe His Gly His Asp Asp Lys Glu Asn Ile Ile Glu Trp Ala 
145 150 160 
3
Pro Arg Thr Gly Glu His Thr Pro Arg Leu Glu Asp Leu Glu Thr Ile ?
175 
Leu Lys Glu Gin Gly Asp Glu Ile Ala Leu Ile Met Val Gly Ala Val 
185 190 
Asn Tyr Tyr Thr Gly Gin Phe Phe Asp Leu Lys Lys Ile Thr Glu Leu 
200 205 
Gly His Ala Ala Gly Ala Met Val Gly Phe Asp Cys Ala His Gly Ala 
215 
Gly Asn Val Asp Leu Gin Leu His Asp Ser Gly Ala Asp Phe Ala Val 
225 230 240 
Trp Cys Thr Tyr Lys Tyr Met Asn Ser Gly Pro Gly Ser Leu Gly Gly 
245 | 255 3mm mmm mmmmm mmmmmmm mmmmmmm 3mm mmmmm Cys Phe Val His Glu Arg His Ala Asn Asn Ser Glu Leu Pro Arg Phe 265 270 Thr Gly Trp Trp Gly His Asn Lys Asp Thr Arg Phe Lys Met Arg Asp 280 285 mmmmmm HAsp Phe Glu Pro Met His Gly Ala Glu Gly Trp Gin Leu Ser Asn Pro 295 Pro Ile Leu Ser Met Val Ala Ile Arg Ala Ser Leu Asp Leu Phe Ala 305 310 320 Gln Ala Gly Phe Glu Asn Leu Arq Lys Lys Ser Ile Gln Leu Thr Asn 335 Tyr Leu Glu Tyr Leu Val Gly Glu Leu Asp Gly Asp Arg Ile Ser Ile 345 350 Ile Thr Pro Arg Asp Pro Lys Asp Arg Gly Cys Gin Leu Ser Leu Ala 360 365 Val Lys Asn Ala Asp Lys Ser Leu Phe Asp Ala Ile Thr Ala Lys Gly 375 Val Ile Ala Asp Trp Arg Glu Pro Asp Val Ile Arg Ile Ala Pro Val 385 390 400 & Pro Leu Tyr Asn Asn Tyr Glu Asp Cys Trp Arg Phe Val Asp Val Leu 415 Lys Ser Glu Leu 420 < 210 > SEQ ID NO 26 
< 211 > LENGTH : 442 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Flexibacter litoralis DSM 6794 
< 400 > SEQUENCE : 26 
Met Asn Phe Glu Thr Thr Lys Asn Phe Ala Ser Gin Leu Asp Asn Asn 
15 101 
Asp Ser Leu Ala His Phe Arg Asp Lys Phe Trp Ile Pro Thr Leu Asn 
25 20 30 
US 9 , 975 , 959 B2 
103 104 
- continued 
? ser le ser Eye Aan the Ser Ile Ser Lys Asn Thr Asn Ser Ser Asn Glu Lys Gly Lys Glu Lys 40 





° Lys Ala Tyr Ile Glu Gin Glu Leu Glu Asp Trp Lys Asn Leu Gly Val 
80 
Glu Gly His Phe His Gly Lys Asn Pro Trp Leu Ser Tyr His Lys Leu 
90 95 
Leu Thr Asn Gin Thr Ala Lys Ile Val Gly Ala Lys Pro Ile Glu Val 
105 110 
? Val Val Met Asn Asn Leu Thr Val Asn Leu His Leu Leu Met Val Ser 
120 
Phe Tyr Arg Pro Asn Gin Lys Arg Phe Lys Ile Leu Met Glu Gly Gly 
135 
?
Ala Phe Pro Ser Asp Gin Tyr Ala Ile Glu Ser Gin Val Lys Phe His 
160 
Gly Phe Ser Pro Asp Asp Ala Ile Val Glu Met Met Pro Arg Lys Asn 
175 170 
Glu Asn Ser Glu Gly Glu Glu Thr Leu Arg Thr Glu Asp Ile Leu Lys 
185 190 
Lys Ile Glu Glu Leu Gly Asp Glu Leu Ala Leu Val Met Phe Gly Gly 
200 
Val Asn Tyr Tyr Thr Gly Gin Phe Phe Asp Leu Glu Lys Ile Thr Gin 
215 
Ala Ala His Lys Val Gly Ala Thr Ala Gly Phe Asp Leu Ala His Ala 
240 
Ala Gly Asn Val Pro Leu Lys Leu His Asp Trp Lys Val Asp Phe Ala 
250 255 mmmmmmm mmmmmmm mmm Thr Trp Cys Ser Tyr Lys Tyr Leu Asn Ser Gly Ala Gly Gly Thr Ser 265 270 Gly Val Phe Ile Asn Glu Lys Tyr Ala Asp Asp Asp Ser Leu Pro Arg 280 mmmmmmmm mmmmmm ?&Phe Ala Gly Trp Trp Gly His Asp Glu Lys Asp Arg Phe Lys Met Lys 295 Lys Gly Phe Ile Pro Met Arg Gly Ala Glu Gly Trp Gin Leu Ser Asn 320 Ala Gln Ile Leu Pro Met Ala Val His Lys Ala Ser Leu Asp Ile Phe 330 335 Glu Glu Ala Gly Phe Glu Asn Leu Arg Gin Lys Ser Glu Gin Leu Thr 345 350 Val Tyr Met Glu Phe Leu Ile Glu Asn Phe Asn Lys Glu Gin Ser Lys 360 Ile Lys Ile Lys Ile Ile Thr Pro Lys Asn Lys Leu Glu Arg Gly Cys 375 380 Gin Leu Ser Leu Val Phe Asp Lys Glu Gly Lys Lys Tyr His Glu Thr 400 Leu Thr Lys Arg Gly Val Ile Ser Asp Trp Arg Glu Pro Asn Val Ile 410 415 Arq Ile Ala Pro Ile Pro Leu Tyr Asn Ser Phe Met Asp Cys Tyr Arg 425 430 Bro Ile Pro Leu Tyr Aan ser SPE ??Phe Tyr Glu Ile Leu Lys Glu Ile Ala Val 440 
US 9 , 975 , 959 B2 
105 106 
- continued 
< 210 > SEQ ID NO 27 
< 211 > LENGTH : 423 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Formosa sp . AK20 
< 400 > SEQUENCE : 27 
Met Ser Asn Tyr Lys Pro Gly Leu Asp Tyr Ala Lys Glu Gin Asp Gin 
Asn Asp Ala Leu Ser His Tyr Arg Ser Gin Phe His Ile Pro Lys Asp 
20 130 25 





Gin Pro Lys Ser Thr Gin Lys Tyr Ile Gin Gin Glu Leu Asp Asp Trp 
Ala Asn Leu Gly Val Glu Gly His Phe Glu Ala Lys Asn Pro Trp Met 
70 75 
Pro Tyr His Glu Phe Leu Thr Asp Ser Met Ala Lys Ile Val Gly Ala 
Lys Pro Ile Glu Val Val Thr Met Asn Thr Leu Thr Thr Asn Leu His 
100 105 110 
Leu Leu Met Val Ser Phe Tyr Gin Pro Thr Lys Thr Lys Tyr Lys Ile 
115 120 
Val Ile Glu Ser Asp Ala Phe Pro Ser Asp Arg Tyr Ala Val Gin Thr 
Gin Leu Glu Phe His Gly Phe Asp Ala Asn Glu Gly Leu Ile Glu Trp 
150 155 
Lys Pro Arg Gin Gly Glu Glu Leu Leu Asn Leu Asp Asp Leu Glu Thr 
Ile Leu Glu Glu Gin Gly Asp Glu Ile Ala Leu Leu Leu Ile Gly Gly 
180 185 190 mmmmm mmmmmm am am 5 mmmmmmm mmmm Val Asn Tyr Tyr Thr Gly Gin Tyr Leu Asp Leu Lys Lys Ile Ala Glu 195 200 Leu Gly His Ala Lys Asn Cys Met Val Gly Ile Asp Leu Ala His Gly Ala Gly Asn Ile Lys Pro Glu Leu His Asp Ser Gly Val Asp Phe Ala 230 235 Ala Trp Cys Thr Tyr Lys Tyr Leu Asn Ser Gly Pro Gly Ser Leu Gly Gly Leu Phe Val His Glu Lys His Ala His Asn Lys Lys Leu Lys Arg 260 265 270 Phe Ala Gly Trp Trp Ser His Asn Lys Ala Thr Arg Phe Asn Met Arg 275 280 Gin Pro Leu Asp Val Ile Pro Gly Ala Glu Gly Trp Gin Leu Ser Asn Pro Pro Ile Leu Ser Met Ala Ala Ile Lys Ala Ser Leu Asp Met Phe 310 315 Asn Glu Val Gly Met Asp Ala Leu Arg Glu Lys Ser Glu Lys Leu Thr Gly Tyr Phe Glu Phe Leu Leu Asn Glu Leu Asn Asn Asp Lys Val Lys 340 345 350 & Ile Ile Thr Pro Ser Asn Pro Lys Glu Arg Gly Cys Gin Leu Ser Ile 355 360 Gin Val Arg Asp Ala Asp Lys Ser Leu His Lys Lys Leu Thr Lys Ala 370 
US 9 , 975 , 959 B2 
107 108 . 
- continued 
E His Ile Ile Thr Asp Trp Arg Glu Pro Asp Val Ile Arg Cys Ala Pro 
385 390 395 400 
Val Pro Leu Tyr Asn Ser Phe Glu Asp Val Tyr Arg Met Val Asp Lys 
405 410 415 
Leu Lys Gin Ile Leu Asn Thr 
420 
< 210 > SEO ID NO 28 
< 211 > LENGTH : 429 
< 212 > TYPE : PRT 
< 213 > ORGANI SM : Fulvivirga imtechensis 
< 400 > SEQUENCE : 28 
? Met Ala Lys Asp Ile Leu His Met Thr Tyr Glu Asn Ser Leu Thr Phe 
15 
Ala Gin Asp Leu Asp Arg Asp Asp Pro Leu Arg His Phe Arg Asn Lys 
25 30 
3 &g
Phe His Ile Pro Gin Leu Asn Asp Lys Asp Val Ile Tyr Phe Thr Gly 
35 40 1 
J 
Asn Ser Leu Gly Leu Gln Pro Lys Asn Thr Arq Val Tyr Ile Glu Glu 
Glu Leu Glu Gly Trp Ala Thr Leu Gly Val Asp Gly His Phe His Ser 
70 65 80 
? Gin Lys Arg Pro Trp Phe Tyr Tyr His Lys Phe Ser Lys Glu Ala Leu 
95 
Ala Lys Ile Val Gly Ala Lys Pro Ser Glu Val Val Ser Met Asn Asn 
105 110 
Leu Thr Val Asn Leu His Leu Met Met Val Ser Phe Tyr Arg Pro Thr 
115 120 mmmmmm mmm Ser Ser Arg Phe Lys Ile Met Ile Glu Ala Gly Ala Phe Pro Ser Asp Gin Tyr Ala Val Glu Ser Gin Ile Lys Phe His Gly Tyr Asn Tyr Glu 145 150 160 mem mmmmmmmmm mmmmmmm Asp Ala Leu Ile Glu Ile Ser Pro Arg Glu Gly Glu Tyr His Leu Arg 175 Thr Glu Asp Ile Leu Ser Lys Ile Glu Glu Asn Lys Asp Ser Leu Ala 185 190 Leu Val Leu Phe Gly Gly Val Gin Tyr Tyr Thr Gly Gin Leu Phe Asp 195 200 Ile Gly Ser Ile Thr Ala Ala Gly His Trp Ala Gly Ala Ile Val Gly Phe Asp Leu Ala His Ala Ala Gly Asn Val Pro Leu Asn Leu His Asn 225 | 230 240 Asp Gin Val Asp Phe Ala Ala Trp Cys Ser Tyr Lys Tyr Leu Asn Ser 255 Gly Pro Gly Gly Val Ser Gly Ile Phe Val His Glu Lys His Gly Asp 265 270 3mm Ala Glu Leu Pro Arg Phe Ala Gly Trp Trp Gly His Asn Glu Ser Glu 275 280 Arg Phe Lys Met Lys Lys Gly Phe Ile Pro Met Ser Gly Ala Asp Gly 
Trp Gln Leu Ser Asn Val Asn Ile Leu Ser Ser Ala Ala His Leu Ala 
305 310 320 0
. | 
Ala Leu Glu Ile Tyr Asp Glu Ala Gly Met Glu Ala Leu Arg Gin Lys 
US 9 , 975 , 959 B2 
109 . 110 
- continued 
325 330 335 
| 
Ser Ile Arq Leu Thr Gly Phe Met Glu Tyr Leu Leu Asn Gly Phe Asn 
340 345 350 Ba Phe An 
& ? Leu Gly Asp Asp Val Leu Lys Ile Ile Thr Pro Thr Asp Pro Ala Ala 
355 360 365 




3 mmm am A Phe Glu His Leu Thr Arg Ser Gly Val Val Ala Asp Trp Arg Glu Pro 385 390 400 
Asp Val Ile Arg Val Ala Pro Val Pro Leu Tyr Asn Thr Phe Glu Asp 
405 415 
Val Tyr Asn Phe Cys Glu Ile Leu Lys Lys Val Ile Phe 
420 425 
< 210 > SEQ ID NO 29 
< 211 > LENGTH : 425 
< 212 > TYPE : PRT 
13 > ORGANISM : Kangiella aqui marina 2 
< 400 > SEQUENCE : 29 
? Met Thr Asp Ile Phe Ser Ile Asp Tyr Ala Arg Gin Leu Asp Gin Gin 
Asp Pro Ile Ser Arg Met Arg Glu Gin Phe His Ile Pro Lys Gin Asp &
o 




Pro Lys Arg Thr Gin Glu Tyr Leu Asn Tyr Glu Leu Ser Gin Trp Gin 
g 1
To 
Lys Leu Gly Val Lys Gly His Phe Ser Gly Asp Phe Pro Trp Met Pro 
80 
D E
Tyr His Glu Phe Leu Thr Glu Glu Ser Ala Lys Leu Val Gly Ala Lys am Asn Ser Glu Val Val Cys Met Asn Ser Leu Thr Ala Asn Leu His Phe Met Met Val Ser Phe Tyr Arg Pro Thr Ala Thr Arg Asn Lys Ile Leu 120 125 Ile Glu Asp His Ala Phe Pro Ser Asp His Tyr Ala Val Glu Ser Gin 
Val Arg Tyr His Gly Phe Asp Pro Asp Gin Ala Met Leu Leu Ala Lys 
160 
Pro Arg Glu Gly Glu Glu Thr Leu Arg Thr Glu Asp Leu Leu Asn Leu 
Ile Glu Leu His Gly Glu Glu Ile Ala Leu Ile Met Leu Pro Gly Val 
Gin Tyr Tyr Thr Gly Gin Val Leu Asp Met Lys Ala Ile Thr Gin Ala 
200 205 |
Gly His Ala Lys Gly Cys Lys Val Gly Phe Asp Leu Ala His Ala Thr 
220 215 
Gly Asn Ile Pro Met His Leu His Asp Trp Asp Val Asp Phe Ala Ala 
240 EAR Trp Cys Ser Tyr Lys Tyr Leu Asn Ser Gly Pro Gly Ser Val Ala Gly 
Cys Phe Val His Glu Lys His His Thr Asn Met Glu Leu Pro Arg Phe &
US 9 , 975 , 959 B2 
111 112 
- continued 
Ala Gly Trp Trp Gly His Asp Lys Asp Ser Arg Phe Lys Met Glu Asn 





His Phe Ile Pro Met Lys Ser Ala Glu Ala Trp Gin Leu Ser Asn Pro 
295 300 
Pro Ile Leu Ser Leu Ala Ala Ile Arq Ala Ser Leu Asp Thr Ile Lys °
Asp Ala Gly Gly Ile Gin Ala Leu Arg Asp Lys Ser Leu Lys Leu Ser 
330 335 
Arg Tyr Leu Arg Asp Leu Leu Glu Gin Glu Leu Ala Asp Glu Ile Asn 
345 mmmm mm Ile Leu Thr Pro Ala Asp Glu Lys Ala Ser Gly Cys Gin Leu Ser Leu 355 360 365 mm Thr Val Asn Leu His Gly Leu Asp Gly Lys Thr Val Phe Asp Arg Ile 375 380 Glu Ala Ala Gly Val Thr Cys Asp Phe Arq His Pro Asn Val Ile Arq 395 400 ?SEE Val Ala Pro Val Pro Leu Tyr Asn Ser Phe Glu Asp Ala Tyr Arg Phe 410 415 Val Thr Ile Leu Lys Asp Ser Leu Lys 
420 425 ?
< 210 > SEQ ID NO 30 
< 211 > LENGTH : 425 | 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Kangiella koreensis DSM 16069 
< 400 > SEQUENCE : 30 
? Met Asn Asn Leu Phe Ser Leu Glu His Ala Gin Gin Leu Asp Gin Gin ?
& Asp Pro Leu His His Met Arg Asp Gin Phe His Ile Pro Lys Gin Asp 
20 30 
Asn Gly Asp Asp Glu Ile Tyr Leu Cys Gly Asn Ser Leu Gly Leu Gin 
35 40 am 
?
Egg a2
Pro Lys Arg Thr Gin Glu Tyr Leu Asn Tyr Glu Leu Asn Gin Trp Gin 
Lys Leu Gly Val Lys Gly His Phe Ser Gly Asp Phe Pro Trp Met Pro 
70 8 
Tyr His Glu Phe Leu Thr Glu Glu Ser Ala Lys Leu Val Gl 
Asn Thr Glu Val Val Cys Met Asn Ser Leu Thr Ala Asn Leu His Phe 
100 110 mmm Met Met Val Ser Phe Tyr Arg Pro Ser Lys Thr Arg Asn Lys Ile Leu 115 120 Ile Glu Asp His Ala Phe Pro Ser Asp His Tyr Ala Val Glu Ser Gin Ile Arg Phe His Gly Phe Asp Pro Asp Gin Ala Met Leu Leu Ala Lys 150 mmmm Pro Arg Glu Gly Glu Glu Thr Leu Arg Thr Glu Asp Leu Leu Asn Leu Ile Glu Met His Gly Asp Glu Ile Ala Leu Ile Met Leu Pro Gly Val 180 190 mm Gin Tyr Tyr Thr Gly Gin Val Leu Asp Met Lys Thr Ile Thr Glu Ala 195 200 Gly His Ala Lys Gly Cys Met Val Gly Phe Asp Leu Ala His Ala Thr 210 




Gly Asn Ile Pro Met Asn Leu His Asp Trp Asn Val Asp Phe Ala Ala 
225 230 235 
Trp Cys Thr Tyr Lys Tyr Leu Asn Ser Gly Pro Gly Ser Val Ala Gly 





&13 Cys Phe Val His Glu Lys His His Ser Asn Leu Glu Leu Pro Arg Phe 265 270 
Ala Gly Trp Trp Gly His Asp Lys Glu Ser Arg Phe Arg Met Glu Asn 
280 
Arg Phe Val Pro Met Gin Ser Ala Glu Ala Trp Gin Val Ser Asn Pro 
295 
Pro Ile Leu Ser Leu Ala Ala Ile Arg Ala Ser Leu Asp Thr Val Lys 
305 310 315 mmmmm mmm mmm Glu Ala Gly Gly Ile Asp Ala Leu Arg Glu Lys Ser Leu Lys Leu Thr 335 mmm Arg Tyr Leu Arg Asp Leu Leu Glu Gin Glu Leu Ser Glu Glu Ile Asn 345 350 | Ile Leu Thr Pro Ala Asp Asn Ser Ala Ser Gly Cys Gin Leu Ser Leu 360 Thr Val Asn Leu His Val Leu Asp Gly Lys Thr Val Phe Asp Arg Ile 375 Glu Ala Ala Gly Val Thr Cys Asp Phe Arg His Pro Asn Val Ile Arq 385 390 395 SEE Val Ala Pro Val Pro Leu Tyr Asn Ser Phe Glu Asp Ala Tyr Arg Phe 415 ? Val Ser Ile Leu Lys Asp Ser Leu Gin 420 425 
1 
< 210 > SEQ ID NO 31 
< 211 > LENGTH : 421 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Lacinutrix sp . 5H - 3 - 7 - 4 
2 
3 
< 400 > SEQUENCE : 31 
Met Ser Asn Tyr Thr Leu Gly Arg Asp Phe Ala Gin Gin Leu Asp Lys 
|
3 Glu Asp Gln Leu Ala His Tyr Arg Asn Gln Phe His Ile Pro Lys Asp 
120 
&
Lys Asn Gly Asp Asp Leu Ile Tyr Leu Cys Gly Asn Ser Leu Gly Leu 





2 0am m smsm 55 Ala Asn Leu Gly Val Glu Gly His Thr Glu Gly Lys Asn Pro Trp Leu ? 23? am Pro Tyr His Glu Phe Leu Thr Glu Ser Met Ala Lys Val Val Gly Ala 85 & Lys Pro Ile Glu Val Val Val Met Asn Thr Leu Thr Ala Asn Leu His 100 mmm & Phe Met Met Val Ser Phe Tyr Lys Pro Thr Lys Lys Arg Tyr Lys Ile 115 120 Leu Ile Glu Ala Asp Ala Phe Pro Ser Asp Lys Tyr Ala Val Glu Ser 135 Gin Leu Arg His His Gly Phe Asp Asp Lys Glu Gly Leu Val Leu Trp 
160 ? 
Lys Ala Arg Glu Gly Glu Glu Leu Ala Asn Tyr Glu Asp Leu Glu Ala 





? Ile Leu Glu Ala Gin Gly Asp Glu Ile Ala Leu Ile Met Ile Gly Gly 
180 185 190 | 
g Val Asn Tyr Tyr Thr Gly Gin Phe Phe Asp Phe Lys Arg Ile Ala Ala 
195 200 205 
??
E 
3 E Leu Gly His Lys Asn Gly Cys Met Val Gly Phe Asp Cys Ala His Gly 
Ala Gly Asn Val Asn Leu Asp Leu His Asn Ser Gly Ala Asp Phe Ala 
225 235 240 
Val Trp Cys Thr Tyr Lys Tyr Met Asn Ala Gly Pro Gly Ser Leu Ser 8gT
A B
Gly Cys Phe Val His Glu Arg His Ala His Asn Lys Asp Leu Asn Arg 
260 265 
Phe Thr Gly Trp Trp Ser His Asn Lys Glu Thr Arg Phe Asn Met Arg 
275 280 285 SET Gly Glu Phe Asp Gin Leu Pro Gly Ala Glu Gly Trp Gin Leu Ser Asn & mmm mmm Pro Pro Ile Leu Ser Met Ala Ala Ile Lys Ala Ser Ala Asp Ile Phe 305 315 320 && E -mm mmma Ala Glu Val Gly Met Glu Lys Leu Thr Gin Lys Ser Lys Lys Leu Thr Gly Tyr Phe Glu Phe Leu Leu Asn Glu Leu Asn Asn Ser Asp Ile Lys 340 345 Ile Ile Thr Pro Ser Asn Pro Asn Glu Arg Gly cys Gin Leu Ser Ile 355 360 365 Gin Val Lys Asn Ala Asp Lys Ala Leu His His Lys Leu Thr Glu Ser JBS &° Gly Val Ile Ser Asp Trp Arg Glu Pro Asp Val Ile Arg Cys Ala Pro 385 395 400 Val Pro Leu Tyr Asn Ser Phe Glu Asp Val Tyr Asn Met Val Glu Arq ? Leu Lys Ala Cys Leu 420 < 210 > SED ID No 32 
< 211 > LENGTH : 428 
< 212 > TYPE : PRT 
< 213 > ORGANISM : cecembia lonarensis TREE cecen 
< 400 > SEQUENCE : 32 
Met Thr Thr Thr Asp Phe Glu Tyr Thr Glu Asp Phe Ala Lys Arg Met ??
? 
Asp Asp Leu Asp Pro Phe Arg His Phe Arg Ser Met Phe His Phe Pro 
20 25 
Tyr Val Asn Gly Lys Glu Ala Ile Tyr Phe Cys Gly Asn Ser Leu Gly 
35 40 8
J EEE Leu Gin Pro Lys Ser Val Arg Glu Tyr Leu Asp Arg Glu Leu Lys Asn 55 Trp Glu Leu Met Ala Val Asp Gly His Phe His Gly Glu Asp Ala Trp 70 mms mem ggg R8 mms mas e Tyr His Val Arg Lys Lys Ser Lys Pro Ala Leu Ala Glu Ile Val Gly 85 Ala His Glu His Glu Val Val Ala Met Asn Asn Leu Ser Ser Asn Leu 100 105 ?
US 9 , 975 , 959 B2 
117 118 . 
- continued 
| 
? ? His Phe Leu Met Val Ser Phe Tyr Arg Pro Thr Lys Glu Arg Tyr Lys 
115 120 ·? | 
Ile Ile Thr Glu Ala Gly Ala Phe Pro Ser Asp Met Tyr Met Leu Glu ?
Thr Gin Val Lys Phe His Gly Phe Asp Pro Ala Asp Ala Ile Ile Glu 
145 150 160 
Val Ala Pro Arg Pro Gly Glu Tyr Thr Ile Arg Thr Glu Asp Ile Leu 
170 175 
Ala Ala Ile Glu Asp Asn Gin Asp Glu Leu Ala Leu Val Met Met Ala 
180 185 190 
Gly Leu Gin Tyr Tyr Thr Gly Gin Val Phe Asp Met Glu Ala Ile Thr 
195 200 
Lys Ala Gly His Gly Ile Gly Val Pro Val Gly Phe Asp Leu Ala His 
Ala Ala Gly Asn Ile Pro Leu Arg Leu His Asp Trp Gly Val Asp Phe 
225 230 240 
3 ?4? 
Ala Ala Trp cys Ser Tyr Lys Tyr Leu Asn Ser Gly Pro Gly Asn Ile 
250 
m 
mmmmm?mmm mm 255 Ser Gly Ile Phe Val His Glu Arg His Ala Asp Asn Thr Glu Leu Pro 260 265 270 Arg Phe Gly Gly Trp Trp Gly His Asp Glu Ala Ile Arg Phe Lys Met 275 280 mmmmmmm mmmmm mmmmmmm mmmmm mmmmmm Glu Lys Gly Phe Glu Pro Met Tyr Gly Ala Asp Gly Trp Gin Leu Ala Asn Ser Asn Val Leu Ala Leu Ala Val His Gin Ala Ser Leu Asp Ile 305 310 320 Phe Gln Glu Ala Gly Met Glu Arg Leu Arg Thr Lys Ser Glu Leu Leu 330 335 Thr Gly Tyr Leu Glu Phe Leu Ile Arq Lys Val Gly Phe Ala Asn Gly 340 345 350 Val Leu Glu Ile Ile Thr Pro Asn Asn Pro Lys Glu Arg Gly Cys Gin 355 360 Leu Ser Leu Leu Val His Lys Gly Gly Lys Leu Val Phe Asp His Leu Tyr Ala Asn Gly Val Val Gly Asp Trp Arg His Pro Asn Val Ile Arq 385 390 400 Val Ala Pro Thr Pro Leu Tyr Asn Ser Phe Thr Asp Val Phe Arg Phe 410 415 Ala Lys Ile Leu Glu His Ser Leu Gin Lys Phe Ala 420 425 ?
< 210 > SEO ID NO 33 
< 211 > LENGTH : 429 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Mucilaginibacter paludis 
< 400 > SEQUENCE : 33 
Met Asn Tyr Gin Asn Thr Leu Ala Phe Ala Arg Glu Leu Asp Glu Gin 
15 s 
Asp Asn Leu Ala Gly Phe Arg Asn Glu Phe Ile Ile Pro Gin His His 
25 30 20 
Gly Arg Asp Met Ile Tyr Leu Cys Gly Asn Ser Leu Gly Leu Gin Pro ?3RE 1 Lys Ala Thr Ala Gly Val Ile Ala Glu Gin Leu Ser Asn Trp Gly Ser 
US 9 , 975 , 959 B2 
119 120 
- continued 
3 Leu Ala Val Glu Gly Trp Phe Glu Gly Asp Ser Pro Trp Met His Tyr 
65 170 m 
His Lys Lys Leu Thr Glu Pro Leu Ala Ala Ile Val Gly Ala Leu Asn 
901 
Thr Glu Val Val Ala Met Asn Thr Leu Thr Val Asn Leu His Phe Leu 
100 110 
Leu Val Ser Phe Tyr Arg Pro Thr Ala Lys Lys Tyr Lys Ile Leu Met 
115 120 
Glu Gly Gly Ala Phe Pro Ser Asp Gin Tyr Ala Ile Glu Ser Gin Val 
135 140 
His Phe His Gly Tyr Gin Pro Asp Asp Ala Ile Ile Glu Val Phe Pro 
145 150 
Arg Ala Gly Glu Asp Thr Leu Arg Thr Glu Asp Ile Ile Arg Thr Ile 
170 mmmmm His Asp His Ala Asp Asp Leu Ala Leu Val Leu Phe Gly Gly Ile Asn 180 | 190 Tyr Tyr Thr Gly Gln Phe Tyr Asp Leu GluGln Ile Thr Gln Ala Ala 195 200 His Gin Val Gly Ala Tyr Ala Gly Phe Asp Leu Ala His Ala Ala Gly 215 220 mmmmmm Asn Val Pro Leu Gin Leu His His Trp Gin Val Asp Phe Ala Cys Trp 225 230 m? mmmmm 
m 
mmmm mmmm mmm Cys Ser Tyr Lys Tyr Met Asn Ser Ser Pro Gly Gly Ile Ser Gly Ala 250 Phe Ile His Glu Lys His Phe Gly Asn Lys Glu Leu Asn Arg Phe Ala 260 270 E Gly Trp Trp Gly Tyr Arg Glu Asp Lys Arg Phe Glu Met Lys Pro Gly 275 280 Phe Lys Pro Gin Glu Gly Ala Glu Gly Trp Gin Val Ser Cys Ser Pro 295 300 Leu Leu Leu Met Ala Ala His Lys Ala Ser Leu Asn Val Phe Glu Lys 305 310 mmmmm Ala Gly Tyr Ile Glu Pro Leu Arg Lys Lys Ser Lys Leu Leu Thr Gly 330 Tyr Leu Glu Tyr Leu Ile Glu Gly Ile Asn Thr Ala His Gin Lys Gln 340 345 350 Leu Phe Lys Ile Ile Thr Pro Lys Asn Glu Asn Glu Arq Gl 355 360 Leu Ser Ile Val Cys Asp Asn Gly Lys Ala Ile Phe Asp Gin Leu Val 375 380 Glu Gly Gly Val Leu Gly Asp Trp Arg Glu Pro Asp Val Ile Arg Leu 385 390 mm Ser Pro Ile Pro Leu Tyr Asn Ser Phe Glu Asp Val Tyr Leu Ala Gly 410 415. Lys Leu Leu Ala Gly Ser Val Thr Gln Phe Phe Ala Glu 420 425 ?< 210 > SEQ ID NO 34 < 211 > LENGTH : 425 < 212 > TYPE : PRT < 213 > ORGANISM : Myroides odoratimimus < 400 > SEQUENCE : 34 Met Ser Phe Glu Asn Thr Leu Ala Tyr Ala Lys Ser Leu Asp Glu Lys 
US 9 , 975 , 959 B2 
121 122 . 
- continued 
1 . 10 15 




& Gly Lys Gin Val Ile Tyr Phe Thr Gly Asn Ser Leu Gly Leu Gin Pro 
40 35 
Lys Arg Ala Val Glu Tyr Val Asn Glu Val Met Asn Asp Trp Gly Ala 
55 
E 
Leu Ala Val Glu Gly His Phe Tyr Ala Glu Lys Pro Trp Trp Asp Tyr 
75 
n 
His Glu Arg Leu Ser Glu Pro Leu Ser Arg Ile Val Gly Ala Lys Ser 
95 85 
Ser Glu Ile Thr Val Met Asn Thr Leu Thr Val Asn Leu His Leu Leu 
105 
?
& Met Thr Thr Phe Tyr Arg Pro Thr Ala Ser Lys Tyr Lys Ile Ile Cys 
115 120 
Glu Glu Lys Ala Phe Pro Ser Asp Gin Tyr Leu Ile Gin Ser Gin Val 
135 
Arg Leu His Gly Leu Asp Pro Lys Glu Ala Ile Ile Glu Leu Lys Lys 
155 
Arg Pro Gly Glu His Asn Phe Arg Leu Glu Asp Ile Leu Glu Lys Ile 
165 175 
Asp Glu Val Gly Glu Glu Val Ala Leu Val Leu Ile Gly Gly Leu Asn 
185 
Tyr Tyr Thr Gly Gin Val Phe Asp Ile Gin Thr Ile Thr Ala His Ala 
195 200 
His Gin Tyr Gly Ala Lys Val Gly Trp Asp Leu Ala His Ala Ala Gly 
215 
Asn Ile Glu Leu Lys Leu His Glu Trp Asn Val Asp Phe Ala Ala Trp 
235 mmmmmmmm ammmm smmmm mmmm mmmmm mmmmmm mmmmmm mmm gmmmm mmm mmmmmmm Cys Ser Tyr Lys Tyr Met Asn Ala Gly Pro Gly Ser Ala Ser Gly Cys 245 255 Phe Ile His Glu Arg Tyr His Thr Asp Lys Asp Leu Val Arg Leu Ala 265 Gly Trp Trp Gly His Asn Lys Glu Arg Arg Phe Leu Met Glu Lys Lys 280 275 Phe Asp Ala Val Glu Ser Ala His Gly Trp Gin Ile Ser Asn Pro Ser 295 &Ile Leu Ser Leu Ala Pro Tyr Leu Ala Ser Ile Glu Met Phe Asp Glu 315 Val Gly Met Glu Ala Leu Ile Thr Lys Gin Arg Lys Ile Thr Ala Tyr 325 335 Leu Glu Phe Val Met Glu Asp Val Ala Lys Ala Val Asn Ala Asn Tyr 345 Glu Leu Ile Thr Pro Lys Glu Glu Ser Glu Arg Gly Ser Gin Leu Ser 355 360 Val Phe Leu His Gly Lys Gly Lys Asp Leu Phe Ser Tyr Leu Met Asn 375 ggg Glu Gly Val Ile Val Asp Trp Arg Glu Pro Asn Val Val Arg Leu Ala 395 Pro Val Pro Phe Tyr Thr Ser Tyr Glu Asp Ile Tyr Arg Phe Gly Glu 405 415 Ile Leu Lys Lys Ala Asp Ser Leu Phe 425 




< 210 > SEQ ID NO 35 
< 211 > LENGTH : 426 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Myxococcus fulvus HN - 1 
1 
1 
< 400 > SEQUENCE : 35 
Met Thr Thr Pro His Ala Phe Glu Asp Thr Glu Ala Phe Ala His Thr net The The Pro His ala Phe Glu Asp Tor Glu ala Phe Ala Hig The 
Leu Asp Ala Glu Asp Ala Leu Arg Gly Tyr Arg Asp Ala Phe His Phe 
25 30 
Pro Pro Gly Pro Asp Gly Lys Pro Val Val Tyr Leu Ala Gly Asn Ser 
45 
Leu Gly Leu Gin Pro Arq Asn Ala Ala Arg Tyr Ile Gln Glu Glu Leu 
REE 23?
Glu Asp Trp Ala Arg Leu Gly Val Glu Gly His His His Gly Arg His 
75 65 
Pro Trp Leu His Tyr His Glu Leu Val Thr Glu Gln Ala Ala Arg Leu 
Val Gly Ala Lys Pro Leu Glu Val Val Val Met Asn Thr Leu Ser Val 
105 110 
&8
Asn Leu His Leu Met Met Val Ser Phe Tyr Arg Pro Thr Lys Gin Arg 
125 
Phe Lys Ile Leu Val Glu Ala Gly Ala Phe Pro Ser Asp Gin Tyr Ala 8
Val Ala Ser Gin Val Arg Phe His Gly His Asp Ala Arg Glu Ala Val 
145 155 8 
& Leu Glu Leu Lys Pro Arg Glu Gly Glu Glu Thr Leu Arg Thr Glu Asp 
mmmm mmmmm mmmmmmmm 8 Ile Leu Asp Thr Leu Glu Arg His Gly His Glu Val Ala Leu Val Met 185 190 m? mmmmm mmmmmmm mmm 8 Leu Gly Ser Val Asn Tyr Leu Thr Gly Gin Ala Phe Asp Leu Ala Ala 205 R Ile Thr Lys Ala Ala His Ala Lys Gly Cys Leu Val Gly Phe Asp Leu Ala His Gly Ala Gly Asn Leu Lys Leu Ser Leu His Asp Asp Gly Pro 225 235 8 Asp Phe Ala Val Trp Cys Ser Tyr Lys Tyr Leu Asn Ala Gly Pro Gly Egn Ala Leu Gly Gly Val Phe Val His Glu Arg His Ala His Thr Lys Asp 265 270 8Leu Pro Arg Phe Glu Gly Trp Trp Gly His Asp Lys Gin Thr Arg Phe 285 Gin Met Gly Pro Thr Phe His Ala Leu Pro Gly Ala Glu Gly Trp Gin ?2 1? Leu Ser Asn Pro Pro Ile Phe Gin Leu Ala Ala Leu Arq Ala Ser Leu 305 310 315 Glu Leu Phe Asp Gin Ala Gly Met Ala Ala Leu Arg Ala Lys Ser Glu 325 Arg Leu Thr Gly Tyr Leu Glu Phe Leu Leu Asp Lys Leu Pro Gin Gly 345 350 
Phe Val Arg Ile Thr Thr Pro Arg Asp Val Lys Gin Arg Gly Ala Gin 
360 365 
Leu Ser Leu Arg Phe Arg Gly Glu Pro Gin Gly Leu Leu Lys Arg Met 
US 9 , 975 , 959 B2 
125 126 
- continued 
370 375 380 
Gly Asp Ala Gly Ile Val Cys Asp Phe Arg Lys Pro Asp Ile Ile Arg 
385 390 | 395 400 
? Ala Ala Pro Ala Pro Leu Tyr Asn Ser Phe Thr Asp Val Tyr Arg Phe 
405 410 415 Asp val Tyr Ars Phe 
1 
Val Lys Ala Leu Glu Gly Tyr Ala Arg Glu 
420 425 Tyr Ala Arg Giu 
< 210 > SEQ ID NO 36 
< 211 > LENGTH : 425 | 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Myxococcus stipitatus DSM 14675 
< 400 > SEQUENCE : 36 
Met Thr Thr His Ser Phe Glu Asp Thr Glu Asp Phe Ala Arg Arg Ala ?
10 
Asp Glu Ala Asp Ala Leu Arg Ser Phe Arg Asp Ala Phe His Phe Pro 
25 30 
&
& 3 Pro Gly Thr Asp Gly Lys Pro Leu Val Tyr Leu Ala Gly Asn Ser Leu 
35 40 
Gly Leu Gin Pro Lys Asn Ala Ala Arg Tyr Val Gin Glu Glu Leu Glu 
R 
Asp Trp Ala Arg Phe Gly Val Glu Gly His His His Gly Arg His Pro 
E 
Trp Leu His Tyr His Glu Leu Val Thr Glu Gin Ala Ala Arg Leu Val 
90 
Gly Ala Lys Pro Gin Glu Val Val Val Met Asn Thr Leu Thr Val Asn 
105 110 
Leu His Leu Met Met Val Ser Phe Tyr Arq Pro Thr Lys Thr Arg Phe 
115 120 125 
Lys Ile Leu Val Glu Gly Gly Ala Phe Pro Ser Asp Gin Tyr Ala Val 
Ala Ser Gln Ala Arg Phe His Gly Tyr Asp Pro Arg Glu Ala Ile Leu 
at ?
mg sm mmmmm ammmm mmmmm mmmmmmmmmm Glu Leu Lys Pro Arg Pro Gly Glu Glu Thr Leu Arg Thr Glu Asp Ile 170 Leu Ala Thr Leu Asp Gin His Gly His Glu Val Ala Leu Val Met Leu 185 | 190 & Gly Ser Val Asn Tyr Leu Thr Gly Gin Ala Phe Asp Ile Pro Ala Ile 195 200 205 Thr Lys Thr Ala His Ala Lys Gly Cys Phe Val Gly Phe Asp Leu Ala His Gly Ala Gly Asn Leu Lys Leu Ala Leu His Asp Asp Gly Pro Asp Phe Ala Val Trp Cys Ser Tyr Lys Tyr Leu Asn Gly Gly Pro Gly Ala 250 Leu Ala Gly Val Phe Val His Glu Arg His Ala Ara Ser Lys Asp Ile 265 270 Pro Arg Phe Glu Gly Trp Trp Gly His Asp Lys Ala Thr Arg Phe Gin 275 280 285 Met Gly Pro Thr Phe Asp Pro Leu Pro Gly Ala Glu Gly Trp Gin Leu ESer Asn Pro Pro Ile Leu Gin Leu Ala Ala Leu Ara Ala Ser Phe Glu 320 &&?
US 9 , 975 , 959 B2 
| 127 1 127 128 
- continued 
| 
? Leu Phe Asp Gin Ala Gly Met Glu Ala Leu Arg Ala Lys Ser Glu Lys 
325 335 ?
& & Leu Thr Gly Tyr Leu Glu Phe Leu Leu Glu Lys Leu Pro Pro Gly Phe 
345 350 m? |Val Arg Ile Ile Thr Pro Arg Asp Val Lys Gin Arg Gly Ala Gin Leu 365 8 360 Egg Ser Leu Arg Phe Lys Gly Glu Ala Gin Gly Met Leu Lys Arg Leu Ser 375 380 
Asp Ala Gly Ile Ile Cys Asp Phe Arg Lys Pro Asp Ile Ile Arg Ala 
390 395 400 21 1 1 
Ala Pro Ala Pro Leu Tyr Cys Ser Phe Thr Asp Val Tyr Arg Phe Val 
405 415 ? 
Arg Thr Leu Glu Ala His Ala Arg Asp 
420 425 
< 210 > SEQ ID NO 37 
< 211 > LENGTH : 426 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Myxococcus xanthus DK 1622 
1 13 
1 
< 400 > SEQUENCE : 37 
Met Thr Thr Pro Tyr Leu Phe Glu Asp Ser Glu Ser Phe Ala Arg Lys 
. 
Leu Asp Ala Glu Asp Ala Leu Arg Gly Tyr Arg Asp Ala Phe His Phe 
Pro Pro Gly Pro Asp Gly Lys Pro Val Val Tyr Leu Ala Gly Asn Ser 
35 
Leu Gly Leu Gin Pro Arg Asn Ala Ala Arg Tyr Ile Gin Glu Glu Leu J
& 
Glu Asp Trp Ala Arg Leu Gly Val Glu Gly His His His Gly Arg His 
& Pro Trp Leu His Tyr His Glu Leu Val Thr Glu His Ala Ala Arg Leu 
85 
Val Gly Ala Lys Pro Leu Glu Val Val Val Met Asn Thr Leu Ser Val 
& Asn Leu His Leu Met Met Val Ser Phe Tyr Arg Pro Thr Lys Gin Arg 
115 
Phe Lys Ile Leu Val Glu Ala G Ala Phe Pro Ser Asp Gin Tyr Ala 
Val Ala Ser Gin Val Arg Phe His Gly Tyr Asp Ala Arg Glu Ala Val ammmm smmmm mmmm 5mm mmmmmm mmmmm mmm mmmmmm Leu Glu Leu Lys Pro Arg Glu Gly Glu Glu Thr Leu Arg Thr Glu Asp 165 | Ile Leu Glu Thr Ile Glu Arg His Gly His Glu Val Ala Leu Val Met Leu Gly Ser Val Asn Tyr Leu Thr Gly Gin Ala Phe Asp Leu Ala Ala 195 Ile Thr Lys Ala Ala His Ala Lys Gly Cys Phe Val Gly Phe Asp Leu Ala His Gly Ala Gly Asn Leu Arg Leu Ser Leu His Asp Asp Gly Pro Asp Phe Ala Val Trp Cys Ser Tyr Lys Tyr Leu Asn Ala Gly Pro Gly 245 Ala Leu Gly Gly Val Phe Val His Glu Arg His Ala His Thr Lys Asp 
US 9 , 975 , 959 B2 
129 130 
- continued 
Leu Pro Arg Phe Glu Gly Trp Trp Gly His Asp Lys Gin Thr Arg Phe 
285 
& ? 3?US 
g a
3 . ? Gin Met Gly Pro Thr Phe Ser Ala Leu Pro Gly Ala Glu Gly Trp Gin 
. Leu Ser Asn Pro Pro Ile Phe Gin Leu Ala Ala Leu Arq Ala Ser Leu 
305 315 320 Phe an Lan Ala Is Leu arg Ala ser See 
Glu Leu Phe Asp Gin Ala Gly Met Ala Ala Leu Arg Ala Lys Ser Glu 
335 
R Arg Leu Thr Gly Tyr Leu Glu Phe Leu Leu Asp Arg Leu Pro Glu Gly 
345 350 mmm Phe Val Arg Ile Thr Thr Pro Arg Asp Val Lys Gin Arg Gly Ala Gin 365 REA&3 Ep
? 
Leu Ser Leu Arg Phe Arg Gly Glu Pro Gin Gly Leu Leu Lys Arg Leu & TRE
& Gly Asp Ala Gly Ile Ile Cys Asp Phe Arg Lys Pro Asp Ile Ile Arg 
385 395 400 
Ala Ala Pro Ala Pro Leu Tyr Asn Ser Phe Thr Asp Val Tyr Arg Phe 
415 
| 
Val Lys Thr Leu Glu Gly His Ala Arg Glu 
420 425 
< 210 > SEQ ID NO 38 
< 211 > LENGTH : 428 | 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Nafulsella turpanensis 
< 400 > SEQUENCE : 38 
? Met Ile Asn Gin Tyr Gln Ser Asn Gln Ala Tyr Ala Arg Glu Gln Asp 
15 ? 
Ala Arq Asp Pro Leu Arq Gin Phe Arg Glu Gin Phe Ile Ile Pro Pro 
25 
12&20 30 
Ala Lys Ser Gly Gly Glu Ala Ile Tyr Phe Cys Gly Asn Ser Leu Gly 
145 40 IgE Leu Gin Pro Lys Asn Thr Arg Ser Tyr Leu Asp Arg Glu Leu Glu Lys RET 60 Trp Ala Thr Tyr Ala Val Asp Gly His Phe His Ala Pro Glu Pro Trp 70 75 
Leu His Tyr His Arg Leu Leu Lys Glu Pro Leu Ala Arg Ile Val Gly 
95 mmm mem Ala Lys Pro Glu Glu Val Val Val Met Asn Asn Leu Ser Ser Asn Leu 100 105 110 His Phe Leu Met Val Ser Phe Tyr Gin Pro Thr Thr Lys Arg Tyr Lys 120 125 
mem mmmmm &gg Egg2Val Leu Met Glu Gly Gly Ala Phe Pro Ser Asp Gin Tyr Ala Val Glu 140 Ser Gin Val Lys Phe Arg Gly Tyr Thr Pro Glu Glu Ala Ile Val Glu 145 150 155 Val Phe Pro Arg Glu Gly Glu Gin Thr Leu Arg Thr Glu Asp Ile Leu 165 175 Ala Ala Ile Glu Gin His Gin Asp Glu Leu Ala Leu Val Leu Phe Ala 180 185 190 Gly Leu Gin Tyr Tyr Thr Gly Gin Val Phe Asp Met Ala Ala Ile Thr 200 205 
Lys Ala Gly Gin Ala Ala Gly Ala Lys Val Gly Phe Asp Leu Ala His 




210 215 220 
? Ala Ala Gly Asn Val Pro Leu Gin Leu His Asp Trp Gly Val Asp Phe 
230 235 240 
Ala Ala Trp Cys Ser Tyr Lys Tyr Leu Asn Ser Gly Pro Gly Ser Asn 
245 | 
E
3 Ser Gly Ile Phe Val His Glu Arq Tyr Ala Asn Gln Ala Glu Leu Pro 
260 270 
Arg Phe Ala Gly Trp Trp Gly His Asp Glu Lys Glu Arg Phe Leu Met 
275 280 RET Gin Lys Gly Phe Lys Pro Met Tyr Gly Ala Asp Gly Trp Gin Leu Ser 295 
Asn Gly Asn Ile Leu Pro Leu Ala Ala Gin Arg Ala Ser Leu Glu Ile 






Phe Glu Gln Ala Gly Met Asp Asn Leu Ara Gln Lys Ser Ile Gin Leu 
Thr Gly Tyr Leu Glu Tyr Leu Ile Arg Glu Glu Val Ser Ser Lys Ala 
340 350 
Asn Arg Leu Gin Ile Ile Thr Pro Ser Gin Pro Glu Glu Arg Gly Cys 
355 360 
Gln Leu Ser Leu Phe Val Glu Lys Asn Gly Lys Gln Leu Phe Glu Gln 
375 
Ile Ser Gin Ala Gly Val Val Gly Asp Trp Arg Glu Pro Asn Val Ile 
390 395 400 
Arg Val Ala Pro Thr Pro Leu Tyr Asn Thr Phe Thr Asp Val Phe Gin 
! ? | 
Phe Ala Gln Leu Leu Lys Lys Ala Ile Lys Glu Gln 
420 
? 
< 210 > SEQ ID NO 39 
< 211 > LENGTH : 428 ) 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Niastella koreensis GR20 - 10 
< 400 > SEQUENCE : 39 
Met Ile Phe Glu Asn Ser His Ser Phe Ala Tyr Val Leu Asp Glu Gln 
Asp Glu Leu Arq Ser Phe Ara Glu Gin Phe Ile Met Pro Val Ile Asp & ?
s 5 
Gly Lys Gin Gin Ile Tyr Phe Leu Gly Asn Ser Leu Gly Leu Gin Pro 
35 40 
Lys Arg Thr Asn Asp Tyr Leu Gin Gin Val Leu Asn Lys Trp Ala Asn ?
Tyr Gly Val Glu Gly Phe Phe Met Gly Glu Gin Pro Trp Leu Gin Tyr 
70 80 g 
? 
Eº See3?6? His Asp His Leu Thr Lys Pro Leu Ser Thr Ile Val Gly Ala Leu Pro &
His Glu Val Val Ala Met Asn Gin Leu ThrVal Asn Leu His Leu Leu g
Leu Val Ser Phe Tyr Asn Pro His Gly Lys Arg Asn Lys Ile Ile Cys 
115 120 
Glu Ala Lys Ala Phe Pro Ser Asp Gin Tyr Met Leu Glu Thr His Val 
Lys Tyr Cys Gly Phe Asn Pro Asp Asp Val Ile Val Glu Val Gly Pro 
150 160 
?
US 9 , 975 , 959 B2 
133 134 
- continued 
| Arg Lys Gly Glu His Thr Ile Arg His Glu Asp Ile Leu Gin Ala Ile 
170 175 
Gin Gin His Lys Asp Glu Leu Ala Leu Val Leu Trp Gly Gly Met Asn 
180 185 190 
33?
Tyr Tyr Thr Gly Gin Leu Phe Asp Met Ala Ala Ile Thr Lys Ala Ala 
195 200 
Gin Ala Val Gly Ala Lys Val Gly Phe Asp Leu Ala His Ala Ala Gly 
215 220 
E
E AREEgg Asn Val Pro Leu Gln Leu His Asn Trp Asn Val Asp Phe Ala Ala Trp 230 235 240 Cys Ser Tyr Lys Tyr Met Asn Ser Gly Pro Gly Gly Ile Gly Gly Ala 250 255 &
Tyr Ile His Glu Arg Tyr His Asn Asp Thr Ser Leu Pro Arg Phe Ala 
260 265 270 
?
Gly Trp Trp Gly Tyr Asp Lys Ala Thr Arg Phe Leu Met Gin Lys Gly 
275 280 
?mmmm mmm mmm mmmma mmmmmm Phe Asn Ala Thr Arg Ser Ala Glu Gly Trp Gin Leu Ser Thr Pro Ser 295 300 ?&Pro Leu Leu Tyr Ala Ala His Arg Ala Ala Leu Asp Leu Phe Met Glu 310 315 320 Ala Gly Phe Asn Arg Leu Gln Asn Lys Arg Gln Leu Leu Asn Lys Trp 330 335 Leu Trp Phe Leu Leu Asp Asp Leu Asn Asn Ala Gin Thr Glu Pro Val 340 345 350 Val Glu Phe Ile Thr Pro Arg Asn Glu Ala Glu Arg Gly Cys Gin Val 355 360 JSer Met Leu Met Leu Gin Gin Gly Lys Gin Val Phe Asp Glu Leu Ala 375 380 Arq Ala Gly Val Ile Val Asp Trp Arq Glu Pro Asn Val Ile Arq Leu 390 395 400 Ala Pro Val Pro Leu Tyr Asn Ser Phe Glu Glu Val Trp Gin Phe Thr 
410 415 
Asn Ile Leu Arg Gin Ile Leu Gin Leu Gin His Ala 
420 425 
< 210 > SEQ ID NO 40 
< 211 > LENGTH : 420 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Nonlabens dokdonensis DSW - 6 
< 400 > SEQUENCE : 401 
Met Asn Phe Lys Thr Asp His Asn Phe Ala Ile Glu Leu Asn Lys Ser ?
g 
Asp Ser Leu Ser Arg Phe Arg Glu Ser Phe His Ile Pro Lys His Thr ?
25 
Asp Gly Thr Asp Ser Ile Tyr Leu Cys Gly Asn Ser Leu Gly Leu Gin 
35 40 
3 3am Pro Arq Gin Thr Lys Thr Phe Leu Asn Gin Glu Leu Asp Asp Trp Ala 55 60 Phe Leu An Gin Glu Leu Asp - Arg Leu Gly Val Glu Gly His Phe His Ala Ala His Pro Trp Met Pro 70 Tyr His Glu Phe Leu Thr Glu Thr Thr Ala Gin Ile Val Gly Ala Lys 
1 85 
Pro His Glu Val Val Ile Met Asn Thr Leu Thr Thr Asn Leu His Leu 
100 105 Leu Ite Lee ? ? ?




Met Met Val Ser Phe Tyr Gin Pro Lys Gly Lys Arg Thr Lys Ile Ile 
115 120 125 
Ile Glu Ala Asp Ala Phe Pro Ser Asp Arg Tyr Ala Val Ala Ser Gin 
Val Lys Phe His Gly His Asp Asp Lys Glu Asn Ile Ile Glu Trp Ser 
145 150 155 &2? 
Pro Arg Ala Gly Glu His Thr Pro Arg Ile Glu Asp Leu Glu Asn Leu 
165 175 
Leu Lys Glu Gin Gly Asp Glu Ile Ala Leu Ile Met Val Gly Ala Val 
190 
3
Asn Tyr Tyr Thr Gly Gin Phe Phe Asp Leu Lys Lys Ile Thr Glu Leu 
195 200 205 
Gly His Ala Ala Gly Ala Met Val Gly Phe Asp Cys Ala His Gly Ala 
Gly Asn Val Asp Leu Gin Leu His Asn Ser Gly Ala Asp Phe Ala Val 
225 230 235 mmmmm mmmmm mmm Trp Cys Thr Tyr Lys Tyr et Asn Ser Gly Pro Gly Ser Leu Gly Gly 245 mmm mmmm 255 , Cys Phe Val His Glu Arq His Ala Ser Asn Ser Asp Leu Pro Arg Phe 270 mmmmmm Thr Gly Trp Trp Gly His Asn Lys Asp Thr Arg Phe Lys Met Arg Asp 275 280 285 Asp Phe Glu Pro Met His Gly Ala Glu Gly Trp Gin Leu Ser Asn Pro Pro Ile Leu Ser Met Val Ala Ile Arg Ala Ser Leu Asp Leu Phe Ala 305 310 315 Gln Ala Gly Phe Glu Asn Leu Arq Gln Lys Ser Ile Gin Leu Thr Asn 325 335 Tyr Leu Glu Tyr Leu Leu Ser Asn Leu Glu Gly Asp Arg Ile Ser Ile 350 & Ile Thr Pro Glu Asn Pro Lys Asp Arg Gly Cys Gln Leu Ser Leu Ala 355 360 365 Val Lys Asn Ala Asp Lys Ser Leu Phe Asp Ala Ile Thr Glu Lys Gly ma Val Ile Ala Asp Trp Arg Glu Pro Asp Val Ile Arg Ile Ala Pro Val 385 390 395 x E Pro Leu Tyr Asn Asn Tyr Glu Asp Cys Trp Arg Phe Val Asp Val Leu 405 415 | Lys Ser Glu Leu 420 
< 210 > SEQ ID NO 41 
< 211 > LENGTH : 431 
< 212 > TYPE : PRT 
< 213 > ORGANI SM : Pedobacter agri 
< 400 > SEQUENCE : 41 
Met Lys Leu Glu Asn Thr Leu Ala Phe Ala Lys Glu Gln Asp Glu Lys 
15 As Gin Aøp Glu Lys 
? & Asp Glu Leu Lys His Phe Arg Asp Gin Phe Leu Phe Pro Lys Tyr Gin 
25 30 g 
Asp Lys Phe Phe Ile Tyr Leu Cys Gly Asn Ser Leu Gly Leu Gin Pro ?
1 
Lys Val Ala Lys Glu Val Ile Asn Ser Gin Leu Asp Asn Trp Ala Asn 
US 9 , 975 , 959 B2 
137 138 
- continued 
Leu Ala Val Glu Gly Trp Phe Asp Gly Glu Glu Pro Trp Met Tyr Tyr 
65 70 75 





? 3 ? Ser Glu Val Cys Pro Met Asn Thr Leu Thr Val Asn Leu His Leu Leu 
100 105 110 
& Met Ile Ser Phe Tyr Gln Pro Gin Gly Lys Arg Phe Lys Ile Ile Met 
115 125 
Glu Gly Gly Ala Phe Pro Ser Asp Gin Tyr Ala Ile Glu Ser Gin Val 
Arg Phe His Gly Phe Asp Pro Ser Asp Ala Ile Ile Glu Val Phe Pro 
145 150 155 
p 
Arg Glu Gly Glu Glu Ile Leu Arg Thr Glu Asp Ile Val Ala Lys Ile 
165 
Lys Glu His Gly Asp Glu Ile Ala Leu Leu Leu Phe Gly Gly Ile Asn 
180 185 | 190 | 
Tyr Tyr Thr Gly Gin Trp Tyr Asp Met Glu Asn Ile Thr Lys Ala Gly 
195 205 
His Ser Ile Gly Ala Met Val Gly Trp Asp Leu Ala His Ala Ala Gly 
8 
- 
sm *mmm *mm mmmmm * Asn Val Pro Val Lys Leu His Asp Trp Asn Val Asp Phe Ala Cys Trp 225 230 235 RR mmmmmmm mmmmmmmm Cys Ser Tyr Lys Tyr Gin Asn Ala Gly Pro Gly Gly Ile Ser Gly Ile 245 Phe Val His Glu Lys His Phe Glu Asn Lys Ala Leu Asn Arg Phe Ala 260 265 270 Gly Trp Trp Gly Tyr Gin Glu Asn Lys Arg Phe Lys Met Glu Lys Gly 275 285 Phe Val Pro Glu Ala Gly Ala Asp Gly Trp Gin Val Ser cys Thr Gin Val Met Pro Met Ala Leu Tyr His Ala Ser Leu Gln Ile Phe Lys Glu 305 310 315 Ala Gly Phe Leu Asn Thr Leu Arg Asn Lys Ser Ile Ser Leu Thr Ser 325 Tyr Leu Glu Phe Val Val Asn Glu Leu Asn Ile Glu Leu Glu Lys Glu 340 345 350 Gin Tyr Lys Ile Ile Thr Pro Lys Asn Ser Ala Glu Arg Gly Ala Gin 355 365 Leu Ser Ile Ile Ala Ala Arg Asn Gly Lys Glu Ile Phe Asp Gly Leu & Leu Ala His Gly Ile Leu Gly Asp Trp Arg Glu Pro Asn Val Ile Arg 385 1390 395 Leu Ser Pro Val Pro Leu Tyr Asn Ser Phe Glu Asp Ile Tyr Gin Thr 405 Gly Lys Ala Leu Ser Glu Val Thr Arq Lys Ile Leu Thr Thr Ala 420 425 430 ?
< 210 > SEQ ID NO 42 
< 211 > LENGTH : 449 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Pedobacter sp . BAL39 
< 400 > SEQUENCE : 42 
US 9 , 975 , 959 B2 
139 140 
Met Lys Val Val Asp Asn Lys Lys Thr Gly Leu Phe Asn Tyr Ile Pro 
15 BE Phe Leu Trp Ile Phe Gly Thr Met Asn Phe Glu Asn Thr Leu Ala Phe 25 30 33 Ala Gin Gly Leu Asp Gin Ala Asp Pro Leu Arg Asp Leu Arg Asn Glu 45 
Phe Leu Phe Pro Gin Gin Asn Gly Lys Pro Phe Ile Tyr Leu Cys Gly 
55 
Asn Ser Leu Gly Leu Gin Pro Lys Val Ala Arg Glu Val Leu Asp Arg 
65 | 75 
Gin Leu Asn Asn Trp Gin Asn Leu Ala Val Glu Gly Trp Phe Glu Gly 
95 
Glu Thr Pro Trp Met Tyr Tyr His Lys Ala Leu Lys Glu Leu Met Ala 
105 110 
Pro Ile Val Gly Ala Arg Pro Ala Glu Val Cys Pro Met Asn Thr Leu 
125 
Thr Val Asn Leu His Leu Leu Met Val Ser Phe Tyr Lys Pro Lys Ala 
135 
Lys Arg Phe Lys Ile Met Met Glu Ala Gly Ala Phe Pro Ser Asp Gin 
145 150 155 Tag mmmmm Tyr Ala Ile Glu Ser Gin Val Arg Phe His Gly Tyr Asp Pro Lys Asp 175 Ala Ile Ile Glu Val Ser Pro Arg Pro Gly Glu Tyr Thr Leu Arg Thr 185 | 190 Glu Asp Ile Leu Glu Gin Ile Ser Leu Gin Gly Asp Gin Ile Ala Leu 205 Val Leu Phe Gly Gly Ile Asn Tyr Phe Thr Gly Gin Trp Phe Asp Met 215 Glu Ala Ile Thr Arg Ala Gly His Gin Ala Gly Ala Val Val Gly Phe 225 230 235 Asp Leu Ala His Ala Ala Gly Asn Val Pro Val Gin Leu His Asp Trp 255 Asp Val Asp Phe Ala Cys Trp Cys Ser Tyr Lys Tyr Gin Asn Ser Gly 265 270 Pro Gly Gly Ile Ser Gly Ile Phe Val His Glu Arg His Phe Gly Asp 285 mmmmm Gin Thr Leu Ser Arg Phe Ala Gly Trp Trp Gly Tyr Gin Glu Ser Gin 295 Arg Phe Lys Met Glu Lys Gly Phe Val Pro Glu Ala Gly Ala Asp Gly 305 310 315 Trp Gin Val Ser Cys Thr Gin Val Met Pro Met Ala Leu Tyr His Ala 335 Ala Leu Gin Ile Phe Glu Lys Ala Gly Phe Ile Gly Pro Leu Arg Lys 345 350 Lys Ser Lys Ala Leu Thr Ala Tyr Leu Phe Tyr Leu Ile Asn Glu Val 365 Asn Asn Glu Leu Cys Glu Met Gin Tyr Gin Val Ile Thr Pro Ser Ser 375 Ala Glu Asp Arg Gly Ala Gin Val Ser Ile Ile Ala Lys Ala Asn Gly 385 390 395 Lys Tyr Ile Phe Glu Gin Leu Val Ala Asn Asn Val Leu Gly Asp Trp 415 Arg Glu Pro Asn Val Ile Arq Leu Ser Pro Val Pro Ser Tyr Asn Ser 
US 9 , 975 , 959 B2 
| 141 141 142 . 
- continued 
420 425 430 
Phe Glu Asp Val Phe Arg Thr Ala Glu Leu Leu Leu Gin Ile Gly Arg 
435 440 445 
Lys 
< 210 > SEQ ID NO 43 
< 211 > LENGTH : 428 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Pedobacter sp . V48 
< 400 > SEQUENCE : 43 
Met Asn Phe Glu Asn Asn Leu Ala Phe Ala Gln Ser Leu Asp Gln Ala 
10 
& Asp Pro Leu Ser Ser Phe Arq His Asp Phe Leu Phe Pro Gin Gin Asn 
20 30 
& Gly Asn Pro Phe Ile Tyr Leu Cys Gly Asn Ser Leu Gly Leu Gin Pro
35 40 45 & gg
A Lys Ala Val Arg Lys Val Val Asp Glu Gin Leu Asn Asn Trp Arg Asn 
50 55 
Leu Ala Val Glu Gly Trp Phe Glu Gly Asp Asn Pro Trp Met Phe Tyr 
75 
His Lys Glu Leu Lys Lys Leu Met Gly Pro Leu Val Gly Ala Ser Thr 
90 
Asp Glu Val Cys Pro Met Asn Thr Leu Thr Val Asn Leu His Leu Leu 
100 110 
Met Val Ser Phe Tyr Lys Pro Val Arg Gly Arg Phe Lys Ile Ile Met 
115 120 125 
Glu Ala Gly Ala Phe Pro Ser Asp Gin Tyr Ala Val Glu Ser Gin Val 
130 135 
m 
mmmmm mmmm mmmm mmm 
5 
mmmm msm mmmmm 5 mm? Arg Phe His Gly Tyr Asp Ala Lys Glu Ala Ile Val Glu Val Ala Pro 155 Arg Ile Gly Glu Tyr Ile Leu Arg Thr Glu Asp Ile Leu Ala Gin Ile 170 Ala Lys His Gly Asp Glu Val Ala Leu Val Leu Phe Ser Gly Val Asn 180 190 | Tyr Phe Thr Gly Gin Trp Phe Asp Met Glu Ala Ile Thr Met Ala Gly 195 200 205 His Ala Glu Gly Ala Val Val Gly Phe Asp Leu Ala His Ala Ala Gly 210 215 Asn Val Pro Leu Lys Leu His Asp Trp Asp Ile Asp Phe Ala Cys Trp 235 E Cys Ser Tyr Lys Tyr Gin Asn Ser Gly Pro Gly Gly Ile Ser Gly Ile 250 Phe Val His Glu Lys His Phe Thr Asp Thr Thr Leu Asn Ara Phe Ala 260 270 Gly Trp Trp Gly Tyr Gin Gin Ala His Arg Phe Lys Met Glu Lys Gly 275 280 285 Phe Leu Pro Glu Pro Gly Ala Asp Gly Trp Gin Val Ser cys Thr Gin 290 295 300 & Val Met Pro Met Ala Leu Tyr Phe Ala Ser Leu Gin Ile Phe Glu Lys 315 | 
Ala Gly Phe Ile Glu Pro Leu Arg Leu Lys Ser Lys Thr Leu Thr Ser 
330 
Tyr Leu Phe His Ile Val Asn Gin Val Asn Lys Leu Leu Ser Cys Glu 
US 9 , 975 , 959 B2 
143 144 
- continued 
340 345 350 
Gin Phe Glu Ile Ile Thr Pro Asp Asn Glu Asn Glu Arg Gly Ala Gin 
355 360 365 
3 Val Ser Ile Ile Ala Lys Gln Lys Gly Lys Glu Ile Phe Glu Lys Leu 
370 375 380 
Ile Ala Asn Asn Val Leu Gly Asp Trp Arg Glu Pro Asn Val Ile Arg 
385 395 400 ag & &SE g
Leu Ser Pro Val Pro Leu Tyr Asn Ser Phe Glu Asp Val Phe Arg Thr 
405 410 415 | 
3 Gly Glu Leu Leu Leu Gin Ile Thr Lys Gly Val Ile 
420 425 
< 210 > SEQ ID NO 44 
< 211 > LENGTH : 428 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Rhodonellum psychrophilum 
< 400 > SEQUENCE : 44 
Met Lys Asp Ile Lys Tyr Glu Tyr Ser Glu Phe Phe Ala Arg Gin Leu 
15 1 ? 
Asp Asn Glu Asp Pro Leu Lys Asp Phe Arg Asn Glu Phe Tyr Phe Pro &
25 
Lys Ile Glu Gly Lys Glu Ala Ile Tyr Phe Cys Gly Asn Ser Leu Gly 
40 45 
Leu Gin Pro Arg Ser Thr Lys Glu Tyr Ile Gin Arg Glu Leu Asp Asn 
55 
Trp Ala Glu Leu Ala Val Asp Gly His Phe Lys Gly Glu Asp Ala Trp 
65 80 75 &Egg Tyr His Val Arg Lys Lys Ser Lys Pro Ala Leu Ser Glu Ile Val Gly 
95 
Ala His Glu His Glu Val Val Ala Met Asn Asn Leu Ser Ser Asn Leu 
105 
His Phe Leu Met Val Ser Phe Tyr Arg Pro Ser Lys Thr Arg Phe Lys 
120 125 
Ile Ile Thr Glu Ala Gly Ala Phe Pro Ser Asp Met Tyr Met Leu Glu 
135 
Thr Gin Val Lys Phe His Gly Leu Asp Pro Glu Lys Thr Ile Ile Glu 
145 155 160 mmmm mmmm smmmm mmmm mmmmm mmm mmmmmm mmmmm Val Ala Pro Arg Pro Gly Glu His Thr Leu Arg Thr Glu Asp Ile Leu 175 Leu Ala Ile Glu Glu Gin Gly Glu Glu Leu Ala Leu Val Met Met Ala 185 Gly Leu Gin Tyr Tyr Thr Gly Gin Val Phe Asp Met Glu Ser Ile Thr 200 205 Arg Ala Gly His Ser Val Gly Ala Asn Val Gly Phe Asp Leu Ala His 215 Ala Ala Gly Asn Val Pro Met Ser Leu His Asp Trp Gly Val Asp Phe 225 235 240 Ala Thr Trp Cys Ser Tyr Lys Tyr Met Asn Ser Gly Pro Gly Asn Val 255 & Ser Gly Val Phe Val His Glu Arg His Ala Gin Asn Pro Asp Leu Pro265 Arg Phe Ala Gly Trp Trp Gly His Asp Glu Glu Glu Arg Phe Lys Met 280 285 
US 9 , 975 , 959 B2 
145 146 
- continued 
| ? ? Glu Lys Gly Phe Lys Pro Met Tyr Gly Ala Asp Gly Trp Gin Val Ala 
290 295 300 | 
| | 
Asn Ser Asn Val Leu Ala Leu Ala Ala His Gin Ser Ser Leu Asp Ile 
305 310 315 
3 S
320 
Phe Glu Arg Ala Gly Ile Lys Asn Leu Arg Glu Lys Ser Glu Leu Leu 
335 330 23 Thr Gly Tyr Leu Glu Phe Leu Ile Gin Gin Ile Ser Gly Asp Ser Gly 340 350 mmm ? Val Ile Glu Ile Ile Thr Pro Lys Asn Pro Gin Glu Arg Gly cys Gin 355 360 365 Leu Ser Leu Leu Val His Lys Gly Gly Lys Ala Val Phe Asp Glu Leu 370 375 380 Tyr Leu Asn Gly Ile Ile Gly Asp Trp Arg His Pro Lys Val Met Arg 385 390 395 400 Ile Ala Pro Thr Pro Leu His Asn Ser Phe Leu Asp Val Phe Arg Phe 415 410 
| | 
Ala Gln Ile Leu Glu Lys Ser Ile Leu Lys Phe Ala 
420 425 
< 210 > SED ID NO 45 
< 211 > LENGTH : 430 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Salinispora arenicola 
< 400 > SEQUENCE : 45 | 
Met Asn Lys Glu Glu Leu Asp Gin Glu Glu Lys Ala Ala Asn Arg Leu 
? 
Asp Thr Ala Asp Pro Gly His Arg His Leu Phe His Leu Pro Pro Ser 
20 25 30 
E Asp Gly Gly Arg Tyr Gin Gin Ala Ala Tyr Leu Ala Gly Asn Ser Leu 
40 
Gly Leu Gin Pro Leu Ala Thr Arg Asp Glu Leu Leu Ala Asp Leu Asp 
55 
Ala Trp Arg Arg Leu Gly Val Glu Gly His Leu Glu Ala Asp Arg Pro 
? 3&A
?2ETHE 
Trp Leu Pro Tyr His Glu Leu Leu Thr Ala Pro Thr Ala Arq Leu Val 
Gly Ala Arg Pro Ala Glu Val Val Val Met Asn Ser Leu Thr Val Asn 






Leu His Leu Leu Met Val Ser Phe Tyr Arg Pro Val Gly Ala Arq Thr 
120 
sam mmm 3mm mmm 
?
8mm EE Rgg8:Arg Ile Val Ile Glu Asp Asn Ala Phe Pro Ser Asp Ser Tyr Ala Val 135 ama mmmmmm Arg Ser Gin Ala Arg Phe His Gly Leu Asp Pro Asp Thr Thr Val Val Arg Leu Ala Pro Arg Pro Gly Glu Asp Thr Leu Arg Thr Val Asp Val Leu Asp Leu Leu Ala Ala Glu Gly Asp Thr Ile Ala Leu Val Leu Leu 180 185 190 Gly Gly Val Asn Tyr Leu Thr Gly Glu Leu Leu Asp Ile Pro Ala Ile 200 2? Thr Ala Ala Gly Arg Ala Ala Gly Ala Ala Val Gly Trp Asp Leu Ala 215 His Ala Ala Gly Asn Val Pro Leu Ser Leu His Asp Trp Asp Val Asp | 
US 9 , 975 , 959 B2 
147 148 
- continued 
Phe Ala Ala Trp Cys Ser Tyr Lys Tyr Leu Asn Ser Gly Pro Gly Gly 
3 Leu Ser Ser Val Phe Val His Glu Arg His Leu Ala Asp Pro Thr Leu 




Pro Arg Phe Glu Gly Trp Trp Ser Thr Asp Ala Ala Val Arg Phe Glu 
275 
Met Ser Pro Val Ala Arg Pro Pro Ala Thr Ala Glu Ala Trp Gin Val 
Ser Asn Pro Pro Ile Phe Ala Met Gly Pro Val Arg Thr Ser Leu Glu 
310 320 
Leu Phe Asp Ser Val Gly Met Thr Ala Leu Arg Glu Arg Ser Val Arg 
mmm mmmmm mmm mmmmmm Leu Thr Gly Tyr Leu Glu Trp Leu Leu Asp Gin Ile Thr Pro Gly Arg 340 345 350 &Gin Leu Ala Val Val Thr Pro Arg Asp Pro Asp Arg Arg Gly Ala Gin 355 Leu Ser Val Arg Val Gly Ser Gly Ser Ala Ala Glu Leu Thr Lys Arg Leu Arg Cys Glu Tyr Gly Val Ile Ala Asp Ala Arg Glu Pro Asp Ile 385 390 400 Val Arg Phe Ala Pro Val Pro Leu Tyr Ser Thr Tyr His Asp Cys Trp 415 
Ara Val Ala Asp Ala Leu Ala Ala Thr Val Glu Val Arg Gly 
420 425 430 
mmmm mmmmm 
mam 
< 210 > SEQ ID NO 46 
< 211 > LENGTH : 425 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Saprospira grandis str . Lewin 
| 
< 400 > SEQUENCE : 46 
| 
Met Gin Glu Val Gin Phe Glu Asp Ala Leu Asp Tyr Ala Lys Ala Gin 
3 8 ? Asp Val Ser Asp Pro Leu Ala His Phe Arq Pro Gln Phe His Phe Pro 
25 30 20 
Lys Gin Ala Asp Gly Ser Pro Ile Ile Tyr Leu Cys Gly Asn Ser Leu 
40 45 8 
Gly Leu Gin Pro Arg Leu Ala Gin Gin Leu Met Gin Asp Glu Met Asp 
55 
Val Trp Lys Glu Leu Ala Val Glu Gly His Phe Lys Ala Glu Arg Pro 
75 
2? 6Trp Met Thr Tyr His Glu Glu Phe Ser Arg Gin Leu Ser Pro Ile Val 
a
smsm 85 Gly Ala Leu Pro Lys Glu Ile Thr Val Met Asn Thr Leu Ser Val Asn 105 110 mmm mmmmm 100 ? . . Leu His Leu Met Met Val Ser Phe Tyr Arg Pro Thr Lys Ser Arg Tyr 120 125 Lys Ile Val Ile Glu Gly Gly Ala Phe Pro Ser Asp Lys Tyr Ala Val 135 Asp Ser Gin Leu Arg Phe His Gly Ile Asp Pro Gin Asp Gly Leu Ile 145 155 160 g31 ? Gin Leu Arg Pro Arg Met Gly Glu Asp His Leu Arg Thr Glu Asp Ile 165 175 1 
Leu Gln Ala Leu Glu Ara Glu Lys Asp Ser Ile Ala Leu Val Met Leu 




180 185 190 
Ser Gly Ile Asn Tyr Tyr Thr Gly Gin Cys Phe Asp Met Lys Ser Ile 
200 
?
E ?E3 ? & | Thr Lys Lys Gly His Glu Ile Gly Ala Met Val Gly Phe Asp Leu Ala 215 ?
His Ala Ala Gly Asn Val Arg Leu Gin Leu His Asp Trp Gly Met Asp 
225 230 235 
Phe Ala Val Trp Cys His Tyr Lys Tyr Leu Asn Ser Gly Pro Gly Cys 
245 
E
Ile Ala Gly Ala Phe Val His Glu Arg His Leu Asn Arg Lys Asp Leu 
260 265 270 
Pro Arg Phe Glu Gly Trp Trp Gly His His Lys Glu Ser Arg Phe Lys 
280 SE 3
Met Pro Ala Thr Phe Glu Pro Ala Pro Asn Ala Asp Ala Trp Gln Ile 
295 
Ser Asn Ala Pro Ile Leu Ala Met Val Pro Met Arq Ala Ser Leu Ala 
305 | 310 315 mmm mmmm &SI Leu Phe Asn Glu Ala Gly Met Asp Arg Leu Leu Ala Lys Ser Lys Lys 325 3 DE A3 Leu Thr Ala Tyr Leu Glu Phe Leu Leu Asn Gin Leu Pro Thr Asp Arq 340 345 350 Ile Arg Ile Leu Thr Pro Lys Asp Pro Lys Asp Arg Gly Ala Gin Leu 360 Ser Ile Gin Val Lys Gly Ala Asp Arg Ser Leu Phe Asp Asp Leu Val 375 3Lys Asn Gly Val Ile Gly Asp Trp Arg Glu Pro Asp Val Ile Arg Ile 
385 395 390 
Ser Pro Ala Pro Ile Tyr Asn Ser Phe Glu Asp Val Tyr Arg Met Val 
405 ? 
Gin Ile Leu Lys Lys Cys Leu Gin Leu 
420 425 mmmm mmm mmm 
mama as mmm mmmm 
< 210 > SEQ ID No 47 
< 211 > LENGTH : 427 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Stigmatella aurantiaca DW4 / 3 - 1 
< 400 > SEQUENCE : 47 
? Met Thr Glu Ala Ser Met Arg Phe Glu Glu Gly Glu Gly Phe Ala Arg 
15 
| 
Arg Met Asp Ala Glu Asp Pro Leu Arg Ser Phe Arg Glu Glu Phe Leu 
20 25 30 
Phe Pro Gin Ser Pro Gin Gly Glu Pro Leu Val Tyr Leu Ala Gly Asn 
45 
?
Ser Leu Gly Leu Gln Pro Arg Arg Ala Gin Gin Tyr Val Gln Glu Glu 
55 mmm Met Glu Asp Trp Ala Arg Leu Gly Val Glu Gly His Phe His Ala Arg me & & Arg Pro Trp Leu Pro Tyr His Glu Asn Leu Thr Gly Gin Thr Ala Arg 85 95 Leu Val Gly Ala Leu Pro Leu Glu Val Val Val Met Asn Thr Leu Ser 100 105 110 Val Asn Leu His Leu Met Met Val Ser Phe Tyr Arg Pro Thr Arg Glu 125 Thr Arg Glu ?? 
US 9 , 975 , 959 B2 
151 152 
- continued 
Arg Phe Lys Ile Leu Ile Glu Gly Gly Ala Phe Pro Ser Asp Gin Tyr 
135 140 
| 






? Val Leu Lys Leu Glu Pro Arg Ala Gly Glu Asp Thr Leu Arg Thr Glu 
175 
Asp Ile Leu Glu Thr Leu Glu Arg His Gly Ser Glu Ile Ala Leu Val 
185 190 
Leu Leu Gly Asn Val Asn Tyr Leu Thr Gly Gin Ala Phe Asp Met Lys 
200 
Ala Leu Thr Gin Ala Ala His Ala Arg Gly Cys Arg Val Gly Phe Asp 
215 
Leu Ala His Gly Ala Gly Asn Leu Arg Leu Ser Leu His Asp Asp Gly 
235 
Pro Asp Phe Ala Val Trp Cys Ser Tyr Lys Tyr Leu Asn Gly Gly Pro 
255 
Gly Ala Leu Gly Gly Val Phe Ile His Glu Arg His Ala Arg Ala Glu 
265 | 270 mmmmmm * ? eg mmmmmmm Gly Leu Pro Arg Phe Glu Gly Trp Trp Gly Asn Asp Lys Ala Ile Arg 280 mmmm mmmm mmmmm mmmmm mmmmmm | Phe Gin Met Gly Pro Asp Phe Val Pro Leu Pro Gly Ala Glu Gly Trp 295 mmm mmmmm Gln Leu Ser Asn Pro Pro Ile Phe Gin Leu Ala Ala Leu Arq Ala Ser 315 Met Glu Leu Phe Asp Arg Ala Thr Met Pro Ser Leu Arg Gly Lys Gly Asp Arg Leu Thr Gly Tyr Leu Glu Phe Leu Leu Asp Arg Leu Pro Ser 345 350 Gly Phe Val Arg Ile Thr Thr Pro Arg Asp Val Lys Ala Arg Gly Ser 360 &3? Gin Leu Ser Leu Arg Phe Ser Lys Asp Pro Arg Arg Leu Leu Thr Arg 375 & EELeu Ser Glu Ala Gly Val Cys Cys Asp Phe Arg Ser Pro Asp Ile Ile 395 Arg Ala Ala Pro Ala Pro Leu Tyr Asn Ser Phe Gin Asp Val Tyr Arg Phe Val Lys Val Leu Glu Ser His Ala Arg Asp 420 425 
< 210 > SEQ ID NO 48 
< 211 > LENGTH : 423 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Xanthomonas axonopodis 
< 400 > SEQUENCE : 48 
Met Thr Asp Pro Leu Ser Arq Ala His Ala Ala Ala Leu Asp Ala Ala 
5 | 15 | 
Asp Pro Leu Arg Asn Leu Arg Asp Ala Phe Val Phe Pro Gin His Gly 
20 25 
Arg Asn Leu Arg Asp Ala Phe Val Phe Pro Gin His Gly &
g 3am ?? Asp Asp Asp Gin Thr Tyr Phe Val Gly Asn Ser Leu Gly Leu Gin Pro ?mm 40 JT Arg Ala Ala Arg Ala Met Val Asp Glu Val Leu Asp Gin Trp Gly Ala 55 ?Leu Ala Val Glu Gly His Phe Thr Gly Pro Thr Gin Trp Leu Thr Tyr 70 75 , ? 
US 9 , 975 , 959 B2 
153 154 
- continued 
His Gin Leu Val Arg Asp Ala Leu Ala Arg Val Val Gly Ala Gin Pro 
90 95 
?JJ g Gly Glu Val Val Ala Met Asn Thr Leu Ser Val Asn Leu His Leu Met 100 105 110 
Met Ala Ser Phe Tyr Arg Pro Thr Ala Glu Arg Gly Ala Ile Leu Ile 
115 
Glu Ala Gly Ala Phe Pro Ser Asp Arg His Ala Val Glu Ser Gin Leu 
130 
Arg Leu His Gly Leu Asp Pro Ala Thr His Leu Ile Glu Val Glu Ala 
145 150 155 
Asp Glu Pro Asn Gly Thr Val Ser Met Ser Ala Ile Ala Glu Ala Ile 
170 175 
Ala Gln His Gly Pro His Leu Ala Leu Val Leu Trp Pro Gly Ile Gln 




Tyr Arg Thr Gly Gin Ala Phe Asp Leu Ala Glu Ile Val Arg Leu Ala 
195 
Arg Ala Gin Gly Ala Ala Val Gly Phe Asp Leu Ala His Ala Val Gly 
210 
Asn Leu Pro Leu Thr Leu His Asp Asp Gly Val Asp Phe Ala Val Trp 
225 230 235 &E
Cys His Tyr Lys Tyr Leu Asn Ala Gly Pro Gly Ala Val Gly Gly Cys 
250 255 
Phe Val His Ala Arg His Ala Thr Ser Asp Leu Pro Arg Met Ala Gly 
260 265 270 
m 
mmmmm mmm mmmmmm mmmmmmmmmm mmmmmmm mmmmm mmmmmm T GE &Trp Trp Gly His Glu Gin Gin Thr Arg Phe Arg Met Asp Pro Gin Phe 275 mmmmm mmmmm mmmmm mmmmmmm Val Pro Ser Pro Gly Ala Glu Gly Trp Gin Leu Ser Asn Pro Pro Val 290 Leu Ala Leu Ala Pro Leu Arq Ala Ser Leu Ala Leu Phe Asp Gln Ala 305 310 315 Gly Met Ala Ala Leu Arq Ala Lys Ser Glu Gin Leu Thr Gly His Leu 330 335 Glu Gin Leu Ile His Ala Arg Ala Pro Gin Val Leu Gin Ile Val Thr 345 350 | 340 & Pro Val Glu Pro Ala Arg Arg Gly Cys Gin Leu Ser Leu Arg Val Ala 355 A Gly Gly Arg Ala Arg Gly Arg Ala Leu Phe Glu His Leu His Ala Ala 370 Gly Val Leu Gly Asp Trp Arg Glu Pro Asp Val Ile Arg Ile Ala Pro 385 390 395 & Val Pro Leu Tyr Asn Arg Phe Ser Asp Leu His Thr Phe Val Glu Gln 410 415 Val Glu Ala Trp Ala Ala Ala 420 < 210 > SEQ ID NO 49 
< 211 > LENGTH : 422 | 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Psychroflexus gondwanensis 
< 400 > SEOUENCE : 49 
Met Lys Tyr Gin Asn Thr Lys Ser Phe Ala Glu Gin Leu Asp Glu Ala 
10 15 
Asp Pro Leu Lys Ala Tyr Arg Ser Glu Phe Leu Phe Pro Lys Ala Lys 
US 9 , 975 , 959 B2 
155 156 
| 25 
Asp Gly Ser Pro Lys Val Tyr Leu Cys Gly Asn Ser Leu Gly Leu Gin 
135 40 
2 &APro Lys Gin Thr Ser Ala Phe Ile Gin Gin Glu Leu Gln Asp Trp Ala 
55 Phe Ile Gin Gin Glu 
Asp Leu Gly Val Glu Gly His Ser His Ala Thr His Pro Trp Met Thr 
65 75 
Ser Asn Glu Asp Leu Ala Asp Ser Met Ala Lys Ile Val Gly Ala Gin 
95 
Pro Gln Glu Val Val Ile Met Asn Thr Leu Thr Val Asn Leu His Leu 
100 110 
& ??Met Met Val Ser Phe Tyr Lys Pro Thr Pro Lys Lys Phe Lys Ile Leu 115 120 
Ile Glu Ser Asp Ala Phe Pro Ser Asp Lys Tyr Ala Val Glu Ser Gin 
135 
Leu Lys Phe His Asn Ile Asp Pro Lys Glu Gly Leu Leu Leu Trp Lys 
145 155 
Pro Arg Pro Gly Glu His Leu Cys Arg Thr Glu Asp Phe Glu Gin Ile 
175 
Ile Glu Glu His Gly Asp Glu Ile Ala Leu Val Met Ile Gly Ser Thr 
180 190 
Asn Tyr Tyr Ser Gly Gin Ala Tyr Asp Leu Lys Arg Ile Thr Glu Val 
195 200 




mmmmm smmm mmmmmm mmmmmmma mmmmmm gmmm mmmm mmm mmm mmmm mmmm mmm 215 Gly Asn Ile Gin Pro Asn Leu His Asp Ile Gly Ala Asp Phe Ala Val 225 235 Trp Cys Thr Tyr Lys Tyr Leu Asn Ser Gly Pro Gly Ser Leu Gly Gly 255 Cys Phe Ile His Glu Lys His Ile Ala Asp Glu His Ile Asn Arg Phe 260 270 Val Gly Trp Trp Gly His Asn Lys Asp Ser Arg Phe Asn Met Arg Val | 275 280 Asp Phe Asp Pro Ile Pro Thr Ala Asp Gly Trp Gin Leu Ser Asn Pro 295 Pro Ile Leu Ser Leu Ala Gly Thr Arg Ser Ser Leu Asp Leu Phe Asp 305 315 Lys Ala Gly Phe Asp Asn Ile Arg Lys Lys Ser Val Leu Leu Thr Gly 335 Phe Leu Glu Phe Leu Ile Asp Asp Leu Asp Met Glu Glu Ile Ser Ile 340 350 Leu Thr Pro Arg Ser Pro Glu Glu Arg Gly Cys Gin Leu Ser Ile Gin 355 360 Val Lys Asn Ala Asn Lys Ser Leu Phe His Gin Leu Met Asp Lys Gly 375 Val Val Ala Asp Trp Arg Glu Pro Asp Val Ile Arg Ile Ala Pro Ala 385 395 & Pro Leu Tyr Asn Ser Tyr Thr Asp Val Phe Thr Phe Val Glu Ile Leu 415 REE Lys His Cys Leu Asn Ala 420 < 210 > SEO ID NO 50 
US 9 , 975 , 959 B2 
157 158 
- continued 
< 211 > LENGTH : 422 
< 212 > TYPE : PRT 
( 213 > ORGANISM : Lewinella cohaerens 
< 400 > SEQUENCE : 50 
? Met Thr Tyr Gin Ala Thr Arg Glu Tyr Ala Gin Ser Gin Asp Asp Lys 
10 | 15 
Asp Pro Met Arg Gly Phe Arg Glu Arg Phe His Leu Pro Arg Gin Ala 
20 25 
Asn Gly Glu Pro Phe Ile Tyr Leu cys Gly Asn Ser Leu Gly Leu Gin 
140 45 
Pro Lys Ser Thr Lys Ala Ala Ile Asp Gin Glu Leu Leu Asp Trp Gin 




Tyr His Glu Phe Leu Thr Glu Lys Met Ala Glu Ile Val Gly Ala Lys 
90 95 
Pro Ile Glu Val Val Met Met Asn Thr Leu Thr Val Asn Leu His Leu 
100 105 
Met Met Val Ser Phe Tyr Arg Pro Glu Gly Lys Arg Thr Lys Ile Leu 
120 125 
Met Glu Ala Asp Ala Phe Pro Ser Asp Arg Tyr Ala Ile Ser Ser Gin 
Leu Lys Phe His Gly Tyr Asp Pro Ala Glu His Leu Val Glu Leu Lys 
145 
Ala Arg Asp Gly Glu Val Leu Ile Arg Glu Glu Asp Ile Ala His Ile 
170 175 
Leu Glu Glu Gin Gly Ala Glu Ile Ala Leu Val Leu Leu Gly Asn Thr 
180 185 
Asn Tyr Tyr Thr Gly Gin Phe Phe Asn Met Pro Glu Ile Thr Lys Leu 
200 205 
Ala His Ala Gin Gly Cys Met Val Gly Phe Asp Cys Ala His Gly Ala 
Gly Asn Val Pro Leu Asp Leu His Asp Ser Gly Ala Asp Phe Ala Val 
225 
Trp Cys Ser Tyr Lys Tyr Ile Asn Ser Gly Pro Gly Ser Val Ser Gly 
250 255 
Cys Phe Val His Glu Arg His Ala His Asp Lys Glu Leu Pro Arg Phe 
260 265 
Thr Gly Trp Trp Gly His Asn Lys Val Thr Arg Phe Gly Met Arg Asp 
280 285 
Asp Phe Asp Pro Ile Pro Gly Val Glu Ala Trp Gin Leu Ser Asn Pro 
Pro Ile Leu Ser Leu Ala Ala Ile Lys Ala Ser Leu Glu Val Phe Ala 
305 
Glu Ala Gly Met Asn Asn Leu Arg Gin Lys Ser Leu Ala Leu Thr Gly 
330 335 
Tyr Leu Glu Tyr Leu Val Asp Gin Leu Pro Gly Gly Lys Ile Ser Ile 
340 345 
Ile Thr Pro Arg Asp Pro Glu Arg Arg Gly Cys Gin Leu Ser Ile Gin 
360 365 
Val Gin Asp Ala Asp Lys Ser Leu Tyr Glu Ala Ile Ser Ala Ala Gly 
Val Ile Ala Asp Trp Arg Glu Pro Asp Val Ile Arg Val Ala Pro Val 
US 9 , 975 , 959 B2 
159 160 
- continued 
385 390 395 400 
Pro Leu Tyr Asn Thr Phe Thr Glu Val Tyr Asp Phe Val Lys Ile Leu 
405 410 415 
Gly Glu Lys Met Glu Ala 
420 
< 210 > SEQ ID NO 51 
< 211 > LENGTH : 425 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Lewinella persica 
< 400 > SEQUENCE : 51 
Met Val Glu Glu Phe Gin Asn Asp Leu Ala Phe Ala Arg Lys Met Asp 
10 . 15 
Glu Arg Asp Glu Leu Arg Ala Tyr Arg Ser Gin Tyr His Met Pro Val 
25 
Gin Ala Asn Gly Gin Pro Tyr Val Tyr Leu cys Gly Asn Ser Leu Gly 
40 
R EIgE3&
E ? 3 
83 3 EJ Leu Gin Pro Lys Ala Thr Glu Gly Tyr Leu Leu Gin Glu Leu Glu Asp Trp Lys Asn Leu Gly Val Glu Gly His Phe His Ala Lys Asn Pro Trp 75 70 
? Met Pro Tyr His Glu Phe Leu Thr Glu Ala Met Ala Ara Val Val Gly 
90 95 
Ala Lys Pro Ser Glu Val Val Val Met Asn Thr Leu Thr Val Asn Leu 
105 
His Leu Met Met Val Ser Phe Tyr Arg Pro Val Gly Arg Arg Lys Lys 
120 
a 
mmmmmm mmmm mm Ile Ile Ile Glu Ala Asp Ala Phe Pro Ser Asp Lys Tyr Ala Val Glu Ser Gin Ile Arg Phe His Gly Leu Ser Pro Glu Asp Cys Leu Ile Glu 150 155 mmmm mmm Leu Lys Ala Arg Asp Gly Glu Val Cys Leu Arg Gin Glu Asp Ile Leu 170 175 Gly Val Ile Asp Ala His Ser Glu Asp Ile Ala Leu Ile Leu Leu Gly 185 Asn Thr Asn Tyr Tyr Thr Gly Gin Phe Phe Asp Met Lys Thr Ile Ser 200 mmmmm mmmm Glu His Gly His Ala Lys Gly Cys Met Val Gly Phe Asp Cys Ala His Gly Ala Gly Asn Val Pro Leu Asn Leu His Asp Ser Gly cys Asp Phe 230 235 Ala Val Trp cys Asn Tyr Lys Tyr Leu Asn Ser Gly Pro Gly Gly Met 250 255 Gly Gly Ala Phe Ile His Glu Arg His Ala Asp Ser Lys Asp Ile Pro 265 Arg Phe Glu Gly Trp Trp Gly His Asn Lys Glu Thr Arg Phe Lys Met 280 : EEArg Asp Ala Phe Asp Pro Thr Pro Gly Thr Glu Ala Trp Gin Leu Ser &A Asn Pro Pro Ile Leu Ala Met Val Ala Val Trp Ser Ala Leu Lys Leu 310 315 Phe Asp Glu Val Gly Met Thr Arg Leu Arg Lys Lys Ala Ile Ser Leu 325 330 335 ?
US 9 , 975 , 959 B2 
161 162 
- continued 
| | Thr Gly Tyr Leu Glu Tyr Leu Val Asn Thr Leu Gly Asp Asp Val Val 
340 345 350 
? & Asn Ile Val Thr Pro Ala Asp Pro Ala Gln Ara 
355 360 Sao Ala can arg gly Ser Gin Leu Ser 365 am ssye Life Ile Gin Val Lys Thr Ala Asp Lys Lys Leu Phe Asn Lys Ile Thr Glu 375 380 ? DEE Ala Gly Val Ile Ala Asp Trp Arg Glu Pro Asp Val Ile Arg Val Ala 385 390 395 400 
Pro Val Pro Met Tyr Asn Ser Tyr Glu Asp Val Tyr Asn Phe Tyr Thr 
405 415 Ser Tyr Glu Aap val E?
| 
Ile Leu Lys Ser Ala Ile Ala Gly Asn 
420 425 
< 210 > SEQ ID NO 52 
< 211 > LENGTH : 424 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Pontibacter roseus 
< 400 > SEQUENCE : 52 
Met Asn Tyr Gln Asn Thr Leu Ala Phe Ala Gln Glu Gln Asp Asn Leu 
15 | Aon Tyr Gin non Thr Leu Ala Phe Ala Gin Glu Gan .
Asp Pro Leu Lys His Phe Lys Asp Arg Phe Tyr Phe Pro Gin Val Asn 
25 & 
Gly Arg Asp Ala Ile Tyr Phe Cys Gly Asn Ser Leu Gly Leu Gin Pro 
40 45 
Lys Ser Ala Gin Met Tyr Ile Asp Asn Glu Met Tyr Lys Trp Ala Asn 
55 
Tyr Ala Val Glu Gly His Phe Lys Val Glu Glu Pro Trp Phe Asn Tyr 
65 
His Arg Leu Leu Thr Asp Gly Ala Ala Arg Val Val Gly Ala Arg Pro 
95 
Gin Glu Val Val Ile Met Asn Gin Leu Thr Val Asn Leu His Leu Met 
105 
Leu Val Ser Phe Tyr Arg Pro Glu Gly Arg Arg Ile Lys Ile Ile Met 
120 125 mmmmm 
5 
we 
mm mmmmmm mmm mmmmmm mmmm mmmm Glu Gly Gly Ala Phe Pro Ser Asp Gin Tyr Ala Leu Glu Thr Gin Val 135 mmmmmm mmmmm Lys Phe His Gly Tyr Thr Pro Glu Glu Ala Ile Ile Glu Leu Phe Pro 145 Arg Glu Gly Glu His Thr Leu Arg Thr Glu Asp Ile Leu Lys Ser Ile 175 Glu Ala Ala Gly Asp Glu Leu Ala Leu Val Leu Met Gly Gly Ile Asn 185 Tyr Tyr Thr Gly Gin Val Tyr Asp Met Ala Ala Ile Thr Gin Ala Gly 200 205 His Gly Val Gly Ala Val Val Gly Phe Asp Leu Ala His Ala Ala Gly 215 Asn Val Pro Leu Gin Leu His Asp Trp Gly Val Asp Phe Ala Val Trp 225 Cys Thr Tyr Lys Tyr Leu Asn Ser Gly Pro Gly Gly Thr Ala Gly Val 255 
Phe Val His Glu Arg His Ala Asn Asn Pro Asp Leu Pro Arg Phe Ala 
265 
Gly Trp Trp Gly His Asp Ala Ser Val Arg Phe Gin Met Lys Lys Gly 
280 285 
US 9 , 975 , 959 B2 
163 164 
- continued 
? & ? ? Phe Ile Pro Met Thr Gly Ala Glu Gly Trp Gin Leu Ser Asn Ala Gin 
295 |- 
& Ile Leu Pro Met Ala Val His Arq Ala Ala Leu Glu Leu Phe Asp Glu 
305 310 315 320 ?mmm Ala Gly Met Asp Asn Leu Arg Ala Lys Ser Glu Lys Leu Thr Gly Tyr 335 mmm Leu Glu Tyr Leu Ile Asp Asp Val His Val Gly Lys Glu Leu Leu Glu 345 Met Ile Thr Pro Arg Asp Pro Gin Ala Arg Gly Cys Gin Ile Ser Leu 355 360 365 
Leu Val Lys Gln Asn Ala Arg Glu Leu Phe Asn Arq Leu Met Glu Ala 
375 
Gly Ile Ile Val Asp Phe Arg Glu Pro Ser Val Ile Arg Val Ala Pro 
385 390 395 400 
& Thr Pro Leu Tyr Asn Ser Phe Glu Glu Val Tyr Arg Phe Ser Glu Ile 
415 
| 
Leu His Asp Cys Leu Gin Ser His 
420 
A 
A 2 1 1 
A 2 1 2 A 
< 210 > SEQ ID NO 53 
< 1 > LENGTH : 1304 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polynucleotide 
A   A 
A 2 2 0 
A 2 2 
< 400 > SEQUENCE : 53 
ccatgggcgg acaccatcat caccaccacg goggcattga aaaactgaaa cagtatcacg 60 
atgaagcgat cagcctggat agccttgatc ccttacagaa attcaaagaa tgctttacat 120 
taccgaagga acctggagca ctgtatttct gcagcaatag tctgggcttg cccgcgaaag 180 
cggcttccca gaaactggaa gaacagttac agcggtggag cgaattaggc gctcgtggat 240 
ggtttgaagg cgagggtaat tggtataaca gottggaaga gcctattgtg cgtccattga 300 
gcaaaatctt aggagoggaa agcaatgaag tgaccctgat gaatagcttg accgtgaatc 360 
tgcacatgtt gttgattagt ttctatcgtc cgaccaaaat gcgttataag atactgattg 420 
atggcccagc ctttccgtcc gatctgtatg ccattaagtc gcatctgcgt tttcataaga 480 
aagaagaagg tcttattctg atagaaccgc gtccgggcga acatctggtg caggaagaag 540 
actttctgcg cgtgataaag aagcaaggag aggaaattgc gttggtgttt ctgaactgeg 600 
tgaattttct gagcggccag gtgctgaaag tggatgaaat cacccgttat gccaaggagg 660 
ctggctgctg cgtcggttat gatctggcgc atgcagcagg caatattccc ttaagcttgo 720 
atgatcttgg cggcgacttt gcggtgggct gctcctacaa atatctgtgc ggaggcccag 780 
gaggtccagg catagcctac gttcacgcgt cacatcacca ccaacagttc gtgcgtttca 840 
gcgggtggtg gggcaatgat ccgaataccc ggttttactt ccccaaagag tttgtgccgt 900 
atggcggtgc gagctcctgg caggtgagca ccccgtcgat tctggcgaaa ctgccgttaa 960 
ttgcggcact ggaggtgttt gaggaagcgg gcatggagaa tatacgtgaa aagagcaaga 1020 
aacaaacagc gttcctgtat accctgttag aaaatgctcg cggcacccat tttgatatga 1080 
taaccccgaa agaaccggag ctgcgtggct gtcagcttag cctgcgtatc aaatgcagcc 1140 
gtagcgaaga gatcttacgg aagctggaac gtttaggcat tacatgcgat ttccgttcgc 1200 
cgaacattct gcgtgtggcg ccgagcccgt tgtacaccag cttttacgaa atctatcgtt 1260 
US 9 , 975 , 959 B2 
165 166 
- continued 




< 210 > SEQ ID NO 54 
< 211 > LENGTH : 431 | 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 




< 400 > SEQUENCE : 54 





E Gin Tyr His Asp Glu Ala Ile Ser Leu Asp Ser Leu Asp Pro Leu Gin 
25 30 
?
Lys Phe Lys Glu Cys Phe Thr Leu Pro Lys Glu Pro Gly Ala Leu Tyr 
40 
Phe Cys Ser Asn Ser Leu Gly Leu Pro Ala Lys Ala Ala Ser Gin Lys 
oEn 
See 
Leu Glu Glu Gin Leu Gin Arg Trp Ser Glu Leu Gly Ala Arg Gly Trp 
70 75 
Phe Glu Gly Glu Gly Asn Trp Tyr Asn Ser Leu Glu Glu Pro Ile Val 
95 
& Arg Pro Leu Ser Lys Ile Leu Gly Ala Glu Ser Asn Glu Val Thr Leu 
105 | 110 
Met Asn Ser Leu Thr Val Asn Leu His Met Leu Leu Ile Ser Phe Tyr 
120 
Arg Pro Thr Lys Met Arg Tyr Lys Ile Leu Ile Asp Gly Pro Ala Phe 
Pro Ser Asp Leu Tyr Ala Ile Lys Ser His Leu Ara Phe His Lys Lys 
150 155 mmm mammm Glu Glu Gly Leu Ile Leu Ile Glu Pro Ara Pro Gly Glu His Leu Val 175 am Gln Glu Glu Asp Phe Leu Arq Val Ile Lys Lys Gln Gly Glu Glu Ile 185 | 190 | Ala Leu Val Phe Leu Asn Cys Val Asn Phe Leu Ser Gly Gin Val Leu 200 Lys Val Asp Glu Ile Thr Arg Tyr Ala Lys Glu Ala Gly Cys Cys Val Gly Tyr Asp Leu Ala His Ala Ala Gly Asn Ile Pro Leu Ser Leu His 230 235 Asp Leu Gly Gly Asp Phe Ala Val Gly Cys Ser Tyr Lys Tyr Leu Cys 255 Gly Gly Pro Gly Gly Pro Gly Ile Ala Tyr Val His Ala Ser His His 265 | 270 His Gin Gin Phe Val Arg Phe Ser Gly Trp Trp Gly Asn Asp Pro Asn 280 Thr Arg Phe Tyr Phe Pro Lys Glu Phe Val Pro Tyr Gly Gly Ala Ser ? Ser Trp Gin Val Ser Thr Pro Ser Ile Leu Ala Lys Leu Pro Leu Ile 310 315 Ala Ala Leu Glu Val Phe Glu Glu Ala Gly Met Glu Asn Ile Arg Glu 335 Lys Ser Lys Lys Gin Thr Ala Phe Leu Tyr Thr Leu Leu Glu Asn Ala 345 350 ?
US 9 , 975 , 959 B2 
167 168 . 
- continued 
? Arg Gly Thr His Phe Asp Met Ile Thr Pro Lys Glu Pro Glu Leu Arg 
355 360 365 






ge 3 3? EE & & Leu Arg Lys Leu Glu Arg Leu Gly Ile Thr Cys Asp Phe Arg Ser Pro 385 390 395 400 ? ?Asn Ile Leu Arg Val Ala Pro Ser Pro Leu Tyr Thr Ser Phe Tyr Glu 405 1 415 410 
Ile Tyr Arg Phe Ala Tyr Thr Phe Leu Glu Val Leu Lys Thr Ile 
420 425 43 0 
< 210 > SEQ ID NO 55 
< 211 > LENGTH : 465 
TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
AAAAA 1 2 2 1 2301 2
2 
< 400 > SEQUENCE : 55 
Met Glu Pro Ser Ser Leu Glu Leu Pro Ala Asp Thr Val Gin Arg Ile 
. 15 




Leu Asp Glu Glu Asp Lys Leu Arg His Phe Arg Glu Cys Phe Tyr Ile 
40 45 
. Pro Lys Ile Gin Asp Leu Pro Pro Val Asp Leu Ser Leu Val Asn Lys 
55 
JR
Asp Glu Asn Ala Ile Tyr Phe Leu Gly Asn Ser Leu Gly Leu Gin Pro Rg 65 
Lys Met Val Lys Thr Tyr Leu Glu Glu Glu Leu Asp Lys Trp Ala Lys E
Ile Ala Ala Tyr Gly His Glu Val Gly Lys Arg Pro Trp Ile Thr Gly 
100 105 
Asp Glu Ser Ile Val Gly Leu Met Lys Asp Ile Val Gly Ala Asn Glu 
120 125 
Lys Glu Ile Ala Leu Met Asn Ala Leu Thr Val Asn Leu His Leu Leu 
135 
Met Leu Ser Phe Phe Lys Pro Thr Pro Lys Arg Tyr Lys Ile Leu Leu 
145 
Glu Ala Lys Ala Phe Pro Ser Asp His Tyr Ala Ile Glu Ser Gin Leu 
Gln Leu His Gly Leu Asn Ile Glu Glu Ser Met Arg Met Ile Lys Pro 
180 185 
Arg Glu Gly Glu Glu Thr Leu Arg Ile Glu Asp Ile Leu Glu Val Ile 
200 205 
Glu Lys Glu Gly Asp Ser Ile Ala Val Ile Leu Phe Ser Gly Val His 
215 220 &
Phe Tyr Thr Gly Gln His Phe Asn Ile Pro Ala Ile Thr Lys Ala Gly 
225 
Gin Ala Lys Gly Cys Tyr Val Gly Phe Asp Leu Ala His Ala Val Gly 
mm Asn Val Glu Leu Tyr Leu His Asp Trp Gly Val Asp Phe Ala Cys Trp 260 265 
Cys Ser Tyr Lys Tyr Leu Asn Ala Gly Ala Gly Gly Ile Ala Gly Ala 
280 285 




Phe Ile His Glu Lys His Ala His Thr Ile Lys Pro Ala Leu Val Gly 
295 300 ?
Trp Met Gly His Glu Leu Ser Thr Arg Phe Lys Met Asp Asn Lys Leu 
310 315 320 
Gin Leu Ile Pro Gly Val Cys Gly Phe Arg Ile Ser Asn Pro Pro Ile 
330 
Leu Leu Val Cys Ser Leu His Ala Ser Leu Glu Ile Phe Lys Gln Ala 
345 350 
Thr Met Lys Ala Leu Arg Lys Lys Ser Val Leu Leu Thr Gly Tyr Leu 
360 365 
Glu Tyr Leu Ile Lys His Asn Tyr Gly Lys Asp Lys Ala Ala Thr Lys 
375 380 mmmm Lys Pro Val Val Asn Ile Ile Thr Pro Ser His Val Glu Glu Arg Gly 390 395 400 Cys Gin Leu Thr Ile Thr Phe Ser Val Pro Asn Lys Asp Val Phe Gin 410 Glu Leu Glu Lys Arg Gly Val Val Cys Asp Lys Arg Asn Pro Asn Gly 425 430 Ile Arg Val Ala Pro Val Pro Leu Tyr Asn Ser Phe His Asp Val Tyr 440 445 
| 
Lys Phe Thr Asn Leu Leu Thr Ser Ile Leu Asp Ser Ala Glu Thr Lys 




< 210 > SEO ID NO 56 
< 211 > LENGTH : 465 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
1 22  30
< 400 > SEOUENCE : 56 
3 ? Met Glu Pro Ser Ser Leu Glu Leu Pro Ala Asp Thr Val Gln Arg Ile 
10 
Ala Ala Glu Leu Lys Cys His Pro Thr Asp Glu Ara Val Ala Leu His 
25 30 
Leu Asp Glu Glu Asp Lys Leu Arg His Phe Arg Glu Cys Phe Tyr Ile 
40 
Pro Lys Ile Gin Asp Leu Pro Pro Val Asp Leu Ser Leu Val Asn Lys am ss 55 & g Asp Glu Asn Ala Ile Tyr Phe Leu Gly Asn Ser Leu Gly Leu Gin Pro 70 Lys Met Val Lys Thr Tyr Leu Glu Glu Glu Leu Asp Lys Trp Ala Lys 85 90 EpA 3 Ile Ala Ala Tyr Gly His Glu Val Gly Lys Arg Pro Trp Ile Thr Gly 105 110 E Asp Glu Ser Ile Val Gly Leu Met Lys Asp Ile Val Gly Ala Asn Glu 120 
Lys Glu Ile Ala Leu Met Asn Ala Leu Thr Val Asn Leu His Leu Leu 
135 




Glu Ala Lys Ala Phe Pro Ser Asp His Tyr Ala Ile Glu Ser Gin Leu 
165 170 9
US 9 , 975 , 959 B2 
171 172 . 
- continued 
? Gin Leu His Gly Leu Asn Ile Glu Glu Ser Met Arg Met Ile Lys Pro 
185 190 SO 3 Arg Glu Gly Glu Glu Thr Leu Arg Ile Glu Asp Ile Leu Glu Val Ile 195 200 205 
3 
Glu Lys Glu Gly Asp Ser Ile Ala Val Ile Leu Phe Ser Gly Val His 
215 
Phe Tyr Thr Gly Gin His Phe Asn Ile Pro Ala Ile Thr Lys Ala Gly 
225 235 
Gin Ala Lys Gly Cys Tyr Val Gly Phe Asp Leu Ala His Ala Val Gly 
255 
Asn Val Glu Leu Tyr Leu His Asp Trp Gly Val Asp Phe Ala Cys Trp 
265 270 
Cys Ser Tyr Lys Tyr Leu Asn Ala Gly Ala Gly Gly Ile Ala Gly Ala 
275 280 285 
Phe Ile His Glu Lys His Ala His Thr Ile Lys Pro Ala Leu Val Gly 
295 
? Trp Leu Gly His Glu Leu Ser Thr Arg Phe Lys Met Asp Asn Lys Leu 
305 315 
?
mmmmm Gin Leu Ile Pro Gly Val Cys Gly Phe Arg Ile Ser Asn Pro Pro Ile 335 mmmmm mm mmmmm mmmmmmmmm Leu Leu Val Cys Ser Leu His Ala Ser Leu Glu Ile Phe Lys Gln Ala 345 350 Thr Met Lys Ala Leu Arq Lys Lys Ser Val Leu Leu Thr Gly Tyr Leu 355 360 365 Glu Tyr Leu Ile Lys His Asn Tyr Gly Lys Asp Lys Ala Ala Thr Lys 375 Lys Pro Val Val Asn Ile Ile Thr Pro Ser His Val Glu Glu Arq Gly 385 395 Cys Gln Leu Thr Ile Thr Phe Ser Val Pro Asn Lys Asp Val Phe Gln 415 Glu Leu Glu Lys Arg Gly Val Val Cys Asp Lys Arg Asn Pro Asn Gly 425 430 Ile Arg Val Ala Pro Val Pro Leu Tyr Asn Ser Phe His Asp Val Tyr 440 445 &435 Lys Phe Thr Asn Leu Leu Thr Ser Ile Leu Asp Ser Ala Glu Thr Lys 455 ?? Asn 465 < 210 > SEQ ID NO 57 
< 211 > LENGTH : 420 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Chlamydophila pecorum 
< 400 > SEQUENCE : 57 
Ile Glu Lys Leu Lys Gin Tyr His Asp Glu Ala Ile Ser Leu Asp Ser 
1 15 ?
Leu Asp Pro Leu Gln Lys Phe Lys Glu Cys Phe Thr Leu Pro Lys Glu J ?
25 30 
? Pro Gly Ala Leu Tyr Phe Cys Ser Asn Ser Leu Gly Leu Pro Ala Lys 
35 40 45 




Gly Ala Arg Gly Trp Phe Glu Gly Glu Gly Asn Trp Tyr Asn Ser Leu 
70 80 




Glu Glu Pro Ile Val Arg Pro Leu Ser Lys Ile Leu Gly Ala Glu Ser 
90 
Asn Glu Val Thr Leu Met Asn Ser Leu ThrVal Asn Leu His Met Leu 
100 105 110 
Leu Ile Ser Phe Tyr Arg Pro Thr Lys Met Arg Tyr Lys Ile Leu Ile 
115 120 
Asp Gly Pro Ala Phe Pro Ser Asp Leu Tyr Ala Ile Lys Ser His Leu &
& Arg Phe His Lys Lys Glu Glu Gly Leu Ile Leu Ile Glu Pro Arg Pro
145 155 150 
Gly Glu His Leu Val Gin Glu Glu Asp Phe Leu Arg Val Ile Lys Lys 
170 
Gin Gly Glu Glu Ile Ala Leu Val Phe Leu Asn cys Val Asn Phe Leu 
180 185 190 
°
Ser Gly Gin Val Leu Lys Val Asp Glu Ile Thr Arg Tyr Ala Lys Glu 
| 195 200 
S
Ala Gly Cys Cys Val Gly Tyr Asp Leu Ala His Ala Ala Gly Asn Ile 3 mmmm mmmmm mmmm Pro Leu Ser Leu His Asp Leu Gly Gly Asp Phe Ala Val Gly Cys Ser 225 230 235 Tyr Lys Tyr Leu Cys Gly Gly Pro Gly Gly Pro Gly Ile Ala Tyr Val 250 mmmmm mmm mm 8?mmmmm mmmmm mmmmm His Ala Ser His His His Gin Gin Phe Val Arg Phe Ser Gly Trp Trp 260 265 270 A Gly Asn Asp Pro Asn Thr Arg Phe Tyr Phe Pro Lys Glu Phe Val Pro 275 280 &ETyr Gly Gly Ala Ser Ser Trp Gin Val Ser Thr Pro Ser Ile Leu Ala Lys Leu Pro Leu Ile Ala Ala Leu Glu Val Phe Glu Glu Ala Gly Met 305 1310 315 H ° Glu Asn Ile Arq Glu Lys Ser Lys Lys Gin Thr Ala Phe Leu Tyr Thr 330 Leu Leu Glu Asn Ala Arg Gly Thr His Phe Asp Met Ile Thr Pro Lys 340 345 | 350 Glu Pro Glu Leu Arg Gly Cys Gin Leu Ser Leu Arg Ile Lys Cys Ser 355 360 Arg Ser Glu Glu Ile Leu Arg Lys Leu Glu Arg Leu Gly Ile Thr Cys & Asp Phe Ara Ser Pro Asn Ile Leu Arq Val Ala Pro Ser Pro Leu Tyr 385 390 395 Thr Ser Phe Tyr Glu Ile Tyr Arg Phe Ala Tyr Thr Phe Leu Glu Val 405 410 Leu Lys Thr Ile 
420 
1 1 
2 1 2 AAAA 
< 210 > SEQ ID NO 58 
< 211 > LENGTH : 465 
< 212 > TYPE : PRT 
( 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 




< 400 > SEQUENCE : 58 
Met Glu Pro Ser Ser Leu Glu Leu Pro Ala Asp Thr Val Gin Arg Ile 
10 15 
m 




Ala Ala Glu Leu Lys Cys His Pro Thr Asp Glu Arg Val Ala Leu His 
30 
Leu Asp Glu Glu Asp Lys Leu Arg His Phe Arg Glu Cys Phe Tyr Ile 
35 40 
& Pro Lys Ile Gin Asp Leu Pro Pro Val Asp Leu Ser Leu Val Asn Lys 
55 
Asp Glu Asn Ala Ile Tyr Phe Leu Gly Asn Ser Leu Gly Leu Gin Pro 
70 80 
E .
R&SEPREE 75 Lys Met Val Lys Thr Tyr Leu Glu Glu Glu Leu Asp Lys Trp Ala Lys 90 Ile Ala Ala Tyr Gly His Glu Val Gly Lys Arg Pro Trp Ile Thr Gly 
110 
Asp Glu Ser Ile Val Gly Leu Met Lys Asp Ile Val Gly Ala Asn Glu 
115 120 
Lys Glu Ile Ala Leu Met Asn Ala Leu Thr Val Asn Leu His Leu Leu 
135 
Met Leu Ser Phe Phe Lys Pro Thr Pro Lys Arg Tyr Lys Ile Leu Leu 
150 155 160 
Glu Ala Lys Ala Phe Pro Ser Asp His Tyr Ala Ile Glu Ser Gin Leu 
170 175 
Gin Leu His Gly Leu Asn Ile Glu Glu Ser Met Arq Met Ile Lys Pro 
190 | 
Arg Glu Gly Glu Glu Thr Leu Arg Ile Glu Asp Ile Leu Glu Val Ile 
195 200 gg 
Glu Lys Glu Gly Asp Ser Ile Ala Val Ile Leu Phe Ser Gly Val His 
215 
Phe Tyr Thr Gly Gin His Phe Asn Ile Pro Ala Ile Thr Lys Ala Gly 
225 230 235 240 
Gin Ala Lys Gly cys Tyr Val Gly Phe Asp Leu Ala His Ala Val Gly 
250 255 gg Asn Val Glu Leu Tyr Leu His Asp Trp Gly Val Asp Phe Ala Cys Trp 
270 
Cys Ser Tyr Lys Tyr Leu Asn Ala Gly Ala Gly Gly Ile Ala Gly Ala 
275 280 
Phe Ile His Glu Lys His Ala His Thr Ile Lys Pro Ala Leu Val Gly 
295 
Trp Phe Gly His Glu Leu Ser Thr Arg Phe Lys Met Asp Asn Lys Leu 
305 310 315 320 
Gin Leu Ile Pro Gly Val Cys Gly Phe Arg Ile Ser Asn Pro Pro Ile 
330 335 
Leu Leu Val Cys Ser Leu His Ala Ser Leu Glu Ile Phe Lys Gin Ala 
350 
E Thr Met Lys Ala Leu Arg Lys Lys Ser Val Leu Leu Thr G Gly Tyr Leu 
355 360 
Glu Tyr Leu Ile Lys His Asn Tyr Gly Lys Asp Lys Ala Ala Thr Lys 
375 
Lys Pro Val Val Asn Ile Ile Thr Pro Ser His Val Glu Glu Arg Gly 
385 390 395 400 
Cys Gln Leu Thr Ile Thr Phe Ser Val Pro Asn Lys Asp Val Phe Gln 
410 415 
Glu Leu Glu Lys Arg Gly Val Val Cys Asp Lys Arg Asn Pro Asn Gly 
430 
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